Mobix Labs (MOBX) S-4/A11 Aug 23Registration of securities issued in business combination transactions (amended)Financial data

Company Profile

Document and Entity Information

Document and Entity Information	3 Months Ended
Document and Entity Information	Mar. 31, 2023
Document and Entity Information
Document Type	S-4/A
Entity Registrant Name	Chavant Capital Acquisition Corp.
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Central Index Key	0001855467
Amendment Flag	true
Amendment Description	AMENDMENT NO. 1

BALANCE SHEETS

BALANCE SHEETS - USD ($)	Mar. 31, 2023	Dec. 31, 2022	Mar. 31, 2022	Dec. 31, 2021	Mar. 18, 2021
Current assets:
Cash	$ 105,038	$ 175,788		$ 240,706
Prepaid expenses				432,591
Total Current Assets	105,038	175,788		673,297
Investment held in trust account	9,092,522	9,835,409		80,002,777
TOTAL ASSETS	9,197,560	10,011,197		80,676,074
Current liabilities:
Accrued expenses	578,352	358,257		69,002
Promissory note - due to sponsor	962,000	662,000
Total Current Liabilities	1,540,352	1,020,257		69,002
Warrant liability	102,000	335,240		1,667,262
PIPE derivative liability	1,281,465	1,065,297
Total Liabilities	2,923,817	2,420,794		1,736,264
Commitments and Contingencies
Ordinary shares subject to possible redemption, $0.0001 par value; 200,000,000 shares authorized; 953,033 and 8,000,000 shares subject to possible redemption at redemption value of $10.22 and $10.00 per share as of December 31, 2022 and 2021, respectively	8,992,522	9,735,409		80,000,000
Shareholders' Deficit:
Preference shares, $0.0001 par value; 1,000,000 shares authorized; none issued and outstanding
Ordinary shares, $0.0001 par value; 200,000,000 shares authorized; 2,000,000 shares issued and outstanding (1)	200	200		200
Additional paid-in capital	30	30		30
Accumulated deficit	(2,719,009)	(2,145,236)		(1,060,420)
Total Shareholders' Deficit	(2,718,779)	(2,145,006)	$ (455,831)	(1,060,190)	$ 0
TOTAL LIABILITIES, SHARES SUBJECT TO POSSIBLE REDEMPTION AND SHAREHOLDERS' DEFICIT	$ 9,197,560	$ 10,011,197		$ 80,676,074

BALANCE SHEETS (Parenthetical)

BALANCE SHEETS (Parenthetical) - $ / shares	Mar. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
UNAUDITED CONDENSED BALANCE SHEETS
Preferred stock, par value, (per share)	$ 0.0001	$ 0.0001	$ 0.0001
Preferred Stock, Shares Authorized	1,000,000	1,000,000	1,000,000
Preferred Stock, Shares Issued	0	0	0
Preferred Stock, Shares Outstanding	0	0	0
Common shares, par value	$ 0.0001	$ 0.0001	$ 0.0001
Common shares, shares authorized	200,000,000	200,000,000	200,000,000
Common shares, shares issued	2,000,000	2,000,000	2,000,000
Common shares, shares outstanding	2,000,000	2,000,000	2,000,000
Temporary Equity, Par or Stated Value Per Share		$ 0.0001	$ 0.0001
Temporary Equity, Shares Authorized		200,000,000	200,000,000
Temporary equity, shares outstanding	856,042	953,033	8,000,000
Ordinary shares subject to possible redemption, per share	$ 10	$ 10.22	$ 10
Shares surrendered to company for cancellation		875,000	875,000

STATEMENTS OF OPERATIONS

STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended				9 Months Ended		12 Months Ended
STATEMENTS OF OPERATIONS - USD ($)	Mar. 31, 2023		Mar. 31, 2022		Dec. 31, 2021		Dec. 31, 2022
General and administrative expense	$ 432,438		$ 354,876		$ 702,456		$ 1,140,064
Administrative expense-related party	30,000		30,000		60,000		120,000
Loss from operations	(462,438)		(384,876)		(762,456)		(1,260,064)
Other income:
Gain from change in fair value of warrant liability	233,240		987,262		1,120,738		1,332,022
Interest earned on marketable securities held in trust account	50,777		1,973		2,777		217,210
Day one loss in PIPE Derivative Liability							(1,108,709)
Gain from change in fair value of PIPE Derivative Liability							43,412
Total other income					1,123,515		483,935
(Loss) Income before income taxes	(312,060)		604,359		361,059		(776,129)
Income tax expense	0						0
Net (Loss) Income	$ (312,060)		$ 604,359		$ 361,059		$ (776,129)
Ordinary shares subject to redemption
Other income:
Weighted average ordinary shares outstanding, basic	873,285		8,000,000		4,527,778		4,795,078
Weighted average ordinary shares outstanding, diluted	873,285		8,000,000		4,527,778	[1]	4,795,078	[1]
Basic net income (loss) per ordinary share	$ 0.10		$ 0.06		$ 0.38		$ (0.10)
Diluted net income (loss) per ordinary share	$ 0.10		$ 0.06		$ 0.38		$ (0.10)
Non-redeemable ordinary share
Other income:
Weighted average ordinary shares outstanding, basic	2,000,000	[2]	2,000,000	[2]	1,868,056		2,000,000
Weighted average ordinary shares outstanding, diluted	2,000,000	[2]	2,000,000	[2]	1,868,056		2,000,000
Basic net income (loss) per ordinary share	$ (0.20)		$ 0.06		$ (0.73)		$ (0.16)
Diluted net income (loss) per ordinary share	$ (0.20)		$ 0.06		$ (0.73)		$ (0.16)

[1] 875,000 ordinary shares were surrendered to the Company for cancellation for no consideration, resulting in 2,000,000 ordinary shares outstanding. All share amounts and related information have been retroactively restated to reflect the share surrender (see Note 7) 875,000 ordinary shares were surrendered to the Company for cancellation for no consideration, resulting in 2,000,000 ordinary shares outstanding. All share amounts and related information have been retroactively restated to reflect the share surrender (see Note 7) .

STATEMENTS OF OPERATIONS (Paren

STATEMENTS OF OPERATIONS (Parenthetical) - shares	Mar. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
UNAUDITED CONDENSED STATEMENTS OF OPERATIONS
Shares surrendered to company for cancellation		875,000	875,000
Common shares, shares outstanding	2,000,000	2,000,000	2,000,000

STATEMENTS OF CHANGES IN SHAREH

STATEMENTS OF CHANGES IN SHAREHOLDERS' DEFICIT AND ORDINARY SHARES SUBJECT TO POSSIBLE REDEMPTION - USD ($)	Ordinary Shares Subject To Possible Redemption [Member]	Ordinary Shares	Additional Paid-in Capital	Accumulated Deficit [Member]	Total
Balance at the beginning (in shares) at Mar. 18, 2021	0	0
Balance at the beginning at Mar. 18, 2021	$ 0	$ 0	$ 0	$ 0	$ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of ordinary shares		$ 200	24,800	0	25,000
Issuance of ordinary shares (in shares)		2,300,000
Issuance of Public Shares and Public Warrants in initial public offering	$ 75,140,000		4,860,000	0	4,860,000
Issuance of Public Shares and Public Warrants in initial public offering (in shares)	8,000,000
Offering cost allocation	$ (1,933,210)		(125,039)	0	(125,039)
Cash proceeds received in excess of fair value for Private Placement Warrants			612,000	0	612,000
Accretion to ordinary shares subject to redemption (Deemed dividend)	6,793,210		(5,371,731)	(1,421,479)	(6,793,210)
Forfeiture of Founder Shares in connection with the expiration of overallotment option			0	0
Forfeiture of Founder Shares in connection with the expiration of overallotment option (in Shares)		(300,000)
Net income (loss)			0	361,059	361,059
Balance at the end at Dec. 31, 2021	$ 80,000,000	$ 200	30	(1,060,420)	(1,060,190)
Balance at the end (in shares) at Dec. 31, 2021	8,000,000	2,000,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)				604,359	604,359
Balance at the end at Mar. 31, 2022	$ 80,000,000	$ 200	30	(456,061)	(455,831)
Balance at the end (in shares) at Mar. 31, 2022	8,000,000	2,000,000
Balance at the beginning (in shares) at Dec. 31, 2021	8,000,000	2,000,000
Balance at the beginning at Dec. 31, 2021	$ 80,000,000	$ 200	30	(1,060,420)	(1,060,190)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance Of Founder Shares					$ 25,000
Issuance Of Founder Shares (in shares)					2,000,000
Redemption of ordinary shares	$ (70,573,278)		0	0
Redemption of ordinary shares (in shares)	(7,046,967)
Subsequent measurement of ordinary shares subject to redemption	$ 308,687		0	(308,687)	$ (308,687)
Net income (loss)			0	(776,129)	(776,129)
Balance at the end at Dec. 31, 2022	$ 9,735,409	$ 200	30	(2,145,236)	(2,145,006)
Balance at the end (in shares) at Dec. 31, 2022	953,033	2,000,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Redemption of ordinary shares	$ (1,004,600)
Redemption of ordinary shares (in shares)	(96,991)
Subsequent measurement of ordinary shares subject to redemption	$ 261,713			(261,713)	(261,713)
Net income (loss)				(312,060)	(312,060)
Balance at the end at Mar. 31, 2023	$ 8,992,522	$ 200	$ 30	$ (2,719,009)	$ (2,718,779)
Balance at the end (in shares) at Mar. 31, 2023	856,042	2,000,000

STATEMENTS OF CASH FLOWS

STATEMENTS OF CASH FLOWS - USD ($)	3 Months Ended		9 Months Ended	12 Months Ended
STATEMENTS OF CASH FLOWS - USD ($)	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2022
Cash Flows from Operating Activities:
Net Income	$ (312,060)	$ 604,359	$ 361,059	$ (776,129)
Adjustments to reconcile net (loss) income to net cash used in operating activities:
Interest earned on marketable securities held in trust account			(2,777)
Day one loss in PIPE Derivative Liability				1,108,709
Change in fair value of warrant liabilities	(233,240)	(987,262)	(1,120,738)	(1,332,022)
Change in fair value of PIPE Derivative Liability				(43,412)
Changes in operating assets and liabilities:
Prepaid expenses		194,568	(432,591)	432,591
Accrued expenses	220,095	68,724	69,002	289,255
Net cash used in operating activities	(191,566)	(121,584)	(1,126,045)	(321,008)
Cash Flows from Investment Activities:
Cash withdrawn from Trust Account in connection with redemption				70,573,278
Reinvest interest earned on marketable securities held in trust account				(217,210)
Investment of cash in Trust Account			(80,000,000)	(188,700)
Net cash provided by investing activities	825,416		(80,000,000)	70,167,368
Cash Flows from Financing Activities:
Proceeds from issuance of ordinary shares to Sponsor			25,000
Proceeds from sale of Units in initial public offering, net of underwriting discounts paid			78,400,000
Redemption of ordinary shares subject to possible redemption	(1,004,600)			(70,573,278)
Proceeds from sale of Private Placement Warrants			3,400,000
Proceeds from promissory note - due to sponsor	300,000		129,602	662,000
Repayment of promissory note - due to sponsor			(129,602)
Payment of offering costs			(458,249)
Net cash used in financing activities	(704,600)		81,366,751	(69,911,278)
Net Change in Cash	(70,750)	(121,584)	240,706	(64,918)
Cash - Beginning of period	175,788	240,706		240,706
Cash - End of period	105,038	$ 119,122	240,706	175,788
Non-Cash investing and financing activities:
Accretion to ordinary shares subject to redemption	$ 261,713		$ 6,793,210	$ 308,687

Organization and Business Opera

Organization and Business Operations	3 Months Ended	12 Months Ended
Organization and Business Operations	Mar. 31, 2023	Dec. 31, 2022
Organization and Business Operations
Organization and Business Operations	Note 1 — Organization and Business Operations Organization and General Chavant Capital Acquisition Corp. (the “Company”) was incorporated as a Cayman Islands exempted company on March 19, 2021. The Company was formed for the purpose of effectuating a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses (a “business combination”). The Company is an early stage and emerging growth company and, as such, the Company is subject to all of the risks associated with early stage and emerging growth companies. As of March 31, 2023, the Company had not commenced any operations. All activity through March 31, 2023 relates to the Company’s formation and its Initial Public Offering (“IPO”) which is described below, identifying a target company for a business combination and negotiation and preparation of documentation relating to the Proposed Mobix Labs Transaction (as defined below). The Company will not generate any operating revenues until after the completion of a business combination. The Company generates non-operating income in the form of interest income from the proceeds derived from the IPO. The Company has selected December 31 as its fiscal year end. On November 15, 2022, the Company and Mobix Labs, Inc., a Delaware corporation (“Mobix Labs”), entered into a business combination agreement (the “Business Combination Agreement”), by and among the Company, Mobix Labs and CLAY Merger Sub II, Inc., a Delaware corporation and newly formed, wholly-owned direct subsidiary of the Company (“Merger Sub”), pursuant to which Merger Sub will be merged with and into Mobix Labs, with Mobix Labs surviving the merger as a wholly-owned direct subsidiary of the Company (the “Proposed Mobix Labs Transaction”). In connection with the Proposed Mobix Labs Transaction, the Company will take the steps necessary to transfer its registration from the Cayman Islands to the State of Delaware (the “Domestication”), where it will then immediately incorporate as a Delaware corporation. The Company will also issue one share of Class A Common Stock in exchange for and on conversion in connection with the Domestication of each ordinary share outstanding immediately prior to the Domestication and will issue a warrant exercisable for one share of Class A Common Stock in exchange for and on conversion in connection with the Domestication of each warrant outstanding immediately prior to the Domestication. The Proposed Mobix Labs Transaction may be terminated by the Company and/or Mobix Labs under certain circumstances at any time prior to the closing. If the Proposed Mobix Labs Transaction occurs, the combined company will be named Mobix Labs, Inc., and its common stock and warrants are expected to be listed on Nasdaq. In connection with the Proposed Mobix Labs Transaction, the Company entered into a subscription agreement (the “PIPE Subscription Agreement”) with an investor (the “PIPE Investor”), pursuant to which the PIPE Investor agreed to purchase 3,000,000 shares of Class A Common Stock at $10.00 per share for an aggregate amount of $30,000,000 (the “PIPE”), subject to, among other things, the approval of the Proposed Mobix Labs Transaction by the Company’s shareholders and the satisfaction of the conditions set forth in the Business Combination Agreement, including a Form S-4 registration statement being declared effective by the SEC. See Note 5 for further discussion of the accounting for the PIPE, including the embedded Make-Whole Features, as defined and described in such note. On April 7, 2023, the Company, Mobix Labs and Merger Sub entered into Amendment No. 1 to the Business Combination Agreement, pursuant to which, the parties have agreed, among other things, that certain securities issued subsequent to March 26, 2023, referred to as “Post-March 26 Financing Securities,” will not be included in the calculation of the “Company Fully Diluted Number” under the Business Combination Agreement, with the effect that the Per Share Exchange Ratio (as defined in the Business Combination Agreement) will not be reduced on account of such issuances. “Post-March 26 Financing Securities” are defined in the Amendment No. 1 as any shares of (i) common stock of Mobix Labs or (ii) common stock of Mobix Labs issuable upon exercise or conversion of warrants, convertible instruments or convertible debt of Mobix Labs, in each case, where such securities were issued for cash and in accordance with Sections 6.01(b)(iii) and (xix) of the Business Combination Agreement, as a result of, or in connection with, any private placement entered into by Mobix Labs after March 26, 2023. Except with the consent of the Company (which consent shall not be unreasonably conditioned, withheld or delayed), Mobix Labs must use the proceeds of the issuance of any Post-March 26 Financing Securities to finance the ongoing business operations of Mobix Labs or to pay transaction expenses. In addition, Amendment No. 1 extended the outside date under the Business Combination Agreement from July 22, 2023 to November 22, 2023. Nasdaq Notice of Non-Compliance with a Continued Listing Rule On March 23, 2023, the Company received a notice from the Listing Qualifications staff of The Nasdaq Stock Market LLC that, for the previous 30 consecutive business days, the minimum Market Value of Listed Securities (“MVLS”) for the Company’s Public Shares (as defined below) was below the $35,000,000 minimum MVLS requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(2) (the “MVLS Rule”). In accordance with the Nasdaq Listing Rules, the Company will have 180 calendar days (until September 19, 2023) to regain compliance with the MVLS Rule. To regain compliance with the MVLS Rule, the MVLS for the Company’s Public Shares must be at least $35,000,000 for a minimum of 10 consecutive business days at any time during this 180-day period. If the Company does not regain compliance with the rule by September 19, 2023, The Nasdaq Stock Market LLC will provide notice that the Company’s Public Shares will be delisted from The Nasdaq Capital Market. In the event of such notification, the Nasdaq Listing Rules permit the Company an opportunity to appeal The Nasdaq Stock Market LLC’s determination. The Company is monitoring the MVLS of its ordinary shares and will consider options available to it to potentially achieve compliance. The Company’s securities are expected to continue to trade on The Nasdaq Capital Market during the 180-day period. Financing The Company’s sponsor is Chavant Capital Partners LLC, a Delaware limited liability company (the “Sponsor”). The registration statement pursuant to which the Company registered its securities offered in the IPO was declared effective on July 19, 2021. On April 7, 2021, the Sponsor purchased an aggregate of 2,875,000 ordinary shares (the “Founder Shares”) for a purchase price of $25,000 , or approximately $0.009 per share. On June 25, 2021, the Sponsor sold an aggregate of 422,581 of such Founder Shares to the underwriters for a purchase price of $3,675 . On July 22, 2021, the Company consummated its IPO of 8,000,000 units (each, a “Unit” and collectively, the “Units”), at $10.00 per Unit, generating gross proceeds of $80,000,000 and incurring offering costs of $2,058,249 . The Company granted the underwriters a 45-day option to purchase up to an additional 1,200,000 Units at the IPO price to cover over-allotments, if any. On September 5, 2021, the over-allotment option expired unexercised and an aggregate of 300,000 Founder Shares was forfeited, resulting in 2,000,000 Founder Shares remaining outstanding. Simultaneously with the consummation of the closing of the IPO, the Company consummated the private placement of an aggregate of 3,400,000 warrants (collectively, the “Private Warrants” and together with the Public Warrants (as defined below), the “Warrants”) at an average price of $1.00 per Private Warrant to the Sponsor and the underwriters, generating total gross proceeds of $3,400,000 (the “Private Placement”). Trust Account Following the closing of the IPO on July 22, 2021, an amount of $80,000,000 from the net proceeds of the sale of the Units in the IPO and the sale of the Private Warrants was placed in the trust account (the “Trust Account”) located in the United States with Continental Stock Transfer & Trust Company acting as trustee. The funds may be invested only in U.S. government securities with a maturity of 185 days or less or in money market funds meeting certain conditions under Rule 2a-7 under the Investment Company Act of 1940, as amended (the “Investment Company Act”), which invest only in direct U.S. government treasury obligations. On July 14, 2022, the Company held an Extraordinary General Meeting of shareholders and obtained shareholder approval of the extension of the date by which the Company must consummate an initial business combination from July 22, 2022 (which is 12 months from the closing of the IPO) to January 22, 2023 (the “Extended Date”) by amending the Company’s amended and restated memorandum and articles of association (the “First Extension Amendment”). The First Extension Amendment became effective upon approval of the Company’s shareholders. In connection with the First Extension Amendment, shareholders holding 7,046,967 ordinary shares of the Company exercised their right to redeem their ordinary shares for a pro rata portion of the funds in the Trust Account. As a result, $70,573,278 was withdrawn from the Trust Account to pay such holders. As a result of the redemption payments and above mentioned extension, the Company deposited $31,450 (at a rate of $0.033 per non-redeeming Public Share) for each subsequent monthly period needed by the Company to complete a business combination by the Extended Date. As of December 31, 2022, the Company deposited an aggregate of $188,700 in the Trust Account which were funded by the promissory notes issued to the Sponsor. On January 6, 2023, the Company held an extraordinary general meeting of shareholders and obtained shareholder approval of the extension of the Combination Period to July 22, 2023 (“Second Extension”). In connection with the meeting, Public Shareholders holding 96,991 Public Shares elected to exercise their right to redeem such shares and $1,004,600 was paid out of the Trust Account in connection with the redemptions. In connection with the approval of the extension amendment, the Company made an initial deposit into the Trust Account of $42,802 (at a rate of $0.05 per non-redeeming Public Share per month) and will continue to deposit $42,802 for each subsequent monthly period, or portion thereof, that is needed by the Company to complete business combination by July 22, 2023. As of March 31, 2023, the Company had deposited an aggregate of $317,107 in the Trust Account in connection with the First Extension and the Second Extension Amendments, and the Trust Account had a total balance of $9,092,522 . The funds held in the Trust Account will not be released from the Trust Account until the earliest of: (i) the completion of the initial business combination ; (ii) the redemption of any Public Shares properly submitted in connection with a shareholder vote to amend the Company’s amended and restated memorandum and articles of association (the “Amended and Restated Memorandum and Articles of Association”) (A) to modify the substance or timing of the Company’s obligation to redeem 100% of the Public Shares if the Company does not complete the initial business combination by July 22, 2023 (or within any extended period of time that we may have to consummate an initial business combination as a result of an amendment to our Amended and Restated Memorandum and Articles of Association) or (B) with respect to any other material provisions relating to shareholders’ rights or pre-initial business combination activity; or (iii) the redemption of the Public Shares if we are unable to complete the Proposed Mobix Labs Transaction or any other initial business combination by July 22, 2023 (or by the end of any such extended period of time), subject to applicable law. The proceeds deposited in the Trust Account could become subject to the claims of our creditors, if any, which could have priority over the claims of our Public Shareholders. The proceeds held in the Trust Account will be invested only in U.S. government treasury obligations with a maturity of 185 days or less or in money market funds meeting certain conditions under Rule 2a-7 under the Investment Company Act that invest only in direct U.S. government treasury obligations. The Company’s management has broad discretion with respect to the specific application of the net proceeds of the IPO and the sale of Private Warrants, although substantially all of the net proceeds are intended to be applied generally toward consummating a business combination. Initial Business Combination The Company is not limited to a particular industry or sector for purposes of consummating a business combination. There is no assurance that the Company will be able to complete a business combination successfully. The Company must complete one or more initial business combinations having an aggregate fair market value of at least 80% of the net assets held in the Trust Account (net of taxes payable) at the time of the signing of a definitive agreement to enter into an initial business combination. However, the Company will only complete a business combination if the post-transaction company owns or acquires 50% or more of the outstanding voting securities of the target or otherwise acquires a controlling interest in the target sufficient for it not to be required to register as an investment company under the Investment Company Act. The Company will provide holders (the “Public Shareholders”) of its ordinary shares sold in the IPO (the “Public Shares”) with the opportunity to redeem all or a portion of their Public Shares upon the completion of a business combination either (i) in connection with a general meeting called to approve a business combination or (ii) without a shareholder vote by means of a tender offer. The decision as to whether the Company will seek shareholder approval of business combination or conduct a tender offer will be made by the Company, solely in its discretion. The Public Shareholders will be entitled to redeem their Public Shares for a pro rata portion of the amount then on deposit in the Trust Account (initially anticipated to be $10.00 per Public Share). These Public Shares were classified as temporary equity upon the completion of the IPO in accordance with the Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) 480, “Distinguishing Liabilities from Equity.” In such case, the Company will proceed with business combination if the Company has net tangible assets of at least $5,000,001 upon such consummation of business combination and a majority of the shares voted are voted in favor of a business combination. If a shareholder vote is not required by law and the Company does not decide to hold a shareholder vote for business or other legal reasons, the Company will, pursuant to its Amended and Restated Memorandum and Articles of Association, conduct the redemptions pursuant to the tender offer rules of the U.S. Securities and Exchange Commission (“SEC”) and file tender offer documents with the SEC prior to completing a business combination. If, however, shareholder approval of the Proposed Mobix Labs Transaction is required by law, or the Company decides to obtain shareholder approval for business or legal reasons, the Company will offer to redeem shares in conjunction with a proxy solicitation pursuant to the proxy rules and not pursuant to the tender offer rules. Additionally, each Public Shareholder may elect to redeem their Public Shares irrespective of whether they vote for or against the proposed transaction, whether they participate in or abstain from voting, or whether they were a shareholder on the record date for the general meeting held to approve the Proposed Mobix Labs Transaction. If the Company seeks shareholder approval in connection with a business combination, the Company’s initial shareholders, Sponsor, officers and directors (the “Initial Shareholders”) have agreed to vote their Founder Shares (as defined below in Note 4) and any Public Shares purchased during or after the IPO in favor of a business combination. The Company has adopted an insider trading policy which requires insiders to: (i) refrain from purchasing shares during certain blackout periods and when they are in possession of any material non-public information and (ii) to clear all trades with the Company’s legal counsel prior to execution. In addition, the Initial Shareholders have agreed to waive their redemption rights with respect to their Founder Shares and Public Shares in connection with the completion of a business combination. Notwithstanding the foregoing, the Amended and Restated Memorandum and Articles of Association provides that a Public Shareholder, together with any affiliate of such shareholder or any other person with whom such shareholder is acting in concert or as a “group” (as defined under Section 13 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), will be restricted from redeeming its shares with respect to more than an aggregate of 15% or more of the ordinary shares sold in the IPO, without the prior consent of the Company. The Company has entered into a letter agreement with its Initial Shareholders, pursuant to which the Initial Shareholders have agreed to not to propose an amendment to the Amended and Restated Memorandum and Articles of Association that would modify the substance or timing of the Company’s obligation to redeem 100% of its Public Shares if the Company does not complete a business combination, unless the Company provides the Public Shareholders with the opportunity to redeem their ordinary shares in conjunction with any such amendment. Liquidation On July 14, 2022, the Company obtained shareholder approval to extend the date by which the Company must consummate an initial business combination from July 22, 2022 to January 22, 2023. On January 6, 2023, the Company obtained shareholder approval to further extend the date to July 22, 2023. If the Company is unable to complete the Proposed Mobix Labs Transaction or any other initial business combination by the Second Extended Date (the “Combination Period”), the Company will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than ten business days thereafter, redeem the Public Shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned on the funds held in the Trust Account (less taxes payable and up to $100,000 of interest to pay dissolution expenses), divided by the number of then issued and outstanding Public Shares, which redemption will completely extinguish Public Shareholders’ rights as shareholders (including the right to receive further liquidation distributions, if any) and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the remaining shareholders and the board of directors, liquidate and dissolve, subject, in each case, to the Company’s obligations under Cayman Islands law to provide for claims of creditors and in all cases subject to the other requirements of applicable law. There will be no redemption rights or liquidating distributions with respect to the Warrants, which will expire worthless if the Company fails to complete its initial business combination within the Combination Period. The Company’s Initial Shareholders have agreed to waive their liquidation rights with respect to the Founder Shares if the Company fails to complete a business combination within the Combination Period. However, if the Company’s Initial Shareholders acquire Public Shares in or after the IPO, they will be entitled to liquidating distributions from the Trust Account with respect to such Public Shares if the Company fails to complete a business combination within the Combination Period. In the event of such distribution, it is possible that the per share value of the residual assets remaining available for distribution (including Trust Account assets) will be only $10.00 per share initially held in the Trust Account. In order to protect the amounts held in the Trust Account, the Sponsor has agreed to be liable to the Company if and to the extent any claims by a vendor for services rendered or products sold to the Company, or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amount of funds in the Trust Account. This liability will not apply with respect to any claims by a third party who executed a waiver of any right, title, interest or claim of any kind in or to any monies held in the Trust Account or to any claims under the Company’s indemnity of the underwriters of the IPO against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the “Securities Act”). Moreover, in the event that an executed waiver is deemed to be unenforceable against a third party, the Sponsor will not be responsible to the extent of any liability for such third-party claims. The Company will seek to reduce the possibility that the Sponsor will have to indemnify the Trust Account due to claims of creditors by endeavoring to have all vendors, service providers, except the independent registered public accounting firm and the Company’s legal counsel, prospective target businesses or other entities with which the Company does business, execute agreements with the Company waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account. Liquidity and Capital Resources; Going Concern In order to fund working capital deficiencies or finance transaction costs in connection with a business combination, our Sponsor or an affiliate of our Sponsor or certain of our officers and directors may, but are not obligated to, loan us funds as may be required. If we complete a business combination, we may repay such loaned amounts out of the proceeds of the Trust Account released to us. In the event that a business combination does not close, we may use a portion of the working capital held outside the Trust Account to repay such loaned amounts, but no proceeds from our Trust Account would be used for such repayment. Up to $1,500,000 of such loans may be convertible into warrants, at a price of $1.00 per warrant, at the option of the lender. The warrants would be identical to the Private Warrants. As of March 31, 2023, the Company has drawn down $962,000 of Working Capital Loans from the Sponsor (see Note 4).The Company anticipates that the cash held outside of the Trust Account in the amount of $105,038 as of March 31, 2023 will not be sufficient to allow the Company to operate for at least the next 12 months from the issuance of the financial statements, assuming that a business combination is not consummated during that time. The Company has incurred and expects to continue to incur significant costs in pursuit of its acquisition plans. These conditions raise substantial doubt about the Company’s ability to continue as a going concern for a period of time within one year after the date that the financial statements are issued. Management plans to address this uncertainty through the initial business combination as discussed above. There is no assurance that the Company’s plans to consummate an initial business combination will be successful or successful within the Combination Period. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.	Note 1 — Organization and Business Operations Organization and General Chavant Capital Acquisition Corp. (the “Company”) was incorporated as a Cayman Islands exempted company on March 19, 2021. The Company was formed for the purpose of effectuating a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses (the “Business Combination”). The Company is an early stage and emerging growth company and, as such, the Company is subject to all of the risks associated with early stage and emerging growth companies. As of December 31, 2022, the Company had not commenced any operations. All activity through December 31, 2022 relates to the Company’s formation and its Initial Public Offering (“IPO”) which is described below, and identifying a target company for a Business Combination. The Company will not generate any operating revenues until after the completion of a Business Combination. The Company generates non-operating income in the form of interest income from the proceeds derived from the IPO. The Company has selected December 31 as its fiscal year end. On November 15, 2022, the Company and Mobix Labs, Inc. (“Mobix Labs”) entered into a business combination agreement, by and among the Company, Mobix Labs and CLAY Merger Sub II, Inc., a Delaware corporation and newly formed, wholly-owned direct subsidiary of the Company (“Merger Sub”), pursuant to which Merger Sub will be merged with and into Mobix Labs, with Mobix Labs surviving the merger as a wholly-owned direct subsidiary of the Company (the “Proposed Mobix Labs Transaction”). The Proposed Mobix Labs Transaction may be terminated by the Company and/or Mobix Labs under certain circumstances at any time prior to the closing as further described in Note 6 - Commitments and Contingencies. If the Proposed Mobix Labs Transaction occurs, the combined company will be named Mobix Labs, Inc., and its common stock and warrants are expected to be listed on Nasdaq. In connection with the Proposed Mobix Labs Transaction, the Company entered into a subscription agreement (the “PIPE Subscription Agreement”) with an investor (the “PIPE Investor”), pursuant to which the PIPE Investor agreed to purchase 3,000,000 shares of Class A Common Stock at $10.00 per share for an aggregate amount of $ 30,000,000 (the “PIPE”), subject to, among other things, the approval of the Proposed Mobix Labs Transaction by the Company’s shareholders and the satisfaction of the conditions set forth in the business combination agreement, including a Form S-4 registration statement being declared effective by the SEC. See Note 6 for further discussion of the accounting for the PIPE, including the embedded Make-Whole Features, as defined and described in such note. Financing The Company’s Sponsor is Chavant Capital Partners LLC, a Delaware limited liability company (the “Sponsor”). The registration statement pursuant to which the Company registered its securities offered in the IPO was declared effective on July 19, 2021.On April 7, 2021, the Sponsor purchased an aggregate of 2,875,000 ordinary shares (the “Founder Shares”) for a purchase price of $25,000 , or approximately $0.009 per share. On June 25, 2021, the Sponsor sold an aggregate of 422,581 of such Founder Shares to the underwriters for a purchase price of $3,675 . On July 22, 2021, the Company consummated its IPO of 8,000,000 Units (each, a “Unit” and collectively, the “Units”), at $10.00 per Unit, generating gross proceeds of $80,000,000 and incurring offering costs of $2,058,249 . The Company granted the underwriters a 45-day option to purchase up to an additional 1,200,000 Units at the IPO price to cover over-allotments, if any. On September 5, 2021, the over-allotment expired unexercised and an aggregate of 300,000 Founder Shares was forfeited, resulting in 2,000,000 Founder Shares remaining outstanding (See Note 7). Simultaneously with the consummation of the closing of the IPO, the Company consummated the private placement of an aggregate of 3,400,000 warrants (each, a “Private Warrant” and collectively, the “Private Warrants” and, together with the Public Warrants, the “Warrants”) at an average price of $1.00 per Private Warrant to the Sponsor and the underwriters, generating total gross proceeds of $3,400,000 (the “Private Placement”). Trust Account Following the closing of the IPO on July 22, 2021, an amount of $80,000,000 from the net proceeds of the sale of the Units in the IPO and the sale of the Private Warrants was placed in the trust account (the “Trust Account”) located in the United States with Continental Stock Transfer & Trust Company acting as trustee. The funds may be invested only in U.S. government securities with a maturity of 185 days or less or in money market funds meeting certain conditions under Rule 2a-7 under the Investment Company Act of 1940 (as amended, the “Investment Company Act”) which invest only in direct U.S. government treasury obligations. On July 14, 2022, the Company held an Extraordinary General Meeting (the “Meeting”) of shareholders and obtained shareholder approval of the extension of the date by which the Company must consummate an initial Business Combination from July 22, 2022 to January 22, 2023 (the “Extended Date”) by amending the Company’s amended and restated memorandum and articles of association (the “Amended and Restated Memorandum and Articles of Association”) (such amendment, the “First Extension Amendment”). The First Extension Amendment became effective upon approval of the Company’s shareholders. In connection with the First Extension Amendment, shareholders holding 7,046,967 ordinary shares of the Company exercised their right to redeem their ordinary shares for a pro rata portion of the funds in the Trust Account. As a result, $70,573,278 was deducted from the Trust Account to pay such holders. As a result of redemption payments and above-mentioned extensions, the Company deposited $31,450 (at a rate of $ 0.033 per non-redeeming Public Share) for each subsequent monthly period needed by the Company to complete a Business Combination by the Extended Date. As of December 31, 2022, the Company deposited an aggregate of $ 188,700 in the Trust Account which were funded by the promissory notes issued to the Sponsor. On January 6, 2023, the Company held an extraordinary general meeting of shareholders and obtained shareholder approval of the extension of the Business Combination period to July 22, 2023 (“Second Extension”). In connection with the meeting, Public Shareholders holding 96,991 Public Shares elected to exercise their right to redeem such shares and $1,004,600 was paid out of the Trust Account in connection with the redemptions. In connection with the approval of the extension amendment, the Company made an initial deposit into the Trust Account of $42,802 (at a rate of $0.05 per non-redeeming Public Share per month) and will continue to deposit $42,802 for each subsequent monthly period, or portion thereof, that is needed by the Company to complete a Business Combination by July 22, 2023. As of March 30, 2023, the Company had deposited an aggregate of $317,107 in the Trust Account in connection with the First Extension Amendment and the Second Extension, and the Trust Account had a total balance of approximately $ 9,090,881 . The funds held in the Trust Account will not be released from the Trust Account until the earliest of (i) the completion of our initial Business Combination, (ii) the redemption of any of Public Shares properly submitted in connection with a shareholder vote to amend our Amended and Restated Memorandum and Articles of Association (A) to modify the substance or timing of our obligation to redeem 100 % of the Public Shares if we do not complete our initial Business Combination by July 22, 2023 (or within any extended period of time that we may have to consummate an initial Business Combination as a result of an amendment to our Amended and Restated Memorandum and Articles of Association) or (B) with respect to any other material provisions relating to shareholders’ rights or pre-initial Business Combination activity or (iii) the redemption of the Public Shares if we are unable to complete the Proposed Mobix Labs Transaction or another or any other initial Business Combination by July 22, 2023 (or by the end of any such extended period of time), subject to applicable law. The proceeds deposited in the Trust Account could become subject to the claims of our creditors, if any, which could have priority over the claims of our Public Shareholders. The proceeds held in the Trust Account will be invested only in U.S. government treasury obligations with a maturity of 185 days or less or in money market funds meeting certain conditions under Rule 2a-7 under the Investment Company Act that invest only in direct U.S. government treasury obligations. The Company’s management has broad discretion with respect to the specific application of the net proceeds of the IPO and the sale of Private Warrants, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination. Initial Business Combination The Company is not limited to a particular industry or sector for purposes of consummating a Business Combination. There is no assurance that the Company will be able to complete a Business Combination successfully. The Company must complete one or more initial Business Combinations having an aggregate fair market value of at least 80% of the net assets held in the Trust Account (net of taxes payable) at the time of the signing of a definitive agreement to enter into an initial Business Combination. However, the Company will only complete a Business Combination if the post-transaction company owns or acquires 50% or more of the outstanding voting securities of the target or otherwise acquires a controlling interest in the target sufficient for it not to be required to register as an investment company under the Investment Company Act 1940. The Company will provide holders (the “Public Shareholders”) of its ordinary shares sold in the IPO (the “Public Shares”) with the opportunity to redeem all or a portion of their Public Shares upon the completion of a Business Combination either (i) in connection with a general meeting called to approve the Business Combination or (ii) without a shareholder vote by means of a tender offer. The decision as to whether the Company will seek shareholder approval of a Business Combination or conduct a tender offer will be made by the Company, solely in its discretion. The Public Shareholders will be entitled to redeem their Public Shares for a pro rata portion of the amount then on deposit in the Trust Account (initially anticipated to be $10.00 per Public Share). These Public Shares were classified as temporary equity upon the completion of the IPO in accordance with the Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) Topic 480, “Distinguishing Liabilities from Equity.” In such case, the Company will proceed with a Business Combination if the Company has net tangible assets of at least $5,000,001 upon such consummation of a Business Combination and a majority of the shares voted are voted in favor of the Business Combination. If a shareholder vote is not required by law and the Company does not decide to hold a shareholder vote for business or other legal reasons, the Company will, pursuant to its Amended and Restated Memorandum and Articles of Association, conduct the redemptions pursuant to the tender offer rules of the U.S. Securities and Exchange Commission (“SEC”) and file tender offer documents with the SEC prior to completing a Business Combination. If, however, shareholder approval of the Proposed Mobix Labs Transactions is required by law, or the Company decides to obtain shareholder approval for business or legal reasons, the Company will offer to redeem shares in conjunction with a proxy solicitation pursuant to the proxy rules and not pursuant to the tender offer rules. Additionally, each Public Shareholder may elect to redeem their Public Shares irrespective of whether they vote for or against the Proposed Mobix Labs Transaction, whether they participate in or abstain from voting, or whether they were a shareholder on the record date for the general meeting held to approve the Proposed Mobix Labs Transaction. If the Company seeks shareholder approval in connection with a Business Combination, the initial shareholders, Sponsor, officers and directors (the “Initial Shareholders”) have agreed to vote their Founder Shares (as defined below in Note 5) and any Public Shares purchased during or after the IPO in favor of a Business Combination. The Company has adopted an insider trading policy which requires insiders to: (i) refrain from purchasing shares during certain blackout periods and when they are in possession of any material non-public information and (ii) to clear all trades with the Company’s legal counsel prior to execution. In addition, the Initial Shareholders have agreed to waive their redemption rights with respect to their Founder Shares and Public Shares in connection with the completion of a Business Combination. Notwithstanding the foregoing, the Amended and Restated Memorandum and Articles of Association provides that a Public Shareholder, together with any affiliate of such shareholder or any other person with whom such shareholder is acting in concert or as a “group” (as defined under Section 13 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), will be restricted from redeeming its shares with respect to more than an aggregate of 15% or more of the ordinary shares sold in the IPO, without the prior consent of the Company. The Company has entered into a letter agreement with its Initial Shareholders, pursuant to which the Initial Shareholders have agreed to not to propose an amendment to the Amended and Restated Memorandum and Articles of Association that would modify the substance or timing of the Company’s obligation to redeem 100% of its Public Shares if the Company does not complete a Business Combination, unless the Company provides the Public Shareholders with the opportunity to redeem their ordinary shares in conjunction with any such amendment. Liquidation On July 14, 2022, the Company obtained shareholder approval to extend the date by which the Company must consummate an initial Business Combination from July 22, 2022 to January 22, 2023. On January 6, 2023, the Company obtained shareholder approval to further extend the date to July 22, 2023. If the Company is unable to complete the Proposed Mobix Labs Transaction or any other initial Business Combination by the Second Extended Date (the “Combination Period”), the Company will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than ten business days thereafter, redeem the Public Shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned on the funds held in the Trust Account (less taxes payable and up to $100,000 of interest to pay dissolution expenses), divided by the number of then issued and outstanding Public Shares, which redemption will completely extinguish Public Shareholders’ rights as shareholders (including the right to receive further liquidation distributions, if any) and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the remaining shareholders and the board of directors, liquidate and dissolve, subject, in each case, to the Company’s obligations under Cayman Islands law to provide for claims of creditors and in all cases subject to the other requirements of applicable law. There will be no redemption rights or liquidating distributions with respect to the Warrants, which will expire worthless if the Company fails to complete its initial Business Combination within the Combination Period. The Company’s Initial Shareholders have agreed to waive their liquidation rights with respect to the Founder Shares if the Company fails to complete a Business Combination within the Combination Period. However, if the Company’s Initial Shareholders acquire Public Shares in or after the IPO, they will be entitled to liquidating distributions from the Trust Account with respect to such Public Shares if the Company fails to complete a Business Combination within the Combination Period. In the event of such distribution, it is possible that the per share value of the residual assets remaining available for distribution (including Trust Account assets) will be only $10.00 per share initially held in the Trust Account. In order to protect the amounts held in the Trust Account, the Sponsor has agreed to be liable to the Company if and to the extent any claims by a vendor for services rendered or products sold to the Company, or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amount of funds in the Trust Account. This liability will not apply with respect to any claims by a third party who executed a waiver of any right, title, interest or claim of any kind in or to any monies held in the Trust Account or to any claims under the Company’s indemnity of the underwriters of the IPO against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the “Securities Act”). Moreover, in the event that an executed waiver is deemed to be unenforceable against a third party, the Sponsor will not be responsible to the extent of any liability for such third-party claims. The Company will seek to reduce the possibility that the Sponsor will have to indemnify the Trust Account due to claims of creditors by endeavoring to have all vendors, service providers, except the independent registered public accounting firm, prospective target businesses or other entities with which the Company does business, execute agreements with the Company waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account. Liquidity and Capital Resources; Going Concern The Company’s liquidity needs prior to the consummation of the IPO were satisfied through the proceeds of $25,000 from the sale of 2,000,000 Founder Shares (Note 7). Subsequent to the consummation of the IPO, the Company’s liquidity needs have been satisfied through the net proceeds from the Private Placement held outside of the Trust Account and the proceeds of the loans described below. In order to fund working capital deficiencies or finance transaction costs in connection with a Business Combination, our Sponsor or an affiliate of our Sponsor or certain of our officers and directors may, but are not obligated to, loan us funds as may be required. If we complete a Business Combination, we may repay such loaned amounts out of the proceeds of the Trust Account released to us. In the event that a Business Combination does not close, we may use a portion of the working capital held outside the Trust Account to repay such loaned amounts, but no proceeds from our Trust Account would be used for such repayment. Up to $1,500,000 of such loans may be convertible into warrants, at a price of $1.00 per warrant, at the option of the lender. The warrants would be identical to the Private Warrants. As of December 31, 2022, the Company has drawn down $662,000 under the Working Capital Loans (as defined in Note 5). The Company anticipates that the cash held outside of the Trust Account in the amount of $ 175,788 as of December 31, 2022 will not be sufficient to allow the Company to operate for at least the next 12 months from the issuance of the financial statements, assuming that a Business Combination is not consummated during that time. The Company has incurred and expects to continue to incur significant costs in pursuit of its acquisition plans. These conditions raise substantial doubt about the Company's ability to continue as a going concern for a period of time within one year after the date that the financial statements are issued. Management plans to address this uncertainty through the initial Business Combination as discussed above. There is no assurance that the Company's plans to consummate an initial Business Combination will be successful or successful within the Combination Period. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended	12 Months Ended
Summary of Significant Accounting Policies	Mar. 31, 2023	Dec. 31, 2022
Summary of Significant Accounting Policies
Summary of Significant Accounting Policies	Note 2 — Summary of Significant Accounting Policies Basis of Presentation The accompanying unaudited condensed financial statements are presented in U.S. dollars in conformity with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X of the SEC. Certain information or footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a complete presentation of financial position, results of operations, or cash flows. In the opinion of management, the unaudited condensed financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances and results for the periods presented. The interim results for the three months ended March 31, 2023 are not necessarily indicative of the results that may be expected through December 31, 2023. The accompanying unaudited condensed financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company’s annual report on Form 10-K filed with the SEC on March 31, 2023. Emerging Growth Company The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002. Section 102(b)(1) of the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”) exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that an emerging growth company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such an election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statements with another public company that is neither an emerging growth company nor an emerging growth company that has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. Fair Value of Financial Instruments The fair value of the Company’s assets and liabilities which qualify as financial instruments under ASC 820, “Fair Value Measurement,” other than the warrant liability and the PIPE derivative liability (as defined in Note 5), approximate the carrying amounts represented in the Company’s balance sheets, primarily due to their short-term nature. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates. Cash Equivalents Cash equivalents include cash on hand and on deposit at banking institutions as well as all highly liquid short-term investments with original maturities of 90 days or less. The Company did not have any cash equivalents as of March 31, 2023 and December 31, 2022. Investments Held in Trust Account As of March 31, 2023, the assets held in the Trust Account were held in cash and U.S. Treasury Securities with maturities of six months or shorter. The Company classifies its investment in money market funds as trading securities. Trading securities are presented on the balance sheets at fair value at the end of each reporting period. Gains and losses resulting from the change in fair value of investments held in the Trust Account are included in trust interest income in the accompanying statements of operations. The estimated fair values of investments held in the Trust Account are determined using available market information. Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed the Federal Deposit Insurance Corporation coverage. The Company has not experienced losses on these accounts. Warrants The Company accounts for warrants based on an assessment of specific terms and applicable authoritative guidance in ASC 480 and ASC 815, “Derivatives and Hedging” (“ASC 815”). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company’s own ordinary shares and whether the warrant holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent reporting period while the warrants are outstanding. Because the Company does not control the occurrence of events, such as a tender offer or exchange, that may trigger cash settlement of the Private Warrants where not all of the shareholders also receive cash, the Private Warrants do not meet the criteria for equity treatment thereunder; as such, the Private Warrants must be recorded as a derivative liability. For issued warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as non-cash gain or loss on the statements of operations. The Company’s Public Warrants are accounted for as equity and Private Warrants are accounted for as a liability. The Private Warrants were recorded at fair value as of July 22, 2021, the closing date of the IPO, and are re-valued at each reporting date, with changes in the fair value reported in the statements of operations. Ordinary Shares Subject to Possible Redemption The Company accounts for its Public Shares in accordance with the guidance in ASC 480. Ordinary shares subject to mandatory redemption (if any) are classified as a liability instrument and are measured at fair value. Conditionally redeemable ordinary shares (including shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) are classified as temporary equity. At all other times, ordinary shares are classified as shareholders’ equity. The Company’s ordinary shares subject to possible redemption feature certain redemption rights that are considered to be outside of the Company’s control and subject to the occurrence of uncertain future events. Accordingly, as of March 31, 2023 and December 31, 2022, 856,042 and 953,033 ordinary shares, respectively, subject to possible redemption are presented, at redemption value, as temporary equity, outside of the shareholders’ deficit section of the Company’s balance sheet. The Company recognizes changes in redemption value immediately as they occur and adjusts the carrying value of redeemable ordinary shares to equal the redemption value at the end of each reporting period. Such changes are reflected in additional paid-in capital, or in the absence of additional capital, in accumulated deficit. In connection with the extensions of the business combination period on July 14, 2022 and January 6, 2023, Public Shareholders elected to redeem an aggregate of 7,046,967 Public Shares and 96,991 Public Shares, respectively. As a result, $70,573,278 and $1,004,600 were paid out of the Trust Account in connection with the redemptions, respectively. During the three months ended March 31, 2023, the Company recorded an accretion of $261,713 composed of $128,407 (extension funds deposited into the Trust Account) and $133,306 (total of interest income and unrealized gain exceeding the $100,000 that can be withheld to pay dissolution expenses), and $261,713 was recorded in accumulated deficit. Derivative Financial Instruments The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with ASC 815. The Company’s derivative instruments were recorded at fair value as of July 22, 2021, the closing date of the IPO, and will be re-valued at each reporting date, with changes in the fair value reported in the statements of operations. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. The PIPE derivative liability is comprised of the Make-Whole Features. The PIPE derivative liability meets the criteria for derivative liability classification. As such, the PIPE derivative liability is recorded at its initial fair value on the date of issuance and each balance sheet date thereafter. Changes in the estimated fair value of the derivative liability are recognized in the statements of operations. Income Taxes The Company follows the asset and liability method of accounting for income taxes under ASC 740, “Income Taxes.” Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that included the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. There were no unrecognized tax benefits as of March 31, 2023 and December 31, 2022. The Company’s management determined that the Cayman Islands is the Company’s only major tax jurisdiction. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. No amounts were accrued for the payment of interest and penalties for the three months ended March 31, 2023 and 2022. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company is subject to income tax examinations by major taxing authorities since inception. The Company is considered to be an exempted Cayman Islands company with no connection to any other taxable jurisdiction and is presently not subject to income taxes or income tax filing requirements in the Cayman Islands or the United States. As such, the Company’s tax provision was zero for the period presented. While the Company is not expected to be subject to United States taxation (other than as a result of a business combination involving a U.S. target), the Company may become subject to United States taxation if it were or deemed to be engaged in a United States trade or business. Any interest payable in respect of U.S. debt obligations (if any) held by the Trust Account is intended to qualify for the portfolio interest exemption or otherwise be exempt from U.S. withholding taxes. Furthermore, shareholders of the Company’s shares may be subject to tax in their respective jurisdictions based on applicable law, for instance, United States persons may be subject to tax on amounts deemed received depending on whether the Company is a passive foreign investment company and whether U.S. persons have made any applicable tax elections permitted under applicable law. Net Income (Loss) Per Share Net income (loss) per ordinary share is calculated by dividing the net income (loss) by the weighted average ordinary shares outstanding for the respective period. With respect to the accretion of ordinary shares subject to possible redemption and consistent with ASC 480-10-S99-3A, “Distinguishing Liabilities and Equity — Overall — SEC Materials,” the Company treated accretion in the same manner as a dividend, paid to the shareholder in the calculation of the net income (loss) per ordinary share. Net income (loss) per share is computed by dividing net loss by the weighted average number of ordinary shares outstanding during the period, excluding ordinary shares forfeited. The Company has not considered the effect of (1) the 9,400,000 ordinary shares issuable upon exercise of the Public Warrants and Private Warrants, and (2) the PIPE in the calculation of diluted loss per share, since the exercise of such Warrants and PIPE are contingent upon the occurrence of future events and the inclusion of such Warrants and PIPE would be anti-dilutive. As a result, diluted loss per share is the same as basic loss per share for the period presented. The Company’s statement of operations includes a presentation of net income (loss) per share for ordinary shares subject to possible redemption in a manner similar to the two-class method of net income (loss) per share. As of March 31, 2023, the Company has 856,042 ordinary shares subject to possible redemption and 2,000,000 Founder Shares. For the three months ended March 31, 2023, earnings and losses are allocated pro rata based on the weighted average of ordinary shares outstanding for the respective period, reflective of the respective participation rights, between the two classes of ordinary shares. The net income (loss) per share (unaudited) presented in the statements of operations is based on the following: For the three months ended For the three months ended March 31, 2023 March 31, 2022 Net (loss) income $ (312,060) $ 604,359 Accretion of temporary equity to redemption value (261,713) — Net (loss) income including accretion of temporary equity to redemption value $ (573,773) $ 604,359 Public Shares Founder Shares Public Shares Founder Shares Basic and diluted net income per share: 873,285 2,000,000 8,000,000 2,000,000 Ownership percentage 30 % 70 % 80 % 20 % Numerator: Net income (loss) including accretion of temporary equity to redemption value $ (174,388) $ (399,384) $ 483,487 $ 120,872 Plus: Accretion applicable to the redeemable class $ 261,713 — — — Allocation of net income (loss) $ 87,325 $ (399,384) $ 483,487 $ 120,872 Denominator: Weighted-average shares outstanding 873,285 2,000,000 8,000,000 2,000,000 Basic and diluted net income (loss) per share: $ 0.10 $ (0.20) $ 0.06 $ 0.06 Risks and Uncertainties In February 2022, the Russian Federation commenced a military action with the country of Ukraine. Although the length and impact of the ongoing military conflict is highly unpredictable, the conflict in Ukraine could lead to market disruptions, including significant volatility in commodity prices, credit and capital markets, as well as supply chain interruptions. As a result of this action, various nations, including the United States, have instituted economic sanctions against the Russian Federation. Further, the impact of this action and related sanctions on the world economy are not determinable as of the date of these financial statements. Recent Accounting Pronouncements The Company does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Company’s financial statements.	Note 2 — Summary of Significant Accounting Policies Basis of Presentation The accompanying financial statements are presented in conformity with accounting principles generally accepted in the United States of America (“GAAP”) and pursuant to the rules and regulations of the SEC. Emerging Growth Company The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002. Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that an emerging growth company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such an election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statements with another public company that is neither an emerging growth company nor an emerging growth company that has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. Fair Value of Financial Instruments The fair value of the Company’s assets and liabilities which qualify as financial instruments under ASC Topic 820, “Fair Value Measurement”, other than warrant liability (see Note 8), approximate the carrying amounts represented in the Company’s balance sheet, primarily due to their short-term nature. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates. Offering Costs associated with the IPO Offering costs consist principally of professional and registration fees incurred through the balance sheet date that are directly attributable to the IPO. Offering costs are allocated based on relative fair value to the ordinary shares subject to possible redemption and Public Warrants. Cash Cash and cash equivalents include cash on hand and on deposit at banking institutions as well as all highly liquid short-term investments with original maturities of 90 days or less. The Company did not have any cash equivalents as of December 31, 2022 and 2021. Investments Held in Trust Account As of December 31, 2022, the assets held in the Trust Account were held in money market funds which invest only in U.S. Treasury Securities. The Company classifies its investment in money market funds as trading securities. Trading securities are presented on the balance sheets at fair value at the end of each reporting period. Gains and losses resulting from the change in fair value of investments held in the Trust Account are included in trust interest income in the accompanying statements of operations. The estimated fair values of investments held in the Trust Account are determined using available market information. As of December 31, 2022 and 2021, the Company had $ 9,835,409 and $ 80,002,777 in investments held in the Trust Account, respectively. At the Meeting on July 14, 2022, shareholders holding 7,046,967 ordinary shares exercised their right to redeem their ordinary shares for a pro rata portion of the funds in the Trust Account and $70,573,278 was removed from the Trust Account to pay such holders. At the meeting on January 6, 2023, shareholders holding 96,991 ordinary shares exercised their right to redeem their ordinary shares for a pro rata portion of the funds in the Trust Account and $1,004,600 (approximately $10.36 per ordinary share) was removed from the Trust Account to pay such holders. Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed the Federal Deposit Insurance Corporation coverage of $250,000 . The Company has not experienced losses on these accounts. Warrants The Company accounts for warrants based on an assessment of specific terms and applicable authoritative guidance in the FASB’s ASC 480, “Distinguishing Liabilities from Equity” and ASC 815, “Derivatives and Hedging.” The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company’s own ordinary shares and whether the warrant holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent reporting period while the warrants are outstanding. Because the Company does not control the occurrence of events, such as a tender offer or exchange, that may trigger cash settlement of the Private Warrants where not all of the shareholders also receive cash, the Private Warrants do not meet the criteria for equity treatment thereunder; as such, the Private Warrants must be recorded as derivative liability. For issued warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as non-cash gain or loss on the statements of operations. The Company’s Public Warrants (Note 7) are accounted for as equity, and the Private Warrants (Note 4) are accounted for as liabilities. The Private Warrants were recorded at fair value as of July 22, 2021, the closing date of the IPO, and are re-valued at each reporting date, with changes in the fair value reported in the statements of operations. Ordinary Shares Subject to Possible Redemption The Company accounts for its ordinary shares subject to possible redemption (“Public Shares”) in accordance with the guidance in ASC 480. Ordinary shares subject to mandatory redemption (if any) are classified as a liability instrument and is measured at fair value. Conditionally redeemable ordinary shares (including shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) is classified as temporary equity. At all other times, ordinary shares are classified as shareholders' equity. The Company’s ordinary shares subject to possible redemption feature certain redemption rights that are considered to be outside of the Company’s control and subject to the occurrence of uncertain future events. Accordingly, as of December 31, 2022 and 2021, 953,033 and 8,000,000 ordinary shares subject to possible redemption, respectively, are presented, at redemption value, as temporary equity, outside of the shareholders' deficit section of the Company’s balance sheet. The Company recognizes changes in redemption value immediately as they occur and adjusts the carrying value of redeemable ordinary shares to equal the redemption value at the end of each reporting period. Such changes are reflected in additional paid-in capital, or in the absence of additional capital, in accumulated deficit. On July 22, 2021, the Company recorded an accretion of $6,793,210 , $5,371,731 of which was recorded in additional paid-in capital and $1,421,479 was recorded in accumulated deficit. In connection with the extension of the Business Combination period on July 14, 2022, Public Shareholders elected to redeem an aggregate of 7,046,967 Public Shares. As a result, $ 70,573,278 was paid out of the Trust Account in connection with the redemptions. For the year ended December 31, 2022, the Company recorded an accretion of $ 188,700 (extension funds deposited into the Trust Account) and $ 119,987 (interest income over $ 100,000 ) and $ 308,687 was recorded in accumulated deficit. Derivative Financial Instruments The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with ASC 815. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value on the issuance date and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. The PIPE Derivative Liability is comprised of the Make-Whole Features (as defined in Note 6). The PIPE Derivative Liability meets the criteria for derivative liability classification. As such, the PIPE Derivative Liability is recorded at its initial fair value on the date of issuance and each balance sheet date thereafter. Changes in the estimated fair value of the derivative liability are recognized as non-cash gain or loss on the statements of operations. The fair value of the derivative liability is discussed in Note 8. Income Taxes The Company follows the asset and liability method of accounting for income taxes under FASB ASC 740, “Income Taxes.” Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that included the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. There were no unrecognized tax benefits as of December 31, 2022. The Company’s management determined that the Cayman Islands is the Company’s only major tax jurisdiction. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. No amounts were accrued for the payment of interest and penalties for the period from March 19, 2021 (inception) through December 31, 2021 and for the year ended December 31, 2022. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company is subject to income tax examinations by major taxing authorities since inception. The Company is considered to be an exempted Cayman Islands company with no connection to any other taxable jurisdiction and is presently not subject to income taxes or income tax filing requirements in the Cayman Islands or the United States. As such, the Company’s tax provision was zero for the period presented. While the Company is not expected to be subject to United States taxation (other than as a result of a Business Combination involving a U.S. target), the Company may become subject to United States taxation if it were or deemed to be engaged in a United States trade or business. Any interest payable in respect of U.S. debt obligations (if any) held by the Trust Account is intended to qualify for the portfolio interest exemption or otherwise be exempt from U.S. withholding taxes. Furthermore, shareholders of the Company’s shares may be subject to tax in their respective jurisdictions based on applicable law, for instance, United States persons may be subject to tax on amounts deemed received depending on whether the Company is a passive foreign investment company and whether U.S. persons have made any applicable tax elections permitted under applicable law. Net Income (Loss) Per Share Net income (loss) per share is computed by dividing net loss by the weighted average number of ordinary shares outstanding during the period, excluding ordinary shares forfeited. The Company has not considered the effect of (1) the 9,400,000 ordinary shares issuable upon exercise of the Public Warrants and Private Warrants, and (2) the PIPE in the calculation of diluted loss per share, since the exercise of such Warrants and PIPE are contingent upon the occurrence of future events and the inclusion of such Warrants and PIPE would be anti-dilutive. As a result, diluted loss per share is the same as basic loss per share for the period presented. The Company’s statement of operations includes a presentation of net income (loss) per share for ordinary shares subject to possible redemption in a manner similar to the two-class method of net income (loss) per share. As of December 31, 2022, the Company has 953,033 ordinary shares subject to possible redemption and 2,000,000 Founder Shares. For the year ended, December 31, 2022, earnings and losses are adjusted for the effects of accretion to ordinary shares subject to possible redemption and are allocated pro rata, reflective of the respective participation rights, between the two classes of ordinary shares. The net income (loss) per share presented in the statements of operations is based on the following: From March 19, 2021 For the Year ended (inception) through December 31, 2022 December 31, 2021 Net loss from inception to IPO date in year 2021 $ — $ (85,612) Net income from IPO date to year-end (total loss from inception to 12/31/2021) less the loss from inception to IPO) — 446,671 Net income (loss) $ (776,129) $ 361,059 Accretion of temporary equity to redemption value (308,687) (6,793,210) Net income (loss) including accretion of temporary equity to redemption value $ (1,084,816) $ (6,432,151) For the Year ended From March 19, 2021 (inception) through December 31, 2022 December 31, 2021 Public Shares Founder Shares Public Shares Founder Shares Basic and diluted net income per share: Total number of shares 4,795,078 2,000,000 8,000,000 2,000,000 Ownership percentage 71 % 29 % 80 % 20 % Numerator: Allocation of net loss – inception to IPO date $ — $ — $ — $ (85,612) Allocation of net income – IPO date to year end (allocated based on ownership percentage) — — 357,337 89,334 Total net income allocation $ — $ — $ 357,337 $ 3,722 Net income (loss) including accretion of temporary equity to redemption value (765,521) (319,295) (5,434,568) (1,358,642) Plus: Accretion applicable to the redeemable class 308,687 — 6,793,210 — Allocation of net income (loss) $ (456,834) $ (319,295) $ 1,715,979 $ (1,354,920) Denominator: Weighted-average shares outstanding 4,795,078 2,000,000 4,527,778 1,868,056 Basic and diluted net income (loss) per share: $ (0.10) $ (0.16) $ 0.38 $ (0.73) Risks and Uncertainties In February 2022, the Russian Federation commenced a military action with the country of Ukraine. Although the length and impact of the ongoing military conflict is highly unpredictable, the conflict in Ukraine could lead to market disruptions, including significant volatility in commodity prices, credit and capital markets, as well as supply chain interruptions. As a result of this action, various nations, including the United States, have instituted economic sanctions against the Russian Federation. Further, the impact of this action and related sanctions on the world economy are not determinable as of the date of these financial statements. Recent Accounting Pronouncements The Company does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Company’s financial statements.

Initial Public Offering

Initial Public Offering	12 Months Ended
Initial Public Offering	Dec. 31, 2022
Initial Public Offering
Initial Public Offering	Note 3 — Initial Public Offering Pursuant to the IPO on July 22, 2021, the Company sold 8,000,000 Units at a price of $10.00 per Unit, generating gross proceeds of $80,000,000 . Each Unit consists of one ordinary share and three-quarters of one redeemable warrant (each, a “Public Warrant”). Each whole Public Warrant entitles the holder to purchase one ordinary share at a price of $11.50 per share, subject to adjustment (see Note 7). The Company incurred offering costs of $2,058,249 , consisting of $1,600,000 of underwriting discounts and commissions and $458,249 of costs related to the IPO.

Private Placement

Private Placement	3 Months Ended	12 Months Ended
Private Placement	Mar. 31, 2023	Dec. 31, 2022
Private Placement
Private Placement	Note 3 — Private Placement Simultaneously with the closing of the IPO, the Sponsor and the underwriters purchased an aggregate of 3,400,000 Private Warrants at an average price of $1.00 per Private Warrant, for an aggregate purchase price of $3,400,000 . Each Private Warrant will entitle the holder to purchase one ordinary share at a price of $11.50 per full share, subject to adjustment. The proceeds from the Private Warrants and the proceeds from the IPO, less underwriting discounts and commissions, were placed in the Trust Account. If the Company does not complete a business combination within the Combination Period, the proceeds from the sale of the Private Warrants will be used to fund the redemption of the Public Shares (subject to the requirements of applicable law). Private Warrant Liability The Company accounts for the Private Warrants as a liability as the number of shares used to calculate the settlement amount are not fixed. This liability is subject to re-measurement at each balance sheet date until exercised, and any change in fair value is recognized in the Company’s statements of operations.	Note 4 — Private Placement Simultaneously with the closing of the IPO , the Sponsor and the underwriters purchased an aggregate of 3,400,000 Private Warrants at an average price of $1.00 per Private Warrant, for an aggregate purchase price of $3,400,000 . Each Private Warrant will entitle the holder to purchase one ordinary share at a price of $11.50 per full share, subject to adjustment (see Note 7). The proceeds from the Private Warrants and the proceeds from the IPO, less underwriting discounts and commissions, were placed in the Trust Account. If the Company does not complete a Business Combination within the Combination Period, the proceeds from the sale of the Private Warrants will be used to fund the redemption of the Public Shares (subject to the requirements of applicable law). Private Warrant Liability The Company accounts for the Private Warrants as liabilities as the number of shares used to calculate the settlement amount are not fixed. This liability is subject to re-measurement at each balance sheet date until exercised, and any change in fair value is recognized in the Company’s statements of operations.

Related Party Transactions

Related Party Transactions	3 Months Ended	12 Months Ended
Related Party Transactions	Mar. 31, 2023	Dec. 31, 2022
Related Party Transactions
Related Party Transactions	Note 4 – Related Party Transactions Founder Shares The Company’s Initial Shareholders have agreed, subject to limited exceptions, not to transfer, assign or sell any of their Founder Shares until the earlier to occur of: (i) one year after the completion of the initial business combination or (ii) the date following the completion of the initial business combination on which the Company completes a liquidation, merger, share exchange or other similar transaction that results in all of the shareholders having the right to exchange their ordinary shares for cash, securities or other property. Notwithstanding the foregoing, if the closing price of the ordinary shares equals or exceeds $12.00 per share (as adjusted for share subdivisions, share capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within any 30 - trading day period commencing at least 150 days after the initial business combination, the Founder Shares will be released from the lockup. Working Capital Loans In order to finance transaction costs in connection with a business combination, the Sponsor or an affiliate of the Sponsor, or certain of the Company’s officers and directors may, but are not obligated to, loan the Company funds as may be required (“Working Capital Loans”). Such Working Capital Loans would be evidenced by promissory notes. The notes may be repaid upon completion of a business combination, without interest, or, at the lender’s discretion, up to $1,500,000 of notes may be converted upon completion of business combination into warrants at a price of $1.00 per warrant. Such warrants would be identical to the Private Warrants. In the event that business combination does not close, the Company may use a portion of proceeds held outside the Trust Account to repay the Working Capital Loans but no proceeds held in the Trust Account would be used to repay the Working Capital Loans. On June 20, 2022, the Company issued an unsecured convertible promissory note in the aggregate principal amount of $360,000 to the Sponsor under which the Company may draw down Working Capital Loans from time to time prior to the maturity date up to such aggregate principal amount. On July 18, 2022, the Company issued an additional unsecured convertible promissory note in the aggregate principal amount of $490,000 to the Sponsor under which the Company may draw down Working Capital Loans from time to time prior to the maturity date up to such aggregate principal amount. Any Working Capital Loans under the promissory notes issued on June 20, 2022 and July 18, 2022 are due on the earlier of five business days after the Company’s initial business combination and December 31, 2023. On January 6, 2023, the Company issued an unsecured convertible promissory note in the aggregate principal amount of $300,000 to the Sponsor, under which the Company was permitted to draw down Working Capital Loans from time to time prior to the maturity date up to such aggregate principal amount, to fund the Company’s ongoing working capital requirements and to fund a portion of the amounts that the Company has agreed to deposit into the Company’s Trust Account as a result of obtaining shareholder approval of the extension amendment proposal. The Company drew down the full amount of the Working Capital Loans under such promissory note. The Working Capital Loan under this promissory note is due on the earlier of five business days after the Company’s initial business combination and July 31, 2024. As of March 31, 2023 and December 31, 2022, the Company had drawn down $962,000 and $662,000 , respectively, of Working Capital Loans under the promissory notes. Administrative Services Arrangement On July 26, 2021, the Company entered into an administrative services agreement with the Sponsor, effective as of the date that the Company’s securities were first listed on The Nasdaq Stock Market (“Nasdaq”), to make available to the Company certain general and administrative services, including office space, utilities and administrative services, as the Company may require from time to time. The Company has agreed to pay $10,000 per month for these services. Upon completion of the Company’s business combination or its liquidation, the Company will cease paying these monthly fees. For the three months ended March 31, 2023 and 2022, the Company incurred expenses of $30,000 and $30,000 under the administrative services agreement, respectively, of which $90,000 and $80,000 are included in accrued expenses as of March 31, 2023 and December 31, 2022, respectively.	Note 5 - Related Party Transactions Founder Shares The Initial Shareholders have agreed, subject to limited exceptions, not to transfer, assign or sell any of their Founder Shares until the earlier to occur of: (i) one year after the completion of the initial Business Combination or (ii) the date following the completion of the initial Business Combination on which the Company completes a liquidation, merger, share exchange or other similar transaction that results in all of the shareholders having the right to exchange their ordinary shares for cash, securities or other property. Notwithstanding the foregoing, if the closing price of the ordinary shares equals or exceeds $12.00 per share (as adjusted for share subdivisions, share capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within any 30 - trading day period commencing at least 150 days after the initial Business Combination, the Founder Shares will be released from the lockup. Promissory Note to Sponsor and Working Capital Loans On April 7, 2021, the Company issued an unsecured promissory note (the “Promissory Note”) to the Sponsor, pursuant to which the Company may borrow up to an aggregate principal amount of $200,000 to cover formation and operating expenses related to the IPO. The Promissory Note is non-interest bearing and payable on the earlier of (i) July 31, 2021 and (ii) the completion of the IPO. The outstanding balance of $129,602 was repaid on July 22, 2021. In order to finance transaction costs in connection with a Business Combination, the Sponsor or an affiliate of the Sponsor, or certain of the Company’s officers and directors may, but are not obligated to, loan the Company funds as may be required (“Working Capital Loans”). Such Working Capital Loans would be evidenced by promissory notes. The notes may be repaid upon completion of a Business Combination, without interest, or, at the lender’s discretion, up to $1,500,000 of notes may be converted upon completion of a Business Combination into warrants at a price of $1.00 per warrant. Such warrants would be identical to the Private Warrants. In the event that a Business Combination does not close, the Company may use a portion of proceeds held outside the Trust Account to repay the Working Capital Loans but no proceeds held in the Trust Account would be used to repay the Working Capital Loans. On June 20, 2022, the Sponsor provided the Company with a Working Capital Loan of $360,000 and the Company issued an unsecured convertible promissory note in the aggregate principal amount of $360,000 to the Sponsor. On July 18, 2022, the Sponsor provided the Company with a Working Capital Loan of $490,000 and the Company issued an unsecured convertible promissory note in the aggregate principal amount of $490,000 to the Sponsor. Any Working Capital Loans under the promissory notes issued on June 20, 2022 and July 18, 2022 are due on the earlier of five business days after the Company's initial Business Combination and December 31, 2023. As of December 31, 2022, the Company had drawn down $662,000 under the Working Capital Loans. On January 6, 2023, the Sponsor provided the Company with an additional Working Capital Loan of $300,000 , and the Company issued an unsecured convertible promissory note in the aggregate principal amount of $300,000 to the Sponsor to fund the Company's ongoing working capital requirements and to fund a portion of the amounts that the Company has agreed to deposit into the Company's Trust Account as a result of obtaining shareholder approval of the extension amendment proposal (See Note 9). The Working Capital Loan under this promissory note is due on the earlier of five business days after the Company's initial Business Combination and July 31, 2024. Administrative Services Arrangement On July 26, 2021, the Company entered into an administrative services agreement with the Sponsor, effective as of the date that the Company’s securities were first listed on The Nasdaq Stock Market LLC, to make available to the Company certain general and administrative services, including office space, utilities and administrative services, as the Company may require from time to time. The Company has agreed to pay $10,000 per month for these services. Upon completion of the Company’s Business Combination or its liquidation, the Company will cease paying these monthly fees. For the year ended December 31, 2022 and for the period from March 19, 2021 (inception) through December 31, 2021 the Company incurred expenses of $120,000 and $60,000 under this agreement, respectively, of which $80,000 and $10,000 are included in accrued expenses as of December 31, 2022 and 2021, respectively.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended	12 Months Ended
Commitments and Contingencies	Mar. 31, 2023	Dec. 31, 2022
Commitments and Contingencies
Commitments and Contingencies	Note 5 — Commitments and Contingencies Registration and Shareholder Rights Pursuant to a registration rights agreement entered into on July 19, 2021, the holders of Founder Shares, Private Warrants and warrants that may be issued upon conversion of Working Capital Loans (and any ordinary shares issuable upon the exercise of the Private Warrants and warrants that may be issued upon conversion of Working Capital Loans) are entitled to registration rights, requiring the Company to register such securities for resale. These holders will be entitled to certain demand and “piggyback” registration rights. However, the registration and shareholder rights agreement provide that the Company will not permit any registration statement filed under the Securities Act to become effective until the termination of the applicable lock-up period for the securities to be registered. The Company will bear the expenses incurred in connection with the filing of any such registration statements. Business Combination Marketing Agreement At the closing of the IPO and in connection with a business combination, the Company and the underwriters entered into an agreement (the “Business Combination Marketing Agreement”), whereby the underwriters are to assist the Company in holding meetings with the Company’s shareholders to discuss potential business combination targets and the target business’s attributes, introduce the Company to potential investors that are interested in purchasing the Company’s securities in connection with the potential business combination, provide financial advisory services to assist the Company in its efforts to obtain any shareholder approval for the business combination and assist the Company with its press releases and public filings in connection with the business combination. Pursuant to the Business Combination Marketing Agreement, the marketing fee payable to the representatives will be 3.5% of the gross proceeds of the IPO, or $2,800,000 , upon the consummation of our business combination. Proposed Mobix Labs Transaction The obligations of the Company and Mobix Labs to consummate the Proposed Mobix Labs Transaction are subject to the satisfaction or waiver of certain customary conditions to closing, including, among other things: (i) the expiration or termination of all applicable waiting periods (or any extension thereof) under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, (ii) the Company having at least $5,000,001 of net tangible assets after giving effect to the PIPE Investment in accordance with the terms of the PIPE Subscription Agreement and following the exercise by Public Shareholders of their redemption rights, (iii) approval by the required shareholders of the Company of the Business Combination Agreement and the Proposed Mobix Labs Transaction, (iv) the absence of any law enacted or order issued or threatened in writing by a governmental authority having the effect of restricting or making the Proposed Mobix Labs Transaction illegal or otherwise prohibiting, restricting or making illegal the consummation of the Proposed Mobix Labs Transaction, (v) shareholder approval of the Company to extend the time period for it to consummate a business combination from January 22, 2023 to July 22, 2023, which shareholder approval has been obtained, (vi) the performance or compliance in all material respects by the parties with all of the agreements and covenants required to be performed by such party under the Business Combination Agreement on or prior to the closing date, (vii) the resignation of certain officers and directors of the Company and Mobix Labs and (viii) the execution and delivery of the amended and restated registration rights agreement. The Business Combination Agreement, as amended, may be terminated by the Company and/or Mobix Labs under certain circumstances at any time prior to the closing, notwithstanding any requisite approval and adoption of the Business Combination Agreement and the Proposed Mobix Labs Transaction by the Mobix Labs stockholders or the Company, including, among others, (i) by the Company or Mobix Labs if the Closing has not occurred on or before July 22, 2023, (ii) by the Company if any Mobix Labs stockholder litigation is commenced or threatened in writing by a Mobix Labs stockholder at any time prior to the effective time and (iii) by the Company if Mobix Labs’ PCAOB audited financial statements were not delivered to the Company, in form and substance reasonably satisfactory to the Company, on or before December 15, 2022 (which right to terminate the Business Combination Agreement under this clause (iii) was required to be exercised before the date of the initial public filing of the registration statement on Form S-4 relating to the Proposed Mobix Labs Transaction with the SEC, and which right the Company elected not to exercise prior to such filing date). PIPE Subscription Agreement Pursuant to the PIPE Subscription Agreement, the Company has agreed and shall use its commercially reasonable efforts to file an SEC registration statement registering the shares of Class A Common Stock acquired by the PIPE Investor (the “PIPE Resale Registration Statement”) for public resale within 45 days of closing. The Company also agreed to issue additional shares of Class A Common Stock to the PIPE Investor (the “Make-Whole Features”) in the event that the volume weighted average price per share of the Class A Common Stock during the 30-day period commencing on the date that is 30 days after the date on which the PIPE Resale Registration Statement is declared effective (the “Adjustment Period VWAP”) is less than $10.00 per share. In such case, the PIPE Investor will be entitled to receive a number of shares of Class A Common Stock equal to the product of (x) the number of shares of Class A Common Stock issued to the PIPE Investor at the closing of the subscription and held by the PIPE Investor through the date that is 30 days after the effective date of the PIPE Resale Registration Statement multiplied by (y) a fraction, (A) the numerator of which is $10.00 minus the Adjustment Period VWAP and (B) the denominator of which is the Adjustment Period VWAP. In the event that the Adjustment Period VWAP is less than $7.00 , the Adjustment Period VWAP will be deemed to be $7.00 . The Company evaluated the accounting treatment for PIPE Subscription Agreement, which contains embedded Make-Whole Features, in accordance with ASC 480 and ASC 815 and has determined to account for the PIPE Subscription Agreement as a freestanding financial instrument and as a liability. The Company has concluded that, although the PIPE Subscription Agreement does not meet the definition of a liability under ASC 480, the PIPE Subscription Agreement should be classified as a liability (the “PIPE derivative liability”) upon the application of ASC 815-40 because (i) the number of additional shares issuable pursuant to the Make-Whole Features depends on whether there is an effective PIPE Resale Registration Statement (i.e., the Adjustment Period VWAP described above cannot be determined until the PIPE Resale Registration Statement has been declared effective) and (ii) an effective registration statement is not an input to the fair value option model for a fixed-for-fixed forward, which precludes the PIPE Subscription Agreement from being considered indexed to the Company’s own stock under Step 2 of the indexation guidance contained in ASC 815-40-15-7. As a result, the Company was required to measure the fair value of the PIPE derivative liability as of the time the Company entered into the PIPE Subscription Agreement and is required to do so at the end of each reporting period and is required to recognize the change in fair value in the Company’s operating results for the current period (See Note 7).	Note 6 — Commitments and Contingencies Registration and Shareholder Rights Pursuant to a registration rights agreement entered into on July 19, 2021, the holders of Founder Shares, Private Warrants and warrants that may be issued upon conversion of Working Capital Loans (and any ordinary shares issuable upon the exercise of the Private Warrants and warrants that may be issued upon conversion of Working Capital Loans) are entitled to registration rights, requiring the Company to register such securities for resale. These holders will be entitled to certain demand and “piggyback” registration rights. However, the registration and shareholder rights agreement provide that the Company will not permit any registration statement filed under the Securities Act to become effective until the termination of the applicable lock-up period for the securities to be registered. The Company will bear the expenses incurred in connection with the filing of any such registration statements. Underwriting Agreement The underwriters received a cash underwriting discounts and commissions of 2.0% of the gross proceeds of the IPO, or $ 1,600,000 . Business Combination Marketing Agreement At the closing of the IPO and in connection with the Business Combination, the Company and the underwriters entered into an agreement (the “Business Combination Marketing Agreement”), whereby the underwriters are to assist the Company in holding meetings with the Company’s shareholders to discuss potential Business Combination targets and the target business’s attributes, introduce the Company to potential investors that are interested in purchasing the Company’s securities in connection with the potential Business Combination, provide financial advisory services to assist the Company in its efforts to obtain any shareholder approval for the Business Combination and assist the Company with its press releases and public filings in connection with the Business Combination. Pursuant to the Business Combination Marketing Agreement, the marketing fee payable to the representatives will be 3.5% of the gross proceeds of the IPO, or $2,800,000 , upon the consummation of our Business Combination. Proposed Mobix Labs Transaction The obligations of the Company and Mobix Labs to consummate the Proposed Mobix Labs Transaction are subject to the satisfaction or waiver of certain customary conditions to closing, including, among other things: (i) the expiration or termination of all applicable waiting periods (or any extension thereof) under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, (ii) the Company having at least $ 5,000,001 of net tangible assets after giving effect to the PIPE Investment in accordance with the terms of the PIPE Subscription Agreement and following the exercise by Public Shareholders of their redemption rights, (iii) approval by the required shareholders of the Company of the business combination agreement and the Proposed Mobix Labs Transaction, (iv) the absence of any law enacted or order issued or threatened in writing by a governmental authority having the effect of restricting or making the Proposed Mobix Labs Transaction illegal or otherwise prohibiting, restricting or making illegal the consummation of the Proposed Mobix Labs Transaction, (v) shareholder approval of the Company to extend the time period for it to consummate a Business Combination from January 22, 2023 to July 22, 2023, which shareholder approval has been obtained, (vi) the performance or compliance in all material respects by the parties with all of the agreements and covenants required to be performed by such party under the business combination agreement on or prior to the closing date, (vii) the resignation of certain officers and directors of the Company and Mobix Labs and (viii) the execution and delivery of the amended and restated registration rights agreement. The business combination agreement may be terminated by the Company and/or Mobix Labs under certain circumstances at any time prior to the closing, notwithstanding any requisite approval and adoption of the business combination agreement and the Proposed Mobix Labs Transaction by the Mobix Labs stockholders or the Company, including, among others, (i) by the Company or Mobix Labs if the Closing has not occurred on or before July 22, 2023, (ii) by the Company if any Mobix Labs stockholder litigation is commenced or threatened in writing by a Mobix Labs stockholder at any time prior to the effective time and (iii) by the Company if Mobix Labs’ PCAOB audited financial statements were not delivered to the Company, in form and substance reasonably satisfactory to the Company, on or before December 15, 2022 (which right to terminate the business combination agreement under this clause (iii) is required to be exercised before the date of the initial public filing of the registration statement on Form S-4 relating to the Proposed Mobix Labs Transaction with the SEC). PIPE Subscription Agreement Pursuant to the PIPE Subscription Agreement, the Company has agreed and shall use its commercially reasonable efforts to file an SEC registration statement registering the shares of Class A Common Stock acquired by the PIPE Investor (the “PIPE Resale Registration Statement”) for public resale within 45 days of closing. The Company also agreed to issue additional shares of Class A Common Stock to the PIPE Investor (the “Make-Whole Features”) in the event that the volume weighted average price per share of the Class A Common Stock during the 30 -day period commencing on the date that is 30 days after the date on which the PIPE Resale Registration Statement is declared effective (the “Adjustment Period VWAP”) is less than $ 10.00 per share. In such case, the PIPE Investor will be entitled to receive a number of shares of Class A Common Stock equal to the product of (x) the number of shares of Class A Common Stock issued to the PIPE Investor at the closing of the subscription and held by the PIPE Investor through the date that is 30 days after the effective date of the PIPE Resale Registration Statement multiplied by (y) a fraction, (A) the numerator of which is $ 10.00 minus the Adjustment Period VWAP and (B) the denominator of which is the Adjustment Period VWAP. In the event that the Adjustment Period VWAP is less than $ 7.00 , the Adjustment Period VWAP will be deemed to be $ 7.00 . The Company evaluated the accounting treatment for PIPE Subscription Agreement, which contains embedded Make-Whole Features, in accordance with ASC 480 and ASC 815 and has determined to account for the PIPE Subscription Agreement as a freestanding financial instrument and as a liability. The Company has concluded that, although the PIPE Subscription Agreement does not meet the definition of a liability under ASC 480, the PIPE Subscription Agreement should be classified as a liability (the “PIPE Derivative Liability”) upon the application of ASC 815-40 because (i) the number of additional shares issuable pursuant to the Make-Whole Features depends on whether there is an effective PIPE Resale Registration Statement (i.e., the Adjustment Period VWAP described above cannot be determined until the PIPE Resale Registration Statement has been declared effective) and (ii) an effective registration statement is not an input to the fair value option model for a fixed-for-fixed forward, which precludes the PIPE Subscription Agreement from being considered indexed to the Company’s own stock under Step 2 of the indexation guidance contained in ASC 815-40-15-7. As a result, the Company is required to measure the fair value of the PIPE Derivative Liability at the time the Company entered into the PIPE Subscription Agreement and at the end of each reporting period and is required to recognize the change in fair value in the Company’s operating results for the current period (See Note 8).

Shareholders' Deficit

Shareholders' Deficit	3 Months Ended	12 Months Ended
Shareholders' Deficit	Mar. 31, 2023	Dec. 31, 2022
Shareholders' Deficit
Shareholders' Deficit	Note 6 — Shareholders’ Deficit Preference Shares The Company is authorized to issue 1,000,000 preference shares with a par value of $0.0001 per share and with such designations, voting and other rights and preferences as may be determined from time to time by the Company’s board of directors. There currently are no preference shares issued or outstanding. Ordinary Shares The Company is authorized to issue 200,000,000 ordinary shares with a par value of $0.0001 per share. Prior to the consummation of the IPO, on April 7, 2021, the Sponsor purchased an aggregate of 2,875,000 ordinary shares. On July 19, 2021, the Company effected a cancellation of 575,000 Founder Shares, resulting in an aggregate of 2,300,000 Founder Shares outstanding. On September 5, 2021, the underwriters’ over-allotment option expired unexercised, resulting in the forfeiture of an additional 300,000 Founder Shares and a total of 2,000,000 Founder Shares outstanding as of March 31, 2023 and December 31, 2022. All shares and associated amounts have been retroactively restated to reflect the share cancellation. Ordinary shareholders of record are entitled to one vote for each share held on all matters to be voted on by shareholders. As of March 31, 2023 and December 31, 2022, there were 856,042 and 953,033 ordinary shares issued in the IPO which are subject to possible redemption, respectively. Public Warrants The Company will not issue fractional Public Warrants and only whole Public Warrants will trade. The Public Warrants will become exercisable on 30 days after the completion of a business combination. No Public Warrants will be exercisable for cash unless the Company has an effective and current registration statement covering the ordinary shares issuable upon exercise of the Public Warrants and a current prospectus relating to such ordinary shares. Notwithstanding the foregoing, if a registration statement covering the ordinary shares issuable upon exercise of the Public Warrants is not effective within 120 days following the consummation of a business combination, warrant holders may, until such time as there is an effective registration statement and during any period when the Company shall have failed to maintain an effective registration statement, exercise Public Warrants on a cashless basis pursuant to an available exemption from registration under the Securities Act. The Public Warrants will expire five years from the closing of a business combination. Once the Public Warrants become exercisable, the Company may redeem the Public Warrants in whole and not in part: ● at a price of $0.01 per warrant; ● at any time after the Public Warrants become exercisable; ● upon not less than 30 days ’ prior written notice of redemption to each warrant holder; ● if, and only if, the reported last sale price of the ordinary shares equals or exceeds $18.00 per share (as adjusted for share subdivisions, share capitalizations, reorganizations, recapitalizations and the like and for certain issuances of ordinary shares and equity-linked securities for capital raising purposes in connection with the closing of our initial business combination), for any 20 trading days within a 30 -day trading period commencing after the Public Warrants become exercisable and ending on the third business day prior to the notice of redemption to warrant holders; and ● if, and only if, there is a current registration statement in effect with respect to the ordinary shares underlying such warrants at the time of redemption and for the entire 30 -day trading period referred to above and continuing each day thereafter until the date of redemption, except if the Public Warrants may be exercised on a cashless basis and such cashless exercise is exempt from registration under the Securities Act. If the Company calls the Public Warrants for redemption, management will have the option to require all holders that wish to exercise the Public Warrants to do so on a “cashless basis,” as described in the warrant agreement. The exercise price and number of ordinary shares issuable on exercise of the Public Warrants may be adjusted in certain circumstances including in the event of a share dividend, extraordinary dividend or recapitalization, reorganization, merger or consolidation. However, except as described below, the Public Warrants will not be adjusted for issuances of ordinary shares at a price below their respective exercise prices. Additionally, in no event will the Company be required to net cash settle the Public Warrants. If the Company is unable to complete business combination within the Combination Period and the Company liquidates the funds held in the Trust Account, holders of warrants will not receive any of such funds with respect to their warrants, nor will they receive any distribution from the Company’s assets held outside of the Trust Account with the respect to such warrants. Accordingly, the Public Warrants may expire worthless. In addition, if (x) the Company issues additional ordinary shares or equity-linked securities for capital raising purposes in connection with the closing of a business combination at an issue price or effective issue price of less than $9.20 per ordinary share (with such issue price or effective issue price to be determined in good faith by the Company’s board of directors, and in the case of any such issuance to the Initial Shareholders or their affiliates, without taking into account any Founder Shares held by them prior to such issuance), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of a business combination on the date of the consummation of a business combination (net of redemptions), and (z) the volume weighted average trading price of the Company’s ordinary shares during the 20 trading day period starting on the trading day prior to the day on which the Company consummates a business combination (such price, the “Market Value”) is below $9.20 per share, the exercise price of the Public Warrants will be adjusted (to the nearest cent) to be equal to 115% of the Market Value and the $18.00 per share redemption trigger price described above will be adjusted (to the nearest cent) to be equal to 180% of the Market Price. The Private Warrants are identical to the Public Warrants, except that the Private Warrants and ordinary shares issuable upon the exercise of the Private Warrants are not transferable, assignable or salable until 30 days after the completion of a business combination, subject to certain limited exceptions. Additionally, the Private Warrants are exercisable on a cashless basis and are non-redeemable so long as they are held by the initial purchasers or their permitted transferees. If the Private Warrants are held by someone other than the initial purchasers or their permitted transferees, the Private Warrants will be redeemable by the Company and exercisable by such holders on the same basis as the Public Warrants.	Note 7 — Shareholders’ Deficit Preference Shares The Company is authorized to issue 1,000,000 preference shares with a par value of $0.0001 per share and with such designations, voting and other rights and preferences as may be determined from time to time by the Company’s board of directors. There currently are no preference shares issued or outstanding. Ordinary Shares The Company is authorized to issue 200,000,000 ordinary shares with a par value of $0.0001 per share. On July 19, 2021, the Company effected a cancellation of 575,000 Founder Shares, resulting in an aggregate of 2,300,000 Founder Shares outstanding. On September 5, 2021, the underwriters’ over-allotment option expired unexercised, resulting in the forfeiture of an additional 300,000 Founder Shares and a total of 2,000,000 Founder Shares outstanding as of December 31, 2022 and 2021 All shares and associated amounts have been retroactively restated to reflect the share cancellation. Ordinary shareholders of record are entitled to one vote for each share held on all matters to be voted on by shareholders. As of December 31, 2022 and 2021, there were 953,033 and 8,000,000 ordinary shares issued in the IPO which are subject to possible redemption, respectively Public Warrants The Company will not issue fractional Public Warrants, and only whole Public Warrants trade. The Public Warrants will become exercisable on 30 days after the completion of a Business Combination. No Public Warrants will be exercisable for cash unless the Company has an effective and current registration statement covering the ordinary shares issuable upon exercise of the Public Warrants and a current prospectus relating to such ordinary shares. Notwithstanding the foregoing, if a registration statement covering the ordinary shares issuable upon exercise of the Public Warrants is not effective within 120 days following the consummation of a Business Combination, Public Warrant holders may, until such time as there is an effective registration statement and during any period when the Company shall have failed to maintain an effective registration statement, exercise Public Warrants on a cashless basis pursuant to an available exemption from registration under the Securities Act. The Public Warrants will expire five years from the closing of a Business Combination. Once the Public Warrants become exercisable, the Company may redeem the Public Warrants in whole and not in part; ● at a price of $0.01 per Public Warrant; ● at any time after the Public Warrants become exercisable; ● upon not less than 30 days ’ prior written notice of redemption to each Public Warrant holder; ● if, and only if, the reported last sale price of the ordinary shares equals or exceeds $18.00 per share (as adjusted for share subdivisions, share capitalizations, reorganizations, recapitalizations and the like and for certain issuances of ordinary shares and equity-linked securities for capital raising purposes in connection with the closing of our initial Business Combination), for any 20 trading days within a 30-day trading period commencing after the Public Warrants become exercisable and ending on the third business day prior to the notice of redemption to Public Warrant holders; and ● if, and only if, there is a current registration statement in effect with respect to the ordinary shares underlying such Public Warrants at the time of redemption and for the entire 30-day trading period referred to above and continuing each day thereafter until the date of redemption, except if the Public Warrants may be exercised on a cashless basis and such cashless exercise is exempt from registration under the Securities Act. If the Company calls the Public Warrants for redemption, management will have the option to require all holders that wish to exercise the Public Warrants to do so on a “cashless basis,” as described in the Warrant Agreement. The exercise price and number of ordinary shares issuable on exercise of the Public Warrants may be adjusted in certain circumstances including in the event of a share dividend, extraordinary dividend or recapitalization, reorganization, merger or consolidation. However, except as described below, the Public Warrants will not be adjusted for issuances of ordinary shares at a price below their respective exercise prices. Additionally, in no event will the Company be required to net cash settle the Public Warrants. If the Company is unable to complete a Business Combination within the Combination Period and the Company liquidates the funds held in the Trust Account, holders of Public Warrants will not receive any of such funds with respect to their Public Warrants, nor will they receive any distribution from the Company’s assets held outside of the Trust Account with the respect to such Public Warrants. Accordingly, the Public Warrants may expire worthless. In addition, if (x) the Company issues additional ordinary shares or equity-linked securities for capital raising purposes in connection with the closing of a Business Combination at an issue price or effective issue price of less than $9.20 per ordinary share (with such issue price or effective issue price to be determined in good faith by the Company’s board of directors, and in the case of any such issuance to the Initial Shareholders or their affiliates, without taking into account any Founder Shares held by them prior to such issuance), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of a Business Combination on the date of the consummation of a Business Combination (net of redemptions), and (z) the volume weighted average trading price of the Company’s ordinary shares during the 20 trading day period starting on the trading day prior to the day on which the Company consummates Business Combination (such price, the “Market Value”) is below $9.20 per share, the exercise price of the Public Warrants will be adjusted (to the nearest cent) to be equal to 115% of the Market Value and the $18.00 per share redemption trigger price described above will be adjusted (to the nearest cent) to be equal to 180% of the Market Price. The Private Warrants are identical to the Public Warrants, except that the Private Warrants and ordinary shares issuable upon the exercise of the Private Warrants are not transferable, assignable or salable until 30 days after the completion of a Business Combination, subject to certain limited exceptions. Additionally, the Private Warrants are exercisable on a cashless basis and are non-redeemable so long as they are held by the initial purchasers or their permitted transferees. If the Private Warrants are held by someone other than the initial purchasers or their permitted transferees, the Private Warrants will be redeemable by the Company and exercisable by such holders on the same basis as the Public Warrants.

Fair Value Measurements

Fair Value Measurements	3 Months Ended	12 Months Ended
Fair Value Measurements	Mar. 31, 2023	Dec. 31, 2022
Fair Value Measurements
Fair Value Measurements	Note 7 — Fair Value Measurements The fair value of the Company’s assets and liabilities, which qualify as financial instruments under ASC 820 approximates the carrying amounts represented in the balance sheet, primarily due to their short-term nature. The Company determines fair value based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels: Level 1 Inputs: Unadjusted quoted prices for identical assets or instruments in active markets. Level 2 Inputs: Quoted prices for similar instruments in active markets and quoted prices for identical or similar instruments in markets that are not active and model derived valuations whose inputs are observable or whose significant value drivers are observable. Level 3 Inputs: Significant inputs into the valuation model are unobservable. The following presents the Company’s fair value hierarchy for assets and liabilities measured at fair value on a recurring basis as of March 31, 2023 and December 31, 2022: Description Level March 31, 2023 Level December 31, 2022 Assets: Investments held in Trust Account 1 $ 9,092,522 1 $ 9,835,409 Liabilities: PIPE derivative liability-Make-Whole Features 3 $ 1,281,465 3 $ 1,065,297 Warrant liability 2 $ 102,000 2 $ 335,240 The Private Warrants are considered to be a Level 2 fair value measurement as of March 31, 2023 and are valued the same as the Public Warrants, which are traded on the market. Transfers to/from Levels 1, 2 and 3 are recognized at the ending of the reporting period. The estimated fair value of the Private Warrants ( $680,000 ) was transferred from a Level 3 measurement to a Level 2 fair value measurement as of March 31, 2022, as the transfer of Private Warrants to anyone who is not a permitted transferee would result in the Private Warrants having substantially the same terms as the Public Warrants, and the Company determined that the fair value of each Private Warrant is equivalent to that of each Public Warrant. Other than as described above, there were no other transfers to/from Level 3 during the three months ended March 31, 2023 and 2022. The PIPE derivative liability was accounted for as a liability in accordance with ASC 815-40 and is presented within non-current liabilities on the balance sheets as of March 31, 2023 and December 31, 2022. The PIPE derivative liability is measured at fair value at inception and on a recurring basis, with changes in fair value presented within change in fair value of derivative liability in the statements of operations. The Make-Whole Features were, initially and as of March 31, 2023, valued using a Monte-Carlo model, which is considered to be a Level 3 fair value measurement. The primary unobservable input utilized in determining the fair value of the PIPE derivative liability is the expected volatility of the Company’s ordinary shares. The expected volatility of the Company’s ordinary shares was determined based on the implied volatility of the Public Warrants and from historical volatility of the common stock of select peer companies of Mobix Labs and comparable “blank-check” companies that had recently completed the business combination. The key inputs into the Monte-Carlo model for the PIPE derivative liability were as follows: Input March 31, 2023 December 31, 2022 Historical 30-days VWAP* as of measurement date $ 10.69 $ 10.19 Risk-free rate 4.76 % 4.46 % Dividend yield — % — % Volatility 0.43% and 58.0 % 1.60% and 64.0 % Term (in years) 0.55 0.31 * Volume-Weighted Average Price The following table presents the changes in the fair value of the PIPE derivative liability and the Private Warrant liability: Private Warrants PIPE Derivative Liability Fair value as of December 31, 2021 $ 1,667,262 $ — Change in fair value (987,262) — Fair value as of March 31, 2022 $ 680,000 $ — Change in fair value (425,000) — Fair value as of June 30, 2022 $ 255,000 $ — Change in fair value (119,000) — Fair value as of September 30, 2022 $ 136,000 $ — Initial measurement on November 15, 2022 — 1,108,709 Change in fair value 199,240 (43,412) Fair value as of December 31, 2022 335,240 $ 1,065,297 Change in fair value (233,240) 216,168 Fair value as of March 31, 2023 $ 102,000 $ 1,281,465	Note 8 — Fair Value Measurements The fair value of the Company’s assets and liabilities, which qualify as financial instruments under the FASB ASC 820, “ Fair Value Measurement ,” approximates the carrying amounts represented in the balance sheet, primarily due to their short-term nature. The Company determines fair value based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels: Level 1 Inputs: Unadjusted quoted prices for identical assets or instruments in active markets. Level 2 Inputs: Quoted prices for similar instruments in active markets and quoted prices for identical or similar instruments in markets that are not active and model derived valuations whose inputs are observable or whose significant value drivers are observable. Level 3 Inputs: Significant inputs into the valuation model are unobservable. As of December 31, 2022 and 2021, assets held in the Trust Account were comprised of $9,835,409 and $80,002,777 , respectively, in money market funds which are invested primarily in U.S. Treasury Securities. Through December 31, 2022, the Company has not withdrawn any of interest earned on the Trust Account. The following presents the Company’s fair value hierarchy for assets and liabilities measured at fair value on a recurring basis as of December 31, 2022 and 2021: Description Level December 31, 2022 Level December 31, 2021 Assets: Investments held in Trust Account 1 $ 9,835,409 1 $ 80,002,777 Liabilities: PIPE Derivative Liability-Make-Whole Features 3 $ 1,065,297 — $ — Warrant Liability 2 $ 335,240 3 $ 1,667,262 The Private Warrants are considered to be a Level 2 fair value measurement as of December 31, 2022 and are valued the same as the Public Warrants which are traded on the market. Transfers to/from Levels 1, 2 and 3 are recognized at the ending of the reporting period. The estimated fair value of the Private Warrants ($ 680,000 ) was transferred from a Level 3 measurement to a Level 2 fair value measurement as of March 31, 2022, as the transfer of Private Warrants to anyone who is not a permitted transferee would result in the Private Warrants having substantially the same terms as the Public Warrants, and the Company determined that the fair value of each Private Warrant is equivalent to that of each Public Warrant. Other than as described above, there were no other transfers to/from Level 3 during the year ended December 31, 2022 and the period from March 7, 2021 (inception) to December 31, 2021. The Private Warrants were considered a Level 3 fair value measurement prior to December 31, 2021, using a Monte-Carlo simulation model. Inherent in a Monte-Carlo simulation model are assumptions related to expected stock-price volatility (pre-merger and post-merger, expected term, dividend yield and risk-free interest rate). The Company estimates the volatility ( 10.50% ) of its ordinary shares based on management’s understanding of the volatility associated with instruments of other similar entities. The risk-free interest rate ( 1.19% ) is based on the U.S. Treasury rate matching the expected term of the Private Warrants. The expected life of the Private Warrant is simulated based on management assumptions regarding the timing and likelihood of completing a Business Combination. The dividend rate is based on the historical rate, which the Company anticipates remaining at zero. The following table provides quantitative information regarding fair value measurement inputs for the Private Warrants at measurement dates for Level 3 fair value measurement: July 22, 2021 December 31, 2021 Exercise price $ 11.50 $ 11.50 Stock price $ 9.39 $ 9.84 Volatility 16.8 % 10.50 % Expected term 5.0 5.0 Risk-free rate 0.71 % 1.19 % Dividend yield 0 % 0 % The PIPE Derivative Liability was accounted for as a liability in accordance with ASC 815-40 and is presented within current liabilities on the balance sheet as of December 31, 2022. The PIPE Derivative Lability is measured at fair value at inception and on a recurring basis, with changes in fair value presented within change in fair value of derivative liability in the statements of operations. The Make-Whole Features were, initially and as of December 31, 2022, valued using a Monte-Carlo model, which is considered to be a Level 3 fair value measurement. The primary unobservable input utilized in determining the fair value of the PIPE Derivative Liability is the expected volatility of the Company’s common stock. The expected volatility of the Company’s common stock was determined based on the implied volatility of the Public Warrants and from historical volatility of the common stock of select peer companies of Mobix Labs and comparable ‘blank-check’ companies that recently completed the business combination. The key inputs into the Monte-Carlo model for the PIPE Derivative Liability were as follows: November 15, 2022 Input (Initial Measurement) December 31, 2022 Historical 30-days VWAP* as of measurement date $ 10.09 $ 10.19 Risk-free rate 4.47 % 4.46 % Dividend yield 0 % 0 % Volatility 2.21% and 64 % 1.60% and 64.0 % Term (in years) 0.43 0.31 * Volume-Weighted Average Price The following table presents the changes in the fair value of the PIPE Derivative Liability and the Private Warrant liability: Private Warrants PIPE Derivative Liability Fair value as of July 22, 2021 (inception) $ — $ — Initial measurement 2,788,000 — Change in fair value (1,120,738) — Fair value as of December 31, 2021 $ 1,667,262 $ — Initial measurement on November 15, 2022 — 1,108,709 Change in fair value (1,332,022) (43,412) Fair value as of December 31, 2022 $ 335,240 $ 1,065,297

Subsequent Events

Subsequent Events	3 Months Ended	12 Months Ended
Subsequent Events	Mar. 31, 2023	Dec. 31, 2022
Subsequent Events.
Subsequent Events	Note 8 – Subsequent Events On April 3, 2023, the Company drew down an additional $60,000 of Working Capital Loans from the Sponsor under the existing promissory notes (see Note 4). On April 7, 2023, the Company entered into Amendment No. 1 to the Business Combination Agreement, as discussed in Note 1. The following events occurred subsequent to the date the unaudited condensed financial statements were issued: Additional Working Capital Loan On May 23, 2023 and July 18, 2023, the Company drew down an additional $80,000 and 48,000 , respectively, in Working Capital Loans from the Sponsor under the existing promissory notes. On June 22, 2023, the Company issued an unsecured non-convertible note in the aggregate principal amount of $500,000 to the Sponsor under which the Company may draw down Working Capital Loans from time to time prior to the maturity date up to such aggregate principal amount. The promissory note bears interest at the rate of 10.0% per annum and is payable in full in cash upon the earlier of (i) the consummation of an initial business combination and (ii) one year from the date of issuance. As of July 31, 2023, the Company had drawn down $100,000 under this promissory note. The Chairman of the board of directors of the Company or an entity affiliated with him and the Chief Executive Officer of the Company provided or will provide the funds to the Sponsor for the Working Capital Loans under this promissory note. As of July 31, 2023, the Company had drawn down an aggregate of $1,250,000 of Working Capital Loans under the promissory notes issued to the Sponsor (see Note 5). Third Extension On July 18, 2023, the Company held an extraordinary general meeting of shareholders and obtained shareholder approval of (i) the extension of the Business Combination period to January 22, 2024 (“Third Extension” and, together with the First Extension and the Second Extension, the “Extensions”), and (ii) the amendment of the Amended and Restated Memorandum and Articles of Association to eliminate from the Amended and Restated Memorandum and Articles (a) the limitation that the Company shall not redeem the Public Shares (as defined below) to the extent that such redemption would cause the Company’s net tangible assets to be less than $5,000,001 and (b) the limitation that the Company shall not consummate a business combination unless the Company has net tangible assets of at least $5,000,001 immediately prior to, or upon consummation of, or any greater net tangible asset or cash requirement that may be contained in the agreement relating to, such business combination (collectively, the “Redemption Limitation”). In connection with the meeting, Public Shareholders holding 77,130 Public Shares elected to exercise their right to redeem such shares and $841,807 (approximately $10.91 per share) was paid out of the Trust Account in connection with the redemptions. In connection with the approval of the extension amendment, the Company made an initial deposit into the Trust Account of $38,946 (at a rate of $0.05 per non-redeeming Public Share per month) and will continue to deposit $38,946 for each subsequent monthly period, or portion thereof, that is needed by the Company to complete a business combination by January 22, 2024.	Note 9 – Subsequent Events Additional Working Capital Loan On January 6, 2023, the Sponsor provided the Company with an additional Working Capital Loan of $300,000 , and the Company issued an unsecured convertible promissory note in the aggregate principal amount of $300,000 to the Sponsor . As of March 30, 2023, the Company had drawn down $962,000 under the Working Capital Loans (see Note 5). Nasdaq Notice of Non-Compliance with a Continued Listing Rule On March 23, 2023, the Company received a notice from the Listing Qualifications staff of The Nasdaq Stock Market LLC that, for the previous 30 consecutive business days, the minimum Market Value of Listed Securities ("MVLS") for the Company's ordinary shares was below the $35 million minimum MVLS requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(2) (the "MVLS Rule"). In accordance with the Nasdaq Listing Rules, the Company will have 180 calendar days (until September 19, 2023) to regain compliance with the MVLS Rule. To regain compliance with the MVLS Rule, the MVLS for the Company's ordinary shares must be at least $35 million for a minimum of 10 consecutive business days at any time during this 180 -day period. If the Company does not regain compliance with the rule by September 19, 2023, The Nasdaq Stock Market LLC will provide notice that the Company's ordinary shares will be delisted from The Nasdaq Capital Market. In the event of such notification, the Nasdaq Listing Rules permit the Company an opportunity to appeal The Nasdaq Stock Market LLC's determination. The Company is monitoring the MVLS of its ordinary shares and will consider options available to it to potentially achieve compliance. The Company's securities are expected to continue to trade on The Nasdaq Capital Market during the 180 -day period.

Summary of Significant Accoun_2

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	3 Months Ended	12 Months Ended
Summary of Significant Accounting Policies (Tables)	Mar. 31, 2023	Dec. 31, 2022
Summary of Significant Accounting Policies
Schedule of basic and diluted net income (loss) per common share	For the three months ended For the three months ended March 31, 2023 March 31, 2022 Net (loss) income $ (312,060) $ 604,359 Accretion of temporary equity to redemption value (261,713) — Net (loss) income including accretion of temporary equity to redemption value $ (573,773) $ 604,359 Public Shares Founder Shares Public Shares Founder Shares Basic and diluted net income per share: 873,285 2,000,000 8,000,000 2,000,000 Ownership percentage 30 % 70 % 80 % 20 % Numerator: Net income (loss) including accretion of temporary equity to redemption value $ (174,388) $ (399,384) $ 483,487 $ 120,872 Plus: Accretion applicable to the redeemable class $ 261,713 — — — Allocation of net income (loss) $ 87,325 $ (399,384) $ 483,487 $ 120,872 Denominator: Weighted-average shares outstanding 873,285 2,000,000 8,000,000 2,000,000 Basic and diluted net income (loss) per share: $ 0.10 $ (0.20) $ 0.06 $ 0.06	From March 19, 2021 For the Year ended (inception) through December 31, 2022 December 31, 2021 Net loss from inception to IPO date in year 2021 $ — $ (85,612) Net income from IPO date to year-end (total loss from inception to 12/31/2021) less the loss from inception to IPO) — 446,671 Net income (loss) $ (776,129) $ 361,059 Accretion of temporary equity to redemption value (308,687) (6,793,210) Net income (loss) including accretion of temporary equity to redemption value $ (1,084,816) $ (6,432,151) For the Year ended From March 19, 2021 (inception) through December 31, 2022 December 31, 2021 Public Shares Founder Shares Public Shares Founder Shares Basic and diluted net income per share: Total number of shares 4,795,078 2,000,000 8,000,000 2,000,000 Ownership percentage 71 % 29 % 80 % 20 % Numerator: Allocation of net loss – inception to IPO date $ — $ — $ — $ (85,612) Allocation of net income – IPO date to year end (allocated based on ownership percentage) — — 357,337 89,334 Total net income allocation $ — $ — $ 357,337 $ 3,722 Net income (loss) including accretion of temporary equity to redemption value (765,521) (319,295) (5,434,568) (1,358,642) Plus: Accretion applicable to the redeemable class 308,687 — 6,793,210 — Allocation of net income (loss) $ (456,834) $ (319,295) $ 1,715,979 $ (1,354,920) Denominator: Weighted-average shares outstanding 4,795,078 2,000,000 4,527,778 1,868,056 Basic and diluted net income (loss) per share: $ (0.10) $ (0.16) $ 0.38 $ (0.73)

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended	12 Months Ended
Fair Value Measurements (Tables)	Mar. 31, 2023	Dec. 31, 2022
Fair Value Measurements
Schedule of Company fair value hierarchy for assets and liabilities measured at fair value on a recurring basis	Description Level March 31, 2023 Level December 31, 2022 Assets: Investments held in Trust Account 1 $ 9,092,522 1 $ 9,835,409 Liabilities: PIPE derivative liability-Make-Whole Features 3 $ 1,281,465 3 $ 1,065,297 Warrant liability 2 $ 102,000 2 $ 335,240	Description Level December 31, 2022 Level December 31, 2021 Assets: Investments held in Trust Account 1 $ 9,835,409 1 $ 80,002,777 Liabilities: PIPE Derivative Liability-Make-Whole Features 3 $ 1,065,297 — $ — Warrant Liability 2 $ 335,240 3 $ 1,667,262
Schedule of quantitative information regarding fair value measurement inputs for the warrants	Input March 31, 2023 December 31, 2022 Historical 30-days VWAP* as of measurement date $ 10.69 $ 10.19 Risk-free rate 4.76 % 4.46 % Dividend yield — % — % Volatility 0.43% and 58.0 % 1.60% and 64.0 % Term (in years) 0.55 0.31 * Volume-Weighted Average Price	July 22, 2021 December 31, 2021 Exercise price $ 11.50 $ 11.50 Stock price $ 9.39 $ 9.84 Volatility 16.8 % 10.50 % Expected term 5.0 5.0 Risk-free rate 0.71 % 1.19 % Dividend yield 0 % 0 %
Schedule of change fair value of the derivative warrant liabilities, measured with Level 3	Private Warrants PIPE Derivative Liability Fair value as of December 31, 2021 $ 1,667,262 $ — Change in fair value (987,262) — Fair value as of March 31, 2022 $ 680,000 $ — Change in fair value (425,000) — Fair value as of June 30, 2022 $ 255,000 $ — Change in fair value (119,000) — Fair value as of September 30, 2022 $ 136,000 $ — Initial measurement on November 15, 2022 — 1,108,709 Change in fair value 199,240 (43,412) Fair value as of December 31, 2022 335,240 $ 1,065,297 Change in fair value (233,240) 216,168 Fair value as of March 31, 2023 $ 102,000 $ 1,281,465	Private Warrants PIPE Derivative Liability Fair value as of July 22, 2021 (inception) $ — $ — Initial measurement 2,788,000 — Change in fair value (1,120,738) — Fair value as of December 31, 2021 $ 1,667,262 $ — Initial measurement on November 15, 2022 — 1,108,709 Change in fair value (1,332,022) (43,412) Fair value as of December 31, 2022 $ 335,240 $ 1,065,297

Organization and Business Ope_2

Organization and Business Operations (Details)														1 Months Ended	3 Months Ended	9 Months Ended	12 Months Ended
Organization and Business Operations (Details)	Jul. 22, 2023	Jul. 18, 2023 USD ($) $ / shares shares	Apr. 03, 2023 USD ($)	Jan. 06, 2023 USD ($) $ / shares shares	Nov. 17, 2022 USD ($)	Nov. 15, 2022 USD ($) $ / shares shares	Jul. 18, 2022 USD ($)	Jul. 14, 2022 USD ($) $ / shares shares	Jun. 20, 2022 USD ($)	Sep. 05, 2021 shares	Jul. 22, 2021 USD ($) $ / shares shares	Jun. 25, 2021 USD ($) shares	Apr. 07, 2021 USD ($) $ / shares shares	Jul. 31, 2023 USD ($)	Mar. 31, 2023 USD ($) item $ / shares shares	Dec. 31, 2021 $ / shares shares	Dec. 31, 2022 USD ($) $ / shares shares	Mar. 30, 2023 USD ($)
Organization and Business Operations
Ordinary shares subject to possible redemption, per share \| $ / shares															$ 10	$ 10	$ 10.22
Price of warrant \| $ / shares															$ 1		$ 1
Underwriting option period											45 days
Aggregate purchase price																	$ 25,000
Number of shares issued \| shares																	2,000,000
Condition for future business combination number of businesses minimum															1		1
Cash held outside of the trust account															$ 105,038		$ 175,788
Loans convertible into warrants															$ 1,500,000		$ 1,500,000
Condition for future business combination use of proceeds percentage															80		80
Condition for future business combination threshold percentage ownership															50		50
Condition for future business combination threshold net tangible assets															$ 5,000,001		$ 5,000,001
Redeem price per share \| $ / shares															$ 10	$ 10	$ 10.22
Redemption limit percentage without prior consent															15		15
Obligation to redeem Public Shares if entity does not complete a Business Combination (as a percent)															100%		100%
Maturity period											185 days				185 days		185 days
Redemption period upon closure															10 days		10 days
Maximum interest to pay dissolution expenses															$ 100,000		$ 100,000
Amount drawn down under working capital					$ 962,000		$ 490,000		$ 360,000						962,000		662,000
Redemption of ordinary shares \| shares				96,991
Cash withdrawn from Trust Account in connection with redemption				$ 1,004,600													$ 70,573,278
Initial deposit into Trust Account				$ 42,802
Monthly deposit of per share amount in trust account to complete business combination \| $ / shares				$ 0.05
Agreed monthly deposit in trust account to complete business combination				$ 42,802
Aggregate deposit in trust account				317,107
Assets held-in-trust				$ 9,092,522
Business combination agreement [Member]
Organization and Business Operations
Price per share \| $ / shares						$ 10
PIPE Subscription Agreement
Organization and Business Operations
Number of units sold \| shares						3,000,000
Ordinary shares subject to possible redemption, per share \| $ / shares						$ 10
Gross proceeds						$ 30,000,000
Redeem price per share \| $ / shares						$ 10
Proposed transaction committed common stock						$ 30,000,000
Price per share \| $ / shares																	$ 10
Subsequent Event
Organization and Business Operations
Ordinary shares subject to possible redemption, per share \| $ / shares		$ 10.91
Redeem price per share \| $ / shares		$ 10.91
Obligation to redeem Public Shares if entity does not complete a Business Combination (as a percent)	100%
Redemption of ordinary shares \| shares		77,130		96,991
Cash withdrawn from Trust Account in connection with redemption		$ 841,807		$ 1,004,600
Initial deposit into Trust Account		$ 38,946		$ 42,802
Monthly deposit of per share amount in trust account to complete business combination \| $ / shares		$ 0.05		$ 0.05
Agreed monthly deposit in trust account to complete business combination		$ 38,946		$ 42,802
Aggregate deposit in trust account															317,107
Assets held-in-trust																		$ 9,090,881
Amount drawn down as of date																		$ 962,000
IPO
Organization and Business Operations
Number of units sold \| shares											8,000,000
Ordinary shares subject to possible redemption, per share \| $ / shares											$ 10
Gross proceeds											$ 80,000,000				$ 2,800,000		$ 2,800,000
Underwriting option period											45 days
Offering costs											$ 2,058,249
Additional units purchased \| shares											1,200,000
Redeem price per share \| $ / shares											$ 10
Private Placement \| Private Warrants
Organization and Business Operations
Sale of Private Placement Warrants (in shares) \| shares															3,400,000		3,400,000
Price of warrant \| $ / shares															$ 1		$ 1
Proceeds from sale of private placement															$ 3,400,000		$ 3,400,000
Over-allotment option
Organization and Business Operations
Ordinary shares subject to possible redemption, per share \| $ / shares											$ 10
Additional units purchased \| shares											1,200,000
Redeem price per share \| $ / shares											$ 10
Founder shares
Organization and Business Operations
Number of shares issued \| shares										2,000,000					2,000,000		2,000,000
Founder shares \| Over-allotment option
Organization and Business Operations
Forfeiture of Founder Shares in connection with the expiration of overallotment option \| shares										300,000
Working Capital loans
Organization and Business Operations
Amount drawn down as of date																	$ 662,000
Ordinary Shares Subject To Possible Redemption
Organization and Business Operations
Number of units sold \| shares																8,000,000
Redemption price per share \| $ / shares								$ 31,450
Redemption of ordinary shares \| shares								7,046,967
Cash withdrawn from Trust Account in connection with redemption				$ 96,991				$ 70,573,278
Monthly deposit of per share amount in trust account to complete business combination \| $ / shares								$ 0.033
Agreed monthly deposit in trust account to complete business combination								$ 31,450
Aggregate deposit in trust account															$ 188,700		$ 188,700
Ordinary Shares Subject To Possible Redemption \| Subsequent Event
Organization and Business Operations
Redemption price per share \| $ / shares				$ 10.36
Redemption of ordinary shares \| shares				96,991
Cash withdrawn from Trust Account in connection with redemption				$ 1,004,600
Sponsor
Organization and Business Operations
Ordinary shares subject to possible redemption, per share \| $ / shares													$ 0.009
Aggregate purchase price													$ 25,000
Number of shares issued \| shares													2,875,000
Redeem price per share \| $ / shares													$ 0.009
Sponsor \| Subsequent Event
Organization and Business Operations
Amount drawn down under working capital			$ 60,000											$ 1,250,000
Representative Designee \| Founder shares
Organization and Business Operations
Aggregate purchase price												$ 3,675
Number of shares issued \| shares												422,581

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details) - USD ($)						3 Months Ended	9 Months Ended	12 Months Ended
	Jul. 18, 2023	Jan. 06, 2023	Jul. 14, 2022	Sep. 05, 2021	Jul. 22, 2021	Mar. 31, 2023	Dec. 31, 2021	Dec. 31, 2022
Summary of Significant Accounting Policies
Cash						$ 105,038	$ 240,706	$ 175,788
Investments held in the Trust Account							$ 80,002,777	9,835,409
Federal Depository Insurance Coverage								$ 250,000
Temporary equity, shares outstanding						856,042	8,000,000	953,033
Unrecognized tax benefits						$ 0		$ 0
Unrecognized tax benefits accrued for interest and penalties						0	$ 0
Provision for income taxes						$ 0		$ 0
Anti-dilutive securities attributable to warrants (in shares)						9,400,000		9,400,000
Offering costs							125,039
Subsequent measurement of ordinary shares subject to redemption					$ 6,793,210
Number of shares issued								2,000,000
Redemption of ordinary shares		96,991
Cash withdrawn from Trust Account in connection with redemption		$ 1,004,600						$ 70,573,278
Funds deposited in trust account							80,000,000	188,700
Subsequent Event
Summary of Significant Accounting Policies
Redemption of ordinary shares	77,130	96,991
Cash withdrawn from Trust Account in connection with redemption	$ 841,807	$ 1,004,600
Additional Paid-in Capital
Summary of Significant Accounting Policies
Offering costs							125,039
Subsequent measurement of ordinary shares subject to redemption					5,371,731
Accumulated Deficit
Summary of Significant Accounting Policies
Offering costs							0
Subsequent measurement of ordinary shares subject to redemption					$ 1,421,479	$ 261,713		308,687
Ordinary Shares Subject To Possible Redemption
Summary of Significant Accounting Policies
Offering costs							$ 1,933,210
Redemption of ordinary shares			7,046,967
Cash withdrawn from Trust Account in connection with redemption		$ 96,991	$ 70,573,278
Redemption price per share			$ 31,450
Funds deposited in trust account						128,407		188,700
Interest income on trust deposits						133,306		119,987
Interest generating deposits in trust account						$ 100,000		$ 100,000
Ordinary Shares Subject To Possible Redemption \| Subsequent Event
Summary of Significant Accounting Policies
Redemption of ordinary shares		96,991
Cash withdrawn from Trust Account in connection with redemption		$ 1,004,600
Redemption price per share		$ 10.36
Founder shares
Summary of Significant Accounting Policies
Number of shares issued				2,000,000		2,000,000		2,000,000

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Net Income (Loss) Per Shares (Details) - USD ($)		3 Months Ended		9 Months Ended	12 Months Ended
	Jul. 22, 2021	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2022	Sep. 05, 2021
Summary of Significant Accounting Policies
Net loss from inception to IPO date				$ (85,612)
Net income from IPO date to year-end (total loss from inception to 12/31) less the loss from inception to IPO)				446,671
Net income (loss)		$ (312,060)	$ 604,359	361,059	$ (776,129)
Accretion of temporary equity to redemption value		(261,713)		(6,793,210)	(308,687)
Net income (loss) including accretion of temporary equity to redemption value		$ (573,773)	604,359	$ 6,432,151	$ 1,084,816
Basic and diluted net income per share:
Total number of shares		2,000,000		2,000,000	2,000,000
Numerator:
Plus: Accretion applicable to the redeemable class	$ 6,793,210
Public Shares [Member]
Summary of Significant Accounting Policies
Accretion of temporary equity to redemption value		$ (261,713)
Net income (loss) including accretion of temporary equity to redemption value		$ (174,388)	$ 483,487
Basic and diluted net income per share:
Total number of shares		873,285	8,000,000	8,000,000	4,795,078
Ownership percentage		30%	80%	80%	71%
Numerator:
Allocation of net income - IPO date to year end (allocated based on ownership percentage)				$ 357,337
Total net income allocation		$ 87,325	$ 483,487	(357,337)
Net income (loss) including accretion of temporary equity to redemption value				(5,434,568)	$ (765,521)
Plus: Accretion applicable to the redeemable class				6,793,210	308,687
Allocation of net income (loss)				$ 1,715,979	$ (456,834)
Denominator:
Weighted average ordinary shares outstanding, basic		873,285	8,000,000	4,527,778	4,795,078
Weighted average ordinary shares outstanding, diluted		873,285	8,000,000	4,527,778	4,795,078
Basic net income (loss) per ordinary share		$ 0.10	$ 0.06	$ 0.38	$ (0.10)
Diluted net income (loss) per ordinary share		$ 0.10	$ 0.06	$ 0.38	$ (0.10)
Founder shares
Summary of Significant Accounting Policies
Net income (loss) including accretion of temporary equity to redemption value		$ (399,384)	$ 120,872
Basic and diluted net income per share:
Total number of shares		2,000,000	2,000,000	2,000,000	2,000,000	2,000,000
Ownership percentage		70%	20%	20%	29%
Numerator:
Allocation of net loss - inception to IPO date				$ (85,612)
Allocation of net income - IPO date to year end (allocated based on ownership percentage)				89,334
Total net income allocation		$ (399,384)	$ 120,872	(3,722)
Net income (loss) including accretion of temporary equity to redemption value				(1,358,642)	$ (319,295)
Allocation of net income (loss)				$ (1,354,920)	$ (319,295)
Denominator:
Weighted average ordinary shares outstanding, basic		2,000,000	2,000,000	1,868,056	2,000,000
Weighted average ordinary shares outstanding, diluted		2,000,000	2,000,000	1,868,056	2,000,000
Basic net income (loss) per ordinary share		$ (0.20)	$ 0.06	$ (0.73)	$ (0.16)
Diluted net income (loss) per ordinary share		$ (0.20)	$ 0.06	$ (0.73)	$ (0.16)

Initial Public Offering (Detail

Initial Public Offering (Details) - USD ($)		3 Months Ended	12 Months Ended
Initial Public Offering (Details) - USD ($)	Jul. 22, 2021	Mar. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Initial Public Offering
Ordinary shares subject to possible redemption, per share		$ 10	$ 10.22	$ 10
IPO
Initial Public Offering
Number of units sold	8,000,000
Ordinary shares subject to possible redemption, per share	$ 10
Gross proceeds	$ 80,000,000	$ 2,800,000	$ 2,800,000
Offering costs	2,058,249
Underwriting discounts and commissions	1,600,000
Other offering costs	$ 458,249
IPO \| Public Warrants
Initial Public Offering
Number of shares in a unit	1
Number of shares issuable per warrant	1
Exercise price of warrants	$ 11.50

Private Placement (Details)

Private Placement (Details) - USD ($)	3 Months Ended	12 Months Ended
Private Placement (Details) - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Subsidiary, Sale of Stock [Line Items]
Price of warrants	$ 1	$ 1
Private Placement \| Private Warrants
Subsidiary, Sale of Stock [Line Items]
Number of warrants to purchase shares issued	3,400,000	3,400,000
Price of warrants	$ 1	$ 1
Aggregate purchase price	$ 3,400,000	$ 3,400,000
Number of shares per warrant	1	1
Exercise price of warrant	$ 11.50	$ 11.50

Related Party Transactions - Fo

Related Party Transactions - Founder Shares (Details) - Founder shares - Sponsor - Class B Common Stock	Apr. 07, 2021 $ / shares
Related Party Transaction [Line Items]
Restrictions on transfer period of time after business combination completion	1 year
Stock price trigger to transfer, assign or sell any shares or warrants of the company, after the completion of the initial business combination (in dollars per share)	$ 12
Threshold trading days for transfer, assign or sale of shares or warrants, after the completion of the initial business combination	20 days
Transfer assign or sell any shares or warrants after completion of initial business combination threshold consecutive trading days	30 days
Threshold period after the business combination in which the 20 trading days within any 30 trading day period commences	150 days

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($)

1 Months Ended

3 Months Ended

9 Months Ended

12 Months Ended

Apr. 03, 2023

Jan. 06, 2023

Nov. 17, 2022

Jul. 18, 2022

Jun. 20, 2022

Jul. 26, 2021

Jul. 31, 2023

Mar. 31, 2023

Mar. 31, 2022

Dec. 31, 2021

Dec. 31, 2022

Jun. 22, 2023

Jul. 22, 2021

Apr. 07, 2021

Related Party Transaction [Line Items]

Repayment of promissory note - related party

$ 129,602

Loan conversion agreement warrant

$ 1,500,000

Price of warrant

$ 1

Aggregate principal amount

$ 490,000

$ 360,000

Amount drawn down under working capital

$ 962,000

490,000

360,000

$ 962,000

$ 662,000

Sponsor

Related Party Transaction [Line Items]

Additional amount drawn down under working capital

$ 300,000

Sponsor | Subsequent Event [Member]

Related Party Transaction [Line Items]

Maximum borrowing capacity of related party promissory note

300,000

Amount drawn down under working capital

$ 60,000

$ 1,250,000

Promissory Note with Related Party

Related Party Transaction [Line Items]

Maximum borrowing capacity of related party promissory note

$ 200,000

Outstanding balance of related party note

$ 129,602

Loan conversion agreement warrant

$ 1,500,000

Price of warrant

$ 1

Aggregate principal amount

300,000

Promissory Note with Related Party | Subsequent Event [Member]

Related Party Transaction [Line Items]

Aggregate principal amount

$ 300,000

Promissory Note with Related Party | Sponsor

Related Party Transaction [Line Items]

Aggregate principal amount

$ 360,000

Amount drawn down under working capital

$ 490,000

Promissory Note with Related Party | Sponsor | Subsequent Event [Member]

Related Party Transaction [Line Items]

Aggregate principal amount

$ 500,000

Administrative Support Agreement

Related Party Transaction [Line Items]

Expenses incurred and paid

$ 30,000

120,000

60,000

Expenses per month

$ 10,000

10,000

Expenses accrued

$ 90,000

$ 10,000

80,000

Related Party Loans

Related Party Transaction [Line Items]

Loan conversion agreement warrant

$ 1,500,000

Price of warrant

$ 1

Commitments and Contingencies (

Commitments and Contingencies (Details)			3 Months Ended	12 Months Ended
Commitments and Contingencies (Details)	Nov. 15, 2022 USD ($)	Jul. 22, 2021 USD ($)	Mar. 31, 2023 USD ($) $ / shares	Dec. 31, 2022 USD ($) $ / shares
Commitments and Contingencies
Net tangible assets after giving effect to the PIPE Investment			$ 5,000,001
PIPE Subscription Agreement
Commitments and Contingencies
Value of gross proceeds from IPO	$ 30,000,000
Minimum period of resale of stock			45 days	45 days
Adjustment VWAP period			30 days	30 days
Share price \| $ / shares			$ 10	$ 10
PIPE Subscription Agreement \| Volume-Weighted Average Price
Commitments and Contingencies
Share price \| $ / shares			$ 7	$ 7
IPO
Commitments and Contingencies
Cash underwriting discount and commission (in percentage)				2%
Aggregate underwriter cash discount and commissions			$ 10	$ 1,600,000
Gross proceeds of the IPO			3.5	3.5
Value of gross proceeds from IPO		$ 80,000,000	$ 2,800,000	$ 2,800,000

Shareholders' Deficit - Prefere

Shareholders' Deficit - Preference Shares (Details) - $ / shares	Mar. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Shareholders' Deficit
Preferred stock, par value, (per share)	$ 0.0001	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	1,000,000	1,000,000	1,000,000
Preferred stock, shares issued	0	0	0
Preferred stock, shares outstanding	0	0	0
Preference Shares
Shareholders' Deficit
Preferred stock, par value, (per share)		$ 0.0001
Preferred stock, shares authorized		1,000,000
Preferred stock, shares issued		0
Preferred stock, shares outstanding		0

Shareholders' Deficit - Ordinar

Shareholders' Deficit - Ordinary Shares (Details)				12 Months Ended
Shareholders' Deficit - Ordinary Shares (Details)	Sep. 05, 2021 shares	Jul. 19, 2021 shares	Apr. 07, 2021 shares	Dec. 31, 2022 Vote $ / shares shares	Mar. 31, 2023 Vote $ / shares shares	Dec. 31, 2021 $ / shares shares
Shareholders' Deficit
Common shares, shares outstanding				2,000,000	2,000,000	2,000,000
Number of shares issued				2,000,000
Common shares, shares authorized (in shares)				200,000,000	200,000,000	200,000,000
Common shares, par value (in dollars per share) \| $ / shares				$ 0.0001	$ 0.0001	$ 0.0001
Common shares, votes per share \| Vote				1	1
Common shares, shares issued (in shares)				2,000,000	2,000,000	2,000,000
Founder shares
Shareholders' Deficit
Number of shares cancellation		575,000
Common shares, shares outstanding		2,300,000
Sponsor
Shareholders' Deficit
Number of shares cancellation		575,000
Common shares, shares outstanding		2,300,000		2,000,000	2,000,000
Number of shares issued			2,875,000
Over-allotment option \| Founder shares
Shareholders' Deficit
Common shares, shares outstanding				2,000,000		2,000,000
Forfeiture of Founder Shares in connection with the expiration of overallotment option	300,000
Over-allotment option \| Sponsor
Shareholders' Deficit
Shares subject to forfeiture	300,000
Ordinary shares subject to redemption \| IPO
Shareholders' Deficit
Ordinary shares issued				953,033	856,042	8,000,000

Shareholders' Deficit - Public

Shareholders' Deficit - Public Warrants (Details) - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Shareholders' Deficit
Warrants exercisable term from the completion of business combination		30 days
Public Warrants
Shareholders' Deficit
Warrants exercisable term from the completion of business combination	30 days
Period of time within which registration statement is expected to become effective	120 days	120 days
Public Warrants expiration term	5 years	5 years
Redemption price per public warrant (in dollars per share)	$ 0.01	$ 0.01
Minimum threshold written notice period for redemption of public warrants	30 days	30 days
Stock price trigger for redemption of public warrants (in dollars per share)	$ 18	$ 18
Threshold period for filling registration statement after business combination	20 days	20 days
Redemption period	30 days	30 days
Share Price	$ 9.20	$ 9.20
Percentage of gross proceeds on total equity proceeds	60%	60%
Threshold consecutive trading days for redemption of public warrants	20 days	20 days
Adjustment of exercise price of warrants based on market value and newly issued price (as a percent)	115%	115%
Public Warrants \| Redemption of Warrants When the Price per Class A Ordinary Share Equals or Exceeds $18.00
Shareholders' Deficit
Stock price trigger for redemption of public warrants (in dollars per share)	$ 18	$ 18
Adjustment of exercise price of warrants based on market value and newly issued price (as a percent)	180%	180%

Fair Value Measurements - Compa

Fair Value Measurements - Company fair value hierarchy for assets and liabilities (Details) - USD ($)		3 Months Ended
	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022	Dec. 31, 2021
Assets:
Investment held in trust account		$ 9,092,522		$ 9,835,409	$ 80,002,777
Liabilities:
PIPE derivative liability-Make-Whole Features		1,281,465		1,065,297
Warrant liability		102,000		335,240	1,667,262
Transfer to/from Level 3		0	$ 0
Private Warrants
Liabilities:
Transferred from Level 3 to Level 2	$ 680,000		$ 680,000
U.S. Treasury Securities
Assets:
Investment held in trust account				9,835,409	80,002,777
Level 1 \| Recurring
Assets:
Investment held in trust account		9,092,522		9,835,409	80,002,777
Level 2
Liabilities:
Warrant liability		102,000		335,240
Level 2 \| Recurring
Liabilities:
Warrant liability				335,240
Level 3 \| Recurring
Liabilities:
PIPE derivative liability-Make-Whole Features		$ 1,281,465		$ 1,065,297
Warrant liability					$ 1,667,262

Fair Value Measurements - Quant

Fair Value Measurements - Quantitative information regarding fair value measurement inputs for the warrants (Details)	Mar. 31, 2023 Y $ / shares	Dec. 31, 2022 Y $ / shares	Nov. 15, 2022	Dec. 31, 2021	Jul. 22, 2021 Y $ / shares
Exercise Price \| Private Warrants
Quantitative information regarding fair value measurement inputs for the Private Placement Warrants
Derivative liability, measurement input		11.50			11.50
Volume-Weighted Average Price \| PIPE Derivative Liability
Quantitative information regarding fair value measurement inputs for the Private Placement Warrants
Derivative liability, measurement input		0.1019	0.1009
Stock Price
Quantitative information regarding fair value measurement inputs for the Private Placement Warrants
Derivative liability, measurement input	10.69	10.19
Stock Price \| Private Warrants
Quantitative information regarding fair value measurement inputs for the Private Placement Warrants
Derivative liability, measurement input		9.84			9.39
Volatility \| Private Warrants
Quantitative information regarding fair value measurement inputs for the Private Placement Warrants
Derivative liability, measurement input		0.1050		0.1050	0.168
Volatility \| Maximum
Quantitative information regarding fair value measurement inputs for the Private Placement Warrants
Derivative liability, measurement input		0.640	0.64
Volatility \| Maximum \| Level 3
Quantitative information regarding fair value measurement inputs for the Private Placement Warrants
Derivative liability, measurement input	0.580
Volatility \| Minimum
Quantitative information regarding fair value measurement inputs for the Private Placement Warrants
Derivative liability, measurement input	0.43	0.0160	0.0221
Expected term
Quantitative information regarding fair value measurement inputs for the Private Placement Warrants
Derivative liability, measurement input \| Y	0.55	0.31
Expected term \| Private Warrants
Quantitative information regarding fair value measurement inputs for the Private Placement Warrants
Derivative liability, measurement input \| Y		5			5
Expected term \| PIPE Derivative Liability
Quantitative information regarding fair value measurement inputs for the Private Placement Warrants
Derivative liability, measurement input		0.0031	0.0043
Risk-free rate
Quantitative information regarding fair value measurement inputs for the Private Placement Warrants
Derivative liability, measurement input	0.0476	0.0446
Risk-free rate \| Private Warrants
Quantitative information regarding fair value measurement inputs for the Private Placement Warrants
Derivative liability, measurement input		0.0119		0.0119	0.0071
Risk-free rate \| PIPE Derivative Liability
Quantitative information regarding fair value measurement inputs for the Private Placement Warrants
Derivative liability, measurement input		0.0446	0.0447
Dividend yield \| Private Warrants
Quantitative information regarding fair value measurement inputs for the Private Placement Warrants
Derivative liability, measurement input		0			0
Dividend yield \| PIPE Derivative Liability
Quantitative information regarding fair value measurement inputs for the Private Placement Warrants
Derivative liability, measurement input		0	0

Fair Value Measurements - Chang

Fair Value Measurements - Change in the Fair Value of the Warrant Liabilities (Details) - USD ($)	3 Months Ended				5 Months Ended	9 Months Ended	12 Months Ended
	Mar. 31, 2023	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2021	Dec. 31, 2022
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Change in fair value of warrant liabilities	$ (233,240)			$ (987,262)		$ (1,120,738)	$ (1,332,022)
Fair value					Change in fair value of warrant liabilities		Change in fair value of warrant liabilities
Private Warrants
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Warrant liability at beginning of period	335,240			1,667,262	$ 0		$ 1,667,262
Initial measurement					2,788,000		0
Change in fair value of warrant liabilities					(1,120,738)		(1,332,022)
Warrant Liability at end of period					1,667,262	1,667,262	335,240
PIPE Derivative Liability
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Warrant liability at beginning of period	1,065,297
Initial measurement							1,108,709
Change in fair value of warrant liabilities							(43,412)
Warrant Liability at end of period							1,065,297
Level 3 \| Private Warrants
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Warrant liability at beginning of period	335,240	$ 255,000	$ 680,000	1,667,262			1,667,262
Change in fair value of warrant liabilities	(233,240)	(119,000)	(425,000)	(987,262)			199,240
Warrant Liability at end of period	102,000	$ 136,000	$ 255,000	$ 680,000	$ 1,667,262	$ 1,667,262	335,240
Level 3 \| PIPE Derivative Liability
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Warrant liability at beginning of period	1,065,297
Initial measurement							1,108,709
Change in fair value of warrant liabilities	216,168						(43,412)
Warrant Liability at end of period	$ 1,281,465						$ 1,065,297

Subsequent Events (Details)

Subsequent Events (Details)	Mar. 23, 2023 USD ($) D	Jun. 22, 2023 USD ($)	Mar. 30, 2023 USD ($)	Jan. 06, 2023 USD ($)	Nov. 15, 2022 $ / shares	Jul. 18, 2022 USD ($)	Jun. 20, 2022 USD ($)	Apr. 07, 2021 USD ($)
Subsequent Events
Aggregate principal amount						$ 490,000	$ 360,000
Business combination agreement [Member]
Subsequent Events
Price per share \| $ / shares					$ 10
Promissory Note with Related Party
Subsequent Events
Maximum borrowing capacity								$ 200,000
Aggregate principal amount				$ 300,000
Sponsor \| Promissory Note with Related Party
Subsequent Events
Aggregate principal amount							$ 360,000
Subsequent Event
Subsequent Events
Amount drawn down under working capital			$ 962,000
MVLS Requirement Amount	$ 35,000,000
Trading Period \| D	180
Subsequent Event \| Promissory Note with Related Party
Subsequent Events
Aggregate principal amount				300,000
Subsequent Event \| Sponsor
Subsequent Events
Maximum borrowing capacity				$ 300,000
Subsequent Event \| Sponsor \| Promissory Note with Related Party
Subsequent Events
Aggregate principal amount		$ 500,000

UNAUDITED CONDENSED BALANCE SHE

UNAUDITED CONDENSED BALANCE SHEETS - USD ($)	Mar. 31, 2023	Dec. 31, 2022	Mar. 31, 2022	Dec. 31, 2021	Mar. 18, 2021
Current assets:
Cash	$ 105,038	$ 175,788		$ 240,706
Prepaid expenses				432,591
Total Current Assets	105,038	175,788		673,297
Investment held in trust account	9,092,522	9,835,409		80,002,777
TOTAL ASSETS	9,197,560	10,011,197		80,676,074
Current liabilities:
Accrued expenses	578,352	358,257		69,002
Promissory note - due to sponsor	962,000	662,000
Total Current Liabilities	1,540,352	1,020,257		69,002
Warrant liability	102,000	335,240		1,667,262
PIPE derivative liability	1,281,465	1,065,297
Total Liabilities	2,923,817	2,420,794		1,736,264
Commitments and Contingencies
Ordinary shares subject to possible redemption, $0.0001 par value; 200,000,000 shares authorized; 856,042 and 953,033 shares subject to possible redemption at redemption value of $10.50 per share and $10.22 per share as of March 31, 2023 and December 31, 2022, respectively	8,992,522	9,735,409		80,000,000
Shareholders' Deficit:
Preference shares, $0.0001 par value; 1,000,000 shares authorized; none issued and outstanding
Ordinary shares, $0.0001 par value; 200,000,000 shares authorized; 2,000,000 shares issued and outstanding	200	200		200
Additional paid-in capital	30	30		30
Accumulated deficit	(2,719,009)	(2,145,236)		(1,060,420)
Total Shareholders' Deficit	(2,718,779)	(2,145,006)	$ (455,831)	(1,060,190)	$ 0
TOTAL LIABILITIES, SHARES SUBJECT TO POSSIBLE REDEMPTION AND SHAREHOLDERS' DEFICIT	$ 9,197,560	$ 10,011,197		$ 80,676,074

UNAUDITED CONDENSED BALANCE S_2

UNAUDITED CONDENSED BALANCE SHEETS (Parenthetical) - $ / shares	Mar. 31, 2023	Dec. 31, 2022
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common shares, par value	$ 0.0001	$ 0.0001
Common shares, shares authorized	200,000,000	200,000,000
Common shares, shares issued	2,000,000	2,000,000
Common shares, shares outstanding	2,000,000	2,000,000
Ordinary shares subject to possible redemption, per value		$ 0.0001
Ordinary shares subject to possible redemption, shares authorized		200,000,000
Ordinary shares subject to possible redemption, shares outstanding	856,042	953,033
Ordinary shares subject to possible redemption, per share	$ 10	$ 10.22
Shares surrendered to company for cancellation		875,000
Ordinary Shares
Ordinary shares subject to possible redemption, per value	$ 0.0001	$ 0.0001
Ordinary shares subject to possible redemption, shares authorized	200,000,000	200,000,000
Ordinary shares subject to redemption
Ordinary shares subject to possible redemption, shares outstanding	856,042	953,033
Ordinary shares subject to possible redemption, per share	$ 10.50	$ 10.22

UNAUDITED CONDENSED STATEMENTS

UNAUDITED CONDENSED STATEMENTS OF OPERATIONS - USD ($)		3 Months Ended
UNAUDITED CONDENSED STATEMENTS OF OPERATIONS - USD ($)		Mar. 31, 2023	Mar. 31, 2022
General and administrative expense		$ 432,438	$ 354,876
Administrative expense-related party		30,000	30,000
Loss from operations		(462,438)	(384,876)
Other income:
Gain from change in fair value of warrant liability		233,240	987,262
Interest earned on marketable securities held in trust account		50,777	1,973
Unrealized gain on marketable securities held in trust account		82,529
Loss from change in fair value of PIPE derivative liability		(216,168)
Total other income		150,378	989,235
(Loss) Income before income taxes		(312,060)	604,359
Income tax expense		0
Net (Loss) Income		$ (312,060)	$ 604,359
Ordinary shares subject to redemption
Other income:
Weighted average ordinary shares outstanding, basic		873,285	8,000,000
Weighted average ordinary shares outstanding, diluted		873,285	8,000,000
Basic net income (loss) per ordinary share		$ 0.10	$ 0.06
Diluted net income (loss) per ordinary share		$ 0.10	$ 0.06
Non-redeemable ordinary share
Other income:
Weighted average ordinary shares outstanding, basic	[1]	2,000,000	2,000,000
Weighted average ordinary shares outstanding, diluted	[1]	2,000,000	2,000,000
Basic net income (loss) per ordinary share		$ (0.20)	$ 0.06
Diluted net income (loss) per ordinary share		$ (0.20)	$ 0.06

[1] 875,000 ordinary shares were surrendered to the Company for cancellation for no consideration, resulting in 2,000,000 ordinary shares outstanding. All share amounts and related information have been retroactively restated to reflect the share surrender (see Note 7) .

UNAUDITED CONDENSED STATEMENT_2

UNAUDITED CONDENSED STATEMENTS OF CHANGES IN SHAREHOLDERS' DEFICIT AND ORDINARY SHARES SUBJECT TO POSSIBLE REDEMPTION - USD ($)	Ordinary Shares Subject To Possible Redemption	Ordinary Shares	Additional Paid-in Capital	Accumulated Deficit	Total
Balance at the beginning (in shares) at Mar. 18, 2021	0	0
Balance at the beginning at Mar. 18, 2021	$ 0	$ 0	$ 0	$ 0	$ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of ordinary shares		$ 200	24,800	0	25,000
Issuance of ordinary shares (in shares)		2,300,000
Issuance of Public Shares and Public Warrants in initial public offering	75,140,000		4,860,000	0	4,860,000
Offering cost allocation	(1,933,210)		(125,039)	0	(125,039)
Cash proceeds received in excess of fair value for Private Placement Warrants			612,000	0	612,000
Accretion to ordinary shares subject to redemption (Deemed dividend)	6,793,210		(5,371,731)	(1,421,479)	(6,793,210)
Forfeiture of Founder Shares in connection with the expiration of overallotment option			0	0
Forfeiture of Founder Shares in connection with the expiration of overallotment option (in Shares)		(300,000)
Net income (loss)			0	361,059	361,059
Balance at the end at Dec. 31, 2021	$ 80,000,000	$ 200	30	(1,060,420)	(1,060,190)
Balance at the end (in shares) at Dec. 31, 2021	8,000,000	2,000,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)				604,359	604,359
Balance at the end at Mar. 31, 2022	$ 80,000,000	$ 200	30	(456,061)	(455,831)
Balance at the end (in shares) at Mar. 31, 2022	8,000,000	2,000,000
Balance at the beginning (in shares) at Dec. 31, 2021	8,000,000	2,000,000
Balance at the beginning at Dec. 31, 2021	$ 80,000,000	$ 200	30	(1,060,420)	(1,060,190)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Redemption of ordinary shares	$ (70,573,278)		0	0
Redemption of ordinary shares (in shares)	(7,046,967)
Subsequent measurement of ordinary shares subject to redemption	$ 308,687		0	(308,687)	(308,687)
Net income (loss)			0	(776,129)	(776,129)
Balance at the end at Dec. 31, 2022	$ 9,735,409	$ 200	30	(2,145,236)	(2,145,006)
Balance at the end (in shares) at Dec. 31, 2022	953,033	2,000,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Redemption of ordinary shares	$ (1,004,600)
Redemption of ordinary shares (in shares)	(96,991)
Subsequent measurement of ordinary shares subject to redemption	$ 261,713			(261,713)	(261,713)
Net income (loss)				(312,060)	(312,060)
Balance at the end at Mar. 31, 2023	$ 8,992,522	$ 200	$ 30	$ (2,719,009)	$ (2,718,779)
Balance at the end (in shares) at Mar. 31, 2023	856,042	2,000,000

UNAUDITED STATEMENTS OF CASH FL

UNAUDITED STATEMENTS OF CASH FLOWS	3 Months Ended
UNAUDITED STATEMENTS OF CASH FLOWS	Mar. 31, 2023 USD ($)
Cash Flows from Operating Activities:
Net (loss) income	$ (312,060)
Adjustments to reconcile net (loss) income to net cash used in operating activities:
Interest earned on marketable securities held in trust account	50,777
Unrealized gain on marketable securities held in trust account	(82,529)
Change in fair value of warrant liability	(233,240)
Change in fair value of PIPE derivative liability	216,168
Changes in operating assets and liabilities:
Accrued expenses	220,095
Net cash used in operating activities	(191,566)
Cash Flows from Investment Activities:
Proceeds from sale of investments in marketable securities	9,866,284
Investment in marketable securities	(9,040,868)
Net cash provided by investing activities	825,416
Net cash from Financing Activities:
Redemption of ordinary shares subject to possible redemption	(1,004,600)
Proceeds from promissory note - due to sponsor	300,000
Net cash used in financing activities	(704,600)
Net Change in Cash	(70,750)
Cash - Beginning of period	175,788
Cash - End of period	105,038
Non-Cash investing and financing activities:
Accretion to ordinary shares subject to redemption	$ 261,713

Organization and Business Ope_3

Organization and Business Operations	3 Months Ended	12 Months Ended
Organization and Business Operations	Mar. 31, 2023	Dec. 31, 2022
Organization and Business Operations
Organization and Business Operations	Note 1 — Organization and Business Operations Organization and General Chavant Capital Acquisition Corp. (the “Company”) was incorporated as a Cayman Islands exempted company on March 19, 2021. The Company was formed for the purpose of effectuating a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses (a “business combination”). The Company is an early stage and emerging growth company and, as such, the Company is subject to all of the risks associated with early stage and emerging growth companies. As of March 31, 2023, the Company had not commenced any operations. All activity through March 31, 2023 relates to the Company’s formation and its Initial Public Offering (“IPO”) which is described below, identifying a target company for a business combination and negotiation and preparation of documentation relating to the Proposed Mobix Labs Transaction (as defined below). The Company will not generate any operating revenues until after the completion of a business combination. The Company generates non-operating income in the form of interest income from the proceeds derived from the IPO. The Company has selected December 31 as its fiscal year end. On November 15, 2022, the Company and Mobix Labs, Inc., a Delaware corporation (“Mobix Labs”), entered into a business combination agreement (the “Business Combination Agreement”), by and among the Company, Mobix Labs and CLAY Merger Sub II, Inc., a Delaware corporation and newly formed, wholly-owned direct subsidiary of the Company (“Merger Sub”), pursuant to which Merger Sub will be merged with and into Mobix Labs, with Mobix Labs surviving the merger as a wholly-owned direct subsidiary of the Company (the “Proposed Mobix Labs Transaction”). In connection with the Proposed Mobix Labs Transaction, the Company will take the steps necessary to transfer its registration from the Cayman Islands to the State of Delaware (the “Domestication”), where it will then immediately incorporate as a Delaware corporation. The Company will also issue one share of Class A Common Stock in exchange for and on conversion in connection with the Domestication of each ordinary share outstanding immediately prior to the Domestication and will issue a warrant exercisable for one share of Class A Common Stock in exchange for and on conversion in connection with the Domestication of each warrant outstanding immediately prior to the Domestication. The Proposed Mobix Labs Transaction may be terminated by the Company and/or Mobix Labs under certain circumstances at any time prior to the closing. If the Proposed Mobix Labs Transaction occurs, the combined company will be named Mobix Labs, Inc., and its common stock and warrants are expected to be listed on Nasdaq. In connection with the Proposed Mobix Labs Transaction, the Company entered into a subscription agreement (the “PIPE Subscription Agreement”) with an investor (the “PIPE Investor”), pursuant to which the PIPE Investor agreed to purchase 3,000,000 shares of Class A Common Stock at $10.00 per share for an aggregate amount of $30,000,000 (the “PIPE”), subject to, among other things, the approval of the Proposed Mobix Labs Transaction by the Company’s shareholders and the satisfaction of the conditions set forth in the Business Combination Agreement, including a Form S-4 registration statement being declared effective by the SEC. See Note 5 for further discussion of the accounting for the PIPE, including the embedded Make-Whole Features, as defined and described in such note. On April 7, 2023, the Company, Mobix Labs and Merger Sub entered into Amendment No. 1 to the Business Combination Agreement, pursuant to which, the parties have agreed, among other things, that certain securities issued subsequent to March 26, 2023, referred to as “Post-March 26 Financing Securities,” will not be included in the calculation of the “Company Fully Diluted Number” under the Business Combination Agreement, with the effect that the Per Share Exchange Ratio (as defined in the Business Combination Agreement) will not be reduced on account of such issuances. “Post-March 26 Financing Securities” are defined in the Amendment No. 1 as any shares of (i) common stock of Mobix Labs or (ii) common stock of Mobix Labs issuable upon exercise or conversion of warrants, convertible instruments or convertible debt of Mobix Labs, in each case, where such securities were issued for cash and in accordance with Sections 6.01(b)(iii) and (xix) of the Business Combination Agreement, as a result of, or in connection with, any private placement entered into by Mobix Labs after March 26, 2023. Except with the consent of the Company (which consent shall not be unreasonably conditioned, withheld or delayed), Mobix Labs must use the proceeds of the issuance of any Post-March 26 Financing Securities to finance the ongoing business operations of Mobix Labs or to pay transaction expenses. In addition, Amendment No. 1 extended the outside date under the Business Combination Agreement from July 22, 2023 to November 22, 2023. Nasdaq Notice of Non-Compliance with a Continued Listing Rule On March 23, 2023, the Company received a notice from the Listing Qualifications staff of The Nasdaq Stock Market LLC that, for the previous 30 consecutive business days, the minimum Market Value of Listed Securities (“MVLS”) for the Company’s Public Shares (as defined below) was below the $35,000,000 minimum MVLS requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(2) (the “MVLS Rule”). In accordance with the Nasdaq Listing Rules, the Company will have 180 calendar days (until September 19, 2023) to regain compliance with the MVLS Rule. To regain compliance with the MVLS Rule, the MVLS for the Company’s Public Shares must be at least $35,000,000 for a minimum of 10 consecutive business days at any time during this 180-day period. If the Company does not regain compliance with the rule by September 19, 2023, The Nasdaq Stock Market LLC will provide notice that the Company’s Public Shares will be delisted from The Nasdaq Capital Market. In the event of such notification, the Nasdaq Listing Rules permit the Company an opportunity to appeal The Nasdaq Stock Market LLC’s determination. The Company is monitoring the MVLS of its ordinary shares and will consider options available to it to potentially achieve compliance. The Company’s securities are expected to continue to trade on The Nasdaq Capital Market during the 180-day period. Financing The Company’s sponsor is Chavant Capital Partners LLC, a Delaware limited liability company (the “Sponsor”). The registration statement pursuant to which the Company registered its securities offered in the IPO was declared effective on July 19, 2021. On April 7, 2021, the Sponsor purchased an aggregate of 2,875,000 ordinary shares (the “Founder Shares”) for a purchase price of $25,000 , or approximately $0.009 per share. On June 25, 2021, the Sponsor sold an aggregate of 422,581 of such Founder Shares to the underwriters for a purchase price of $3,675 . On July 22, 2021, the Company consummated its IPO of 8,000,000 units (each, a “Unit” and collectively, the “Units”), at $10.00 per Unit, generating gross proceeds of $80,000,000 and incurring offering costs of $2,058,249 . The Company granted the underwriters a 45-day option to purchase up to an additional 1,200,000 Units at the IPO price to cover over-allotments, if any. On September 5, 2021, the over-allotment option expired unexercised and an aggregate of 300,000 Founder Shares was forfeited, resulting in 2,000,000 Founder Shares remaining outstanding. Simultaneously with the consummation of the closing of the IPO, the Company consummated the private placement of an aggregate of 3,400,000 warrants (collectively, the “Private Warrants” and together with the Public Warrants (as defined below), the “Warrants”) at an average price of $1.00 per Private Warrant to the Sponsor and the underwriters, generating total gross proceeds of $3,400,000 (the “Private Placement”). Trust Account Following the closing of the IPO on July 22, 2021, an amount of $80,000,000 from the net proceeds of the sale of the Units in the IPO and the sale of the Private Warrants was placed in the trust account (the “Trust Account”) located in the United States with Continental Stock Transfer & Trust Company acting as trustee. The funds may be invested only in U.S. government securities with a maturity of 185 days or less or in money market funds meeting certain conditions under Rule 2a-7 under the Investment Company Act of 1940, as amended (the “Investment Company Act”), which invest only in direct U.S. government treasury obligations. On July 14, 2022, the Company held an Extraordinary General Meeting of shareholders and obtained shareholder approval of the extension of the date by which the Company must consummate an initial business combination from July 22, 2022 (which is 12 months from the closing of the IPO) to January 22, 2023 (the “Extended Date”) by amending the Company’s amended and restated memorandum and articles of association (the “First Extension Amendment”). The First Extension Amendment became effective upon approval of the Company’s shareholders. In connection with the First Extension Amendment, shareholders holding 7,046,967 ordinary shares of the Company exercised their right to redeem their ordinary shares for a pro rata portion of the funds in the Trust Account. As a result, $70,573,278 was withdrawn from the Trust Account to pay such holders. As a result of the redemption payments and above mentioned extension, the Company deposited $31,450 (at a rate of $0.033 per non-redeeming Public Share) for each subsequent monthly period needed by the Company to complete a business combination by the Extended Date. As of December 31, 2022, the Company deposited an aggregate of $188,700 in the Trust Account which were funded by the promissory notes issued to the Sponsor. On January 6, 2023, the Company held an extraordinary general meeting of shareholders and obtained shareholder approval of the extension of the Combination Period to July 22, 2023 (“Second Extension”). In connection with the meeting, Public Shareholders holding 96,991 Public Shares elected to exercise their right to redeem such shares and $1,004,600 was paid out of the Trust Account in connection with the redemptions. In connection with the approval of the extension amendment, the Company made an initial deposit into the Trust Account of $42,802 (at a rate of $0.05 per non-redeeming Public Share per month) and will continue to deposit $42,802 for each subsequent monthly period, or portion thereof, that is needed by the Company to complete business combination by July 22, 2023. As of March 31, 2023, the Company had deposited an aggregate of $317,107 in the Trust Account in connection with the First Extension and the Second Extension Amendments, and the Trust Account had a total balance of $9,092,522 . The funds held in the Trust Account will not be released from the Trust Account until the earliest of: (i) the completion of the initial business combination ; (ii) the redemption of any Public Shares properly submitted in connection with a shareholder vote to amend the Company’s amended and restated memorandum and articles of association (the “Amended and Restated Memorandum and Articles of Association”) (A) to modify the substance or timing of the Company’s obligation to redeem 100% of the Public Shares if the Company does not complete the initial business combination by July 22, 2023 (or within any extended period of time that we may have to consummate an initial business combination as a result of an amendment to our Amended and Restated Memorandum and Articles of Association) or (B) with respect to any other material provisions relating to shareholders’ rights or pre-initial business combination activity; or (iii) the redemption of the Public Shares if we are unable to complete the Proposed Mobix Labs Transaction or any other initial business combination by July 22, 2023 (or by the end of any such extended period of time), subject to applicable law. The proceeds deposited in the Trust Account could become subject to the claims of our creditors, if any, which could have priority over the claims of our Public Shareholders. The proceeds held in the Trust Account will be invested only in U.S. government treasury obligations with a maturity of 185 days or less or in money market funds meeting certain conditions under Rule 2a-7 under the Investment Company Act that invest only in direct U.S. government treasury obligations. The Company’s management has broad discretion with respect to the specific application of the net proceeds of the IPO and the sale of Private Warrants, although substantially all of the net proceeds are intended to be applied generally toward consummating a business combination. Initial Business Combination The Company is not limited to a particular industry or sector for purposes of consummating a business combination. There is no assurance that the Company will be able to complete a business combination successfully. The Company must complete one or more initial business combinations having an aggregate fair market value of at least 80% of the net assets held in the Trust Account (net of taxes payable) at the time of the signing of a definitive agreement to enter into an initial business combination. However, the Company will only complete a business combination if the post-transaction company owns or acquires 50% or more of the outstanding voting securities of the target or otherwise acquires a controlling interest in the target sufficient for it not to be required to register as an investment company under the Investment Company Act. The Company will provide holders (the “Public Shareholders”) of its ordinary shares sold in the IPO (the “Public Shares”) with the opportunity to redeem all or a portion of their Public Shares upon the completion of a business combination either (i) in connection with a general meeting called to approve a business combination or (ii) without a shareholder vote by means of a tender offer. The decision as to whether the Company will seek shareholder approval of business combination or conduct a tender offer will be made by the Company, solely in its discretion. The Public Shareholders will be entitled to redeem their Public Shares for a pro rata portion of the amount then on deposit in the Trust Account (initially anticipated to be $10.00 per Public Share). These Public Shares were classified as temporary equity upon the completion of the IPO in accordance with the Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) 480, “Distinguishing Liabilities from Equity.” In such case, the Company will proceed with business combination if the Company has net tangible assets of at least $5,000,001 upon such consummation of business combination and a majority of the shares voted are voted in favor of a business combination. If a shareholder vote is not required by law and the Company does not decide to hold a shareholder vote for business or other legal reasons, the Company will, pursuant to its Amended and Restated Memorandum and Articles of Association, conduct the redemptions pursuant to the tender offer rules of the U.S. Securities and Exchange Commission (“SEC”) and file tender offer documents with the SEC prior to completing a business combination. If, however, shareholder approval of the Proposed Mobix Labs Transaction is required by law, or the Company decides to obtain shareholder approval for business or legal reasons, the Company will offer to redeem shares in conjunction with a proxy solicitation pursuant to the proxy rules and not pursuant to the tender offer rules. Additionally, each Public Shareholder may elect to redeem their Public Shares irrespective of whether they vote for or against the proposed transaction, whether they participate in or abstain from voting, or whether they were a shareholder on the record date for the general meeting held to approve the Proposed Mobix Labs Transaction. If the Company seeks shareholder approval in connection with a business combination, the Company’s initial shareholders, Sponsor, officers and directors (the “Initial Shareholders”) have agreed to vote their Founder Shares (as defined below in Note 4) and any Public Shares purchased during or after the IPO in favor of a business combination. The Company has adopted an insider trading policy which requires insiders to: (i) refrain from purchasing shares during certain blackout periods and when they are in possession of any material non-public information and (ii) to clear all trades with the Company’s legal counsel prior to execution. In addition, the Initial Shareholders have agreed to waive their redemption rights with respect to their Founder Shares and Public Shares in connection with the completion of a business combination. Notwithstanding the foregoing, the Amended and Restated Memorandum and Articles of Association provides that a Public Shareholder, together with any affiliate of such shareholder or any other person with whom such shareholder is acting in concert or as a “group” (as defined under Section 13 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), will be restricted from redeeming its shares with respect to more than an aggregate of 15% or more of the ordinary shares sold in the IPO, without the prior consent of the Company. The Company has entered into a letter agreement with its Initial Shareholders, pursuant to which the Initial Shareholders have agreed to not to propose an amendment to the Amended and Restated Memorandum and Articles of Association that would modify the substance or timing of the Company’s obligation to redeem 100% of its Public Shares if the Company does not complete a business combination, unless the Company provides the Public Shareholders with the opportunity to redeem their ordinary shares in conjunction with any such amendment. Liquidation On July 14, 2022, the Company obtained shareholder approval to extend the date by which the Company must consummate an initial business combination from July 22, 2022 to January 22, 2023. On January 6, 2023, the Company obtained shareholder approval to further extend the date to July 22, 2023. If the Company is unable to complete the Proposed Mobix Labs Transaction or any other initial business combination by the Second Extended Date (the “Combination Period”), the Company will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than ten business days thereafter, redeem the Public Shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned on the funds held in the Trust Account (less taxes payable and up to $100,000 of interest to pay dissolution expenses), divided by the number of then issued and outstanding Public Shares, which redemption will completely extinguish Public Shareholders’ rights as shareholders (including the right to receive further liquidation distributions, if any) and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the remaining shareholders and the board of directors, liquidate and dissolve, subject, in each case, to the Company’s obligations under Cayman Islands law to provide for claims of creditors and in all cases subject to the other requirements of applicable law. There will be no redemption rights or liquidating distributions with respect to the Warrants, which will expire worthless if the Company fails to complete its initial business combination within the Combination Period. The Company’s Initial Shareholders have agreed to waive their liquidation rights with respect to the Founder Shares if the Company fails to complete a business combination within the Combination Period. However, if the Company’s Initial Shareholders acquire Public Shares in or after the IPO, they will be entitled to liquidating distributions from the Trust Account with respect to such Public Shares if the Company fails to complete a business combination within the Combination Period. In the event of such distribution, it is possible that the per share value of the residual assets remaining available for distribution (including Trust Account assets) will be only $10.00 per share initially held in the Trust Account. In order to protect the amounts held in the Trust Account, the Sponsor has agreed to be liable to the Company if and to the extent any claims by a vendor for services rendered or products sold to the Company, or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amount of funds in the Trust Account. This liability will not apply with respect to any claims by a third party who executed a waiver of any right, title, interest or claim of any kind in or to any monies held in the Trust Account or to any claims under the Company’s indemnity of the underwriters of the IPO against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the “Securities Act”). Moreover, in the event that an executed waiver is deemed to be unenforceable against a third party, the Sponsor will not be responsible to the extent of any liability for such third-party claims. The Company will seek to reduce the possibility that the Sponsor will have to indemnify the Trust Account due to claims of creditors by endeavoring to have all vendors, service providers, except the independent registered public accounting firm and the Company’s legal counsel, prospective target businesses or other entities with which the Company does business, execute agreements with the Company waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account. Liquidity and Capital Resources; Going Concern In order to fund working capital deficiencies or finance transaction costs in connection with a business combination, our Sponsor or an affiliate of our Sponsor or certain of our officers and directors may, but are not obligated to, loan us funds as may be required. If we complete a business combination, we may repay such loaned amounts out of the proceeds of the Trust Account released to us. In the event that a business combination does not close, we may use a portion of the working capital held outside the Trust Account to repay such loaned amounts, but no proceeds from our Trust Account would be used for such repayment. Up to $1,500,000 of such loans may be convertible into warrants, at a price of $1.00 per warrant, at the option of the lender. The warrants would be identical to the Private Warrants. As of March 31, 2023, the Company has drawn down $962,000 of Working Capital Loans from the Sponsor (see Note 4).The Company anticipates that the cash held outside of the Trust Account in the amount of $105,038 as of March 31, 2023 will not be sufficient to allow the Company to operate for at least the next 12 months from the issuance of the financial statements, assuming that a business combination is not consummated during that time. The Company has incurred and expects to continue to incur significant costs in pursuit of its acquisition plans. These conditions raise substantial doubt about the Company’s ability to continue as a going concern for a period of time within one year after the date that the financial statements are issued. Management plans to address this uncertainty through the initial business combination as discussed above. There is no assurance that the Company’s plans to consummate an initial business combination will be successful or successful within the Combination Period. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.	Note 1 — Organization and Business Operations Organization and General Chavant Capital Acquisition Corp. (the “Company”) was incorporated as a Cayman Islands exempted company on March 19, 2021. The Company was formed for the purpose of effectuating a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses (the “Business Combination”). The Company is an early stage and emerging growth company and, as such, the Company is subject to all of the risks associated with early stage and emerging growth companies. As of December 31, 2022, the Company had not commenced any operations. All activity through December 31, 2022 relates to the Company’s formation and its Initial Public Offering (“IPO”) which is described below, and identifying a target company for a Business Combination. The Company will not generate any operating revenues until after the completion of a Business Combination. The Company generates non-operating income in the form of interest income from the proceeds derived from the IPO. The Company has selected December 31 as its fiscal year end. On November 15, 2022, the Company and Mobix Labs, Inc. (“Mobix Labs”) entered into a business combination agreement, by and among the Company, Mobix Labs and CLAY Merger Sub II, Inc., a Delaware corporation and newly formed, wholly-owned direct subsidiary of the Company (“Merger Sub”), pursuant to which Merger Sub will be merged with and into Mobix Labs, with Mobix Labs surviving the merger as a wholly-owned direct subsidiary of the Company (the “Proposed Mobix Labs Transaction”). The Proposed Mobix Labs Transaction may be terminated by the Company and/or Mobix Labs under certain circumstances at any time prior to the closing as further described in Note 6 - Commitments and Contingencies. If the Proposed Mobix Labs Transaction occurs, the combined company will be named Mobix Labs, Inc., and its common stock and warrants are expected to be listed on Nasdaq. In connection with the Proposed Mobix Labs Transaction, the Company entered into a subscription agreement (the “PIPE Subscription Agreement”) with an investor (the “PIPE Investor”), pursuant to which the PIPE Investor agreed to purchase 3,000,000 shares of Class A Common Stock at $10.00 per share for an aggregate amount of $ 30,000,000 (the “PIPE”), subject to, among other things, the approval of the Proposed Mobix Labs Transaction by the Company’s shareholders and the satisfaction of the conditions set forth in the business combination agreement, including a Form S-4 registration statement being declared effective by the SEC. See Note 6 for further discussion of the accounting for the PIPE, including the embedded Make-Whole Features, as defined and described in such note. Financing The Company’s Sponsor is Chavant Capital Partners LLC, a Delaware limited liability company (the “Sponsor”). The registration statement pursuant to which the Company registered its securities offered in the IPO was declared effective on July 19, 2021.On April 7, 2021, the Sponsor purchased an aggregate of 2,875,000 ordinary shares (the “Founder Shares”) for a purchase price of $25,000 , or approximately $0.009 per share. On June 25, 2021, the Sponsor sold an aggregate of 422,581 of such Founder Shares to the underwriters for a purchase price of $3,675 . On July 22, 2021, the Company consummated its IPO of 8,000,000 Units (each, a “Unit” and collectively, the “Units”), at $10.00 per Unit, generating gross proceeds of $80,000,000 and incurring offering costs of $2,058,249 . The Company granted the underwriters a 45-day option to purchase up to an additional 1,200,000 Units at the IPO price to cover over-allotments, if any. On September 5, 2021, the over-allotment expired unexercised and an aggregate of 300,000 Founder Shares was forfeited, resulting in 2,000,000 Founder Shares remaining outstanding (See Note 7). Simultaneously with the consummation of the closing of the IPO, the Company consummated the private placement of an aggregate of 3,400,000 warrants (each, a “Private Warrant” and collectively, the “Private Warrants” and, together with the Public Warrants, the “Warrants”) at an average price of $1.00 per Private Warrant to the Sponsor and the underwriters, generating total gross proceeds of $3,400,000 (the “Private Placement”). Trust Account Following the closing of the IPO on July 22, 2021, an amount of $80,000,000 from the net proceeds of the sale of the Units in the IPO and the sale of the Private Warrants was placed in the trust account (the “Trust Account”) located in the United States with Continental Stock Transfer & Trust Company acting as trustee. The funds may be invested only in U.S. government securities with a maturity of 185 days or less or in money market funds meeting certain conditions under Rule 2a-7 under the Investment Company Act of 1940 (as amended, the “Investment Company Act”) which invest only in direct U.S. government treasury obligations. On July 14, 2022, the Company held an Extraordinary General Meeting (the “Meeting”) of shareholders and obtained shareholder approval of the extension of the date by which the Company must consummate an initial Business Combination from July 22, 2022 to January 22, 2023 (the “Extended Date”) by amending the Company’s amended and restated memorandum and articles of association (the “Amended and Restated Memorandum and Articles of Association”) (such amendment, the “First Extension Amendment”). The First Extension Amendment became effective upon approval of the Company’s shareholders. In connection with the First Extension Amendment, shareholders holding 7,046,967 ordinary shares of the Company exercised their right to redeem their ordinary shares for a pro rata portion of the funds in the Trust Account. As a result, $70,573,278 was deducted from the Trust Account to pay such holders. As a result of redemption payments and above-mentioned extensions, the Company deposited $31,450 (at a rate of $ 0.033 per non-redeeming Public Share) for each subsequent monthly period needed by the Company to complete a Business Combination by the Extended Date. As of December 31, 2022, the Company deposited an aggregate of $ 188,700 in the Trust Account which were funded by the promissory notes issued to the Sponsor. On January 6, 2023, the Company held an extraordinary general meeting of shareholders and obtained shareholder approval of the extension of the Business Combination period to July 22, 2023 (“Second Extension”). In connection with the meeting, Public Shareholders holding 96,991 Public Shares elected to exercise their right to redeem such shares and $1,004,600 was paid out of the Trust Account in connection with the redemptions. In connection with the approval of the extension amendment, the Company made an initial deposit into the Trust Account of $42,802 (at a rate of $0.05 per non-redeeming Public Share per month) and will continue to deposit $42,802 for each subsequent monthly period, or portion thereof, that is needed by the Company to complete a Business Combination by July 22, 2023. As of March 30, 2023, the Company had deposited an aggregate of $317,107 in the Trust Account in connection with the First Extension Amendment and the Second Extension, and the Trust Account had a total balance of approximately $ 9,090,881 . The funds held in the Trust Account will not be released from the Trust Account until the earliest of (i) the completion of our initial Business Combination, (ii) the redemption of any of Public Shares properly submitted in connection with a shareholder vote to amend our Amended and Restated Memorandum and Articles of Association (A) to modify the substance or timing of our obligation to redeem 100 % of the Public Shares if we do not complete our initial Business Combination by July 22, 2023 (or within any extended period of time that we may have to consummate an initial Business Combination as a result of an amendment to our Amended and Restated Memorandum and Articles of Association) or (B) with respect to any other material provisions relating to shareholders’ rights or pre-initial Business Combination activity or (iii) the redemption of the Public Shares if we are unable to complete the Proposed Mobix Labs Transaction or another or any other initial Business Combination by July 22, 2023 (or by the end of any such extended period of time), subject to applicable law. The proceeds deposited in the Trust Account could become subject to the claims of our creditors, if any, which could have priority over the claims of our Public Shareholders. The proceeds held in the Trust Account will be invested only in U.S. government treasury obligations with a maturity of 185 days or less or in money market funds meeting certain conditions under Rule 2a-7 under the Investment Company Act that invest only in direct U.S. government treasury obligations. The Company’s management has broad discretion with respect to the specific application of the net proceeds of the IPO and the sale of Private Warrants, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination. Initial Business Combination The Company is not limited to a particular industry or sector for purposes of consummating a Business Combination. There is no assurance that the Company will be able to complete a Business Combination successfully. The Company must complete one or more initial Business Combinations having an aggregate fair market value of at least 80% of the net assets held in the Trust Account (net of taxes payable) at the time of the signing of a definitive agreement to enter into an initial Business Combination. However, the Company will only complete a Business Combination if the post-transaction company owns or acquires 50% or more of the outstanding voting securities of the target or otherwise acquires a controlling interest in the target sufficient for it not to be required to register as an investment company under the Investment Company Act 1940. The Company will provide holders (the “Public Shareholders”) of its ordinary shares sold in the IPO (the “Public Shares”) with the opportunity to redeem all or a portion of their Public Shares upon the completion of a Business Combination either (i) in connection with a general meeting called to approve the Business Combination or (ii) without a shareholder vote by means of a tender offer. The decision as to whether the Company will seek shareholder approval of a Business Combination or conduct a tender offer will be made by the Company, solely in its discretion. The Public Shareholders will be entitled to redeem their Public Shares for a pro rata portion of the amount then on deposit in the Trust Account (initially anticipated to be $10.00 per Public Share). These Public Shares were classified as temporary equity upon the completion of the IPO in accordance with the Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) Topic 480, “Distinguishing Liabilities from Equity.” In such case, the Company will proceed with a Business Combination if the Company has net tangible assets of at least $5,000,001 upon such consummation of a Business Combination and a majority of the shares voted are voted in favor of the Business Combination. If a shareholder vote is not required by law and the Company does not decide to hold a shareholder vote for business or other legal reasons, the Company will, pursuant to its Amended and Restated Memorandum and Articles of Association, conduct the redemptions pursuant to the tender offer rules of the U.S. Securities and Exchange Commission (“SEC”) and file tender offer documents with the SEC prior to completing a Business Combination. If, however, shareholder approval of the Proposed Mobix Labs Transactions is required by law, or the Company decides to obtain shareholder approval for business or legal reasons, the Company will offer to redeem shares in conjunction with a proxy solicitation pursuant to the proxy rules and not pursuant to the tender offer rules. Additionally, each Public Shareholder may elect to redeem their Public Shares irrespective of whether they vote for or against the Proposed Mobix Labs Transaction, whether they participate in or abstain from voting, or whether they were a shareholder on the record date for the general meeting held to approve the Proposed Mobix Labs Transaction. If the Company seeks shareholder approval in connection with a Business Combination, the initial shareholders, Sponsor, officers and directors (the “Initial Shareholders”) have agreed to vote their Founder Shares (as defined below in Note 5) and any Public Shares purchased during or after the IPO in favor of a Business Combination. The Company has adopted an insider trading policy which requires insiders to: (i) refrain from purchasing shares during certain blackout periods and when they are in possession of any material non-public information and (ii) to clear all trades with the Company’s legal counsel prior to execution. In addition, the Initial Shareholders have agreed to waive their redemption rights with respect to their Founder Shares and Public Shares in connection with the completion of a Business Combination. Notwithstanding the foregoing, the Amended and Restated Memorandum and Articles of Association provides that a Public Shareholder, together with any affiliate of such shareholder or any other person with whom such shareholder is acting in concert or as a “group” (as defined under Section 13 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), will be restricted from redeeming its shares with respect to more than an aggregate of 15% or more of the ordinary shares sold in the IPO, without the prior consent of the Company. The Company has entered into a letter agreement with its Initial Shareholders, pursuant to which the Initial Shareholders have agreed to not to propose an amendment to the Amended and Restated Memorandum and Articles of Association that would modify the substance or timing of the Company’s obligation to redeem 100% of its Public Shares if the Company does not complete a Business Combination, unless the Company provides the Public Shareholders with the opportunity to redeem their ordinary shares in conjunction with any such amendment. Liquidation On July 14, 2022, the Company obtained shareholder approval to extend the date by which the Company must consummate an initial Business Combination from July 22, 2022 to January 22, 2023. On January 6, 2023, the Company obtained shareholder approval to further extend the date to July 22, 2023. If the Company is unable to complete the Proposed Mobix Labs Transaction or any other initial Business Combination by the Second Extended Date (the “Combination Period”), the Company will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than ten business days thereafter, redeem the Public Shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned on the funds held in the Trust Account (less taxes payable and up to $100,000 of interest to pay dissolution expenses), divided by the number of then issued and outstanding Public Shares, which redemption will completely extinguish Public Shareholders’ rights as shareholders (including the right to receive further liquidation distributions, if any) and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the remaining shareholders and the board of directors, liquidate and dissolve, subject, in each case, to the Company’s obligations under Cayman Islands law to provide for claims of creditors and in all cases subject to the other requirements of applicable law. There will be no redemption rights or liquidating distributions with respect to the Warrants, which will expire worthless if the Company fails to complete its initial Business Combination within the Combination Period. The Company’s Initial Shareholders have agreed to waive their liquidation rights with respect to the Founder Shares if the Company fails to complete a Business Combination within the Combination Period. However, if the Company’s Initial Shareholders acquire Public Shares in or after the IPO, they will be entitled to liquidating distributions from the Trust Account with respect to such Public Shares if the Company fails to complete a Business Combination within the Combination Period. In the event of such distribution, it is possible that the per share value of the residual assets remaining available for distribution (including Trust Account assets) will be only $10.00 per share initially held in the Trust Account. In order to protect the amounts held in the Trust Account, the Sponsor has agreed to be liable to the Company if and to the extent any claims by a vendor for services rendered or products sold to the Company, or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amount of funds in the Trust Account. This liability will not apply with respect to any claims by a third party who executed a waiver of any right, title, interest or claim of any kind in or to any monies held in the Trust Account or to any claims under the Company’s indemnity of the underwriters of the IPO against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the “Securities Act”). Moreover, in the event that an executed waiver is deemed to be unenforceable against a third party, the Sponsor will not be responsible to the extent of any liability for such third-party claims. The Company will seek to reduce the possibility that the Sponsor will have to indemnify the Trust Account due to claims of creditors by endeavoring to have all vendors, service providers, except the independent registered public accounting firm, prospective target businesses or other entities with which the Company does business, execute agreements with the Company waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account. Liquidity and Capital Resources; Going Concern The Company’s liquidity needs prior to the consummation of the IPO were satisfied through the proceeds of $25,000 from the sale of 2,000,000 Founder Shares (Note 7). Subsequent to the consummation of the IPO, the Company’s liquidity needs have been satisfied through the net proceeds from the Private Placement held outside of the Trust Account and the proceeds of the loans described below. In order to fund working capital deficiencies or finance transaction costs in connection with a Business Combination, our Sponsor or an affiliate of our Sponsor or certain of our officers and directors may, but are not obligated to, loan us funds as may be required. If we complete a Business Combination, we may repay such loaned amounts out of the proceeds of the Trust Account released to us. In the event that a Business Combination does not close, we may use a portion of the working capital held outside the Trust Account to repay such loaned amounts, but no proceeds from our Trust Account would be used for such repayment. Up to $1,500,000 of such loans may be convertible into warrants, at a price of $1.00 per warrant, at the option of the lender. The warrants would be identical to the Private Warrants. As of December 31, 2022, the Company has drawn down $662,000 under the Working Capital Loans (as defined in Note 5). The Company anticipates that the cash held outside of the Trust Account in the amount of $ 175,788 as of December 31, 2022 will not be sufficient to allow the Company to operate for at least the next 12 months from the issuance of the financial statements, assuming that a Business Combination is not consummated during that time. The Company has incurred and expects to continue to incur significant costs in pursuit of its acquisition plans. These conditions raise substantial doubt about the Company's ability to continue as a going concern for a period of time within one year after the date that the financial statements are issued. Management plans to address this uncertainty through the initial Business Combination as discussed above. There is no assurance that the Company's plans to consummate an initial Business Combination will be successful or successful within the Combination Period. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Summary of Significant Accoun_6

Summary of Significant Accounting Policies	3 Months Ended	12 Months Ended
Summary of Significant Accounting Policies	Mar. 31, 2023	Dec. 31, 2022
Summary of Significant Accounting Policies
Summary of Significant Accounting Policies	Note 2 — Summary of Significant Accounting Policies Basis of Presentation The accompanying unaudited condensed financial statements are presented in U.S. dollars in conformity with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X of the SEC. Certain information or footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a complete presentation of financial position, results of operations, or cash flows. In the opinion of management, the unaudited condensed financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances and results for the periods presented. The interim results for the three months ended March 31, 2023 are not necessarily indicative of the results that may be expected through December 31, 2023. The accompanying unaudited condensed financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company’s annual report on Form 10-K filed with the SEC on March 31, 2023. Emerging Growth Company The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002. Section 102(b)(1) of the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”) exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that an emerging growth company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such an election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statements with another public company that is neither an emerging growth company nor an emerging growth company that has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. Fair Value of Financial Instruments The fair value of the Company’s assets and liabilities which qualify as financial instruments under ASC 820, “Fair Value Measurement,” other than the warrant liability and the PIPE derivative liability (as defined in Note 5), approximate the carrying amounts represented in the Company’s balance sheets, primarily due to their short-term nature. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates. Cash Equivalents Cash equivalents include cash on hand and on deposit at banking institutions as well as all highly liquid short-term investments with original maturities of 90 days or less. The Company did not have any cash equivalents as of March 31, 2023 and December 31, 2022. Investments Held in Trust Account As of March 31, 2023, the assets held in the Trust Account were held in cash and U.S. Treasury Securities with maturities of six months or shorter. The Company classifies its investment in money market funds as trading securities. Trading securities are presented on the balance sheets at fair value at the end of each reporting period. Gains and losses resulting from the change in fair value of investments held in the Trust Account are included in trust interest income in the accompanying statements of operations. The estimated fair values of investments held in the Trust Account are determined using available market information. Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed the Federal Deposit Insurance Corporation coverage. The Company has not experienced losses on these accounts. Warrants The Company accounts for warrants based on an assessment of specific terms and applicable authoritative guidance in ASC 480 and ASC 815, “Derivatives and Hedging” (“ASC 815”). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company’s own ordinary shares and whether the warrant holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent reporting period while the warrants are outstanding. Because the Company does not control the occurrence of events, such as a tender offer or exchange, that may trigger cash settlement of the Private Warrants where not all of the shareholders also receive cash, the Private Warrants do not meet the criteria for equity treatment thereunder; as such, the Private Warrants must be recorded as a derivative liability. For issued warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as non-cash gain or loss on the statements of operations. The Company’s Public Warrants are accounted for as equity and Private Warrants are accounted for as a liability. The Private Warrants were recorded at fair value as of July 22, 2021, the closing date of the IPO, and are re-valued at each reporting date, with changes in the fair value reported in the statements of operations. Ordinary Shares Subject to Possible Redemption The Company accounts for its Public Shares in accordance with the guidance in ASC 480. Ordinary shares subject to mandatory redemption (if any) are classified as a liability instrument and are measured at fair value. Conditionally redeemable ordinary shares (including shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) are classified as temporary equity. At all other times, ordinary shares are classified as shareholders’ equity. The Company’s ordinary shares subject to possible redemption feature certain redemption rights that are considered to be outside of the Company’s control and subject to the occurrence of uncertain future events. Accordingly, as of March 31, 2023 and December 31, 2022, 856,042 and 953,033 ordinary shares, respectively, subject to possible redemption are presented, at redemption value, as temporary equity, outside of the shareholders’ deficit section of the Company’s balance sheet. The Company recognizes changes in redemption value immediately as they occur and adjusts the carrying value of redeemable ordinary shares to equal the redemption value at the end of each reporting period. Such changes are reflected in additional paid-in capital, or in the absence of additional capital, in accumulated deficit. In connection with the extensions of the business combination period on July 14, 2022 and January 6, 2023, Public Shareholders elected to redeem an aggregate of 7,046,967 Public Shares and 96,991 Public Shares, respectively. As a result, $70,573,278 and $1,004,600 were paid out of the Trust Account in connection with the redemptions, respectively. During the three months ended March 31, 2023, the Company recorded an accretion of $261,713 composed of $128,407 (extension funds deposited into the Trust Account) and $133,306 (total of interest income and unrealized gain exceeding the $100,000 that can be withheld to pay dissolution expenses), and $261,713 was recorded in accumulated deficit. Derivative Financial Instruments The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with ASC 815. The Company’s derivative instruments were recorded at fair value as of July 22, 2021, the closing date of the IPO, and will be re-valued at each reporting date, with changes in the fair value reported in the statements of operations. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. The PIPE derivative liability is comprised of the Make-Whole Features. The PIPE derivative liability meets the criteria for derivative liability classification. As such, the PIPE derivative liability is recorded at its initial fair value on the date of issuance and each balance sheet date thereafter. Changes in the estimated fair value of the derivative liability are recognized in the statements of operations. Income Taxes The Company follows the asset and liability method of accounting for income taxes under ASC 740, “Income Taxes.” Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that included the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. There were no unrecognized tax benefits as of March 31, 2023 and December 31, 2022. The Company’s management determined that the Cayman Islands is the Company’s only major tax jurisdiction. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. No amounts were accrued for the payment of interest and penalties for the three months ended March 31, 2023 and 2022. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company is subject to income tax examinations by major taxing authorities since inception. The Company is considered to be an exempted Cayman Islands company with no connection to any other taxable jurisdiction and is presently not subject to income taxes or income tax filing requirements in the Cayman Islands or the United States. As such, the Company’s tax provision was zero for the period presented. While the Company is not expected to be subject to United States taxation (other than as a result of a business combination involving a U.S. target), the Company may become subject to United States taxation if it were or deemed to be engaged in a United States trade or business. Any interest payable in respect of U.S. debt obligations (if any) held by the Trust Account is intended to qualify for the portfolio interest exemption or otherwise be exempt from U.S. withholding taxes. Furthermore, shareholders of the Company’s shares may be subject to tax in their respective jurisdictions based on applicable law, for instance, United States persons may be subject to tax on amounts deemed received depending on whether the Company is a passive foreign investment company and whether U.S. persons have made any applicable tax elections permitted under applicable law. Net Income (Loss) Per Share Net income (loss) per ordinary share is calculated by dividing the net income (loss) by the weighted average ordinary shares outstanding for the respective period. With respect to the accretion of ordinary shares subject to possible redemption and consistent with ASC 480-10-S99-3A, “Distinguishing Liabilities and Equity — Overall — SEC Materials,” the Company treated accretion in the same manner as a dividend, paid to the shareholder in the calculation of the net income (loss) per ordinary share. Net income (loss) per share is computed by dividing net loss by the weighted average number of ordinary shares outstanding during the period, excluding ordinary shares forfeited. The Company has not considered the effect of (1) the 9,400,000 ordinary shares issuable upon exercise of the Public Warrants and Private Warrants, and (2) the PIPE in the calculation of diluted loss per share, since the exercise of such Warrants and PIPE are contingent upon the occurrence of future events and the inclusion of such Warrants and PIPE would be anti-dilutive. As a result, diluted loss per share is the same as basic loss per share for the period presented. The Company’s statement of operations includes a presentation of net income (loss) per share for ordinary shares subject to possible redemption in a manner similar to the two-class method of net income (loss) per share. As of March 31, 2023, the Company has 856,042 ordinary shares subject to possible redemption and 2,000,000 Founder Shares. For the three months ended March 31, 2023, earnings and losses are allocated pro rata based on the weighted average of ordinary shares outstanding for the respective period, reflective of the respective participation rights, between the two classes of ordinary shares. The net income (loss) per share (unaudited) presented in the statements of operations is based on the following: For the three months ended For the three months ended March 31, 2023 March 31, 2022 Net (loss) income $ (312,060) $ 604,359 Accretion of temporary equity to redemption value (261,713) — Net (loss) income including accretion of temporary equity to redemption value $ (573,773) $ 604,359 Public Shares Founder Shares Public Shares Founder Shares Basic and diluted net income per share: 873,285 2,000,000 8,000,000 2,000,000 Ownership percentage 30 % 70 % 80 % 20 % Numerator: Net income (loss) including accretion of temporary equity to redemption value $ (174,388) $ (399,384) $ 483,487 $ 120,872 Plus: Accretion applicable to the redeemable class $ 261,713 — — — Allocation of net income (loss) $ 87,325 $ (399,384) $ 483,487 $ 120,872 Denominator: Weighted-average shares outstanding 873,285 2,000,000 8,000,000 2,000,000 Basic and diluted net income (loss) per share: $ 0.10 $ (0.20) $ 0.06 $ 0.06 Risks and Uncertainties In February 2022, the Russian Federation commenced a military action with the country of Ukraine. Although the length and impact of the ongoing military conflict is highly unpredictable, the conflict in Ukraine could lead to market disruptions, including significant volatility in commodity prices, credit and capital markets, as well as supply chain interruptions. As a result of this action, various nations, including the United States, have instituted economic sanctions against the Russian Federation. Further, the impact of this action and related sanctions on the world economy are not determinable as of the date of these financial statements. Recent Accounting Pronouncements The Company does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Company’s financial statements.	Note 2 — Summary of Significant Accounting Policies Basis of Presentation The accompanying financial statements are presented in conformity with accounting principles generally accepted in the United States of America (“GAAP”) and pursuant to the rules and regulations of the SEC. Emerging Growth Company The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002. Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that an emerging growth company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such an election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statements with another public company that is neither an emerging growth company nor an emerging growth company that has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. Fair Value of Financial Instruments The fair value of the Company’s assets and liabilities which qualify as financial instruments under ASC Topic 820, “Fair Value Measurement”, other than warrant liability (see Note 8), approximate the carrying amounts represented in the Company’s balance sheet, primarily due to their short-term nature. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates. Offering Costs associated with the IPO Offering costs consist principally of professional and registration fees incurred through the balance sheet date that are directly attributable to the IPO. Offering costs are allocated based on relative fair value to the ordinary shares subject to possible redemption and Public Warrants. Cash Cash and cash equivalents include cash on hand and on deposit at banking institutions as well as all highly liquid short-term investments with original maturities of 90 days or less. The Company did not have any cash equivalents as of December 31, 2022 and 2021. Investments Held in Trust Account As of December 31, 2022, the assets held in the Trust Account were held in money market funds which invest only in U.S. Treasury Securities. The Company classifies its investment in money market funds as trading securities. Trading securities are presented on the balance sheets at fair value at the end of each reporting period. Gains and losses resulting from the change in fair value of investments held in the Trust Account are included in trust interest income in the accompanying statements of operations. The estimated fair values of investments held in the Trust Account are determined using available market information. As of December 31, 2022 and 2021, the Company had $ 9,835,409 and $ 80,002,777 in investments held in the Trust Account, respectively. At the Meeting on July 14, 2022, shareholders holding 7,046,967 ordinary shares exercised their right to redeem their ordinary shares for a pro rata portion of the funds in the Trust Account and $70,573,278 was removed from the Trust Account to pay such holders. At the meeting on January 6, 2023, shareholders holding 96,991 ordinary shares exercised their right to redeem their ordinary shares for a pro rata portion of the funds in the Trust Account and $1,004,600 (approximately $10.36 per ordinary share) was removed from the Trust Account to pay such holders. Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed the Federal Deposit Insurance Corporation coverage of $250,000 . The Company has not experienced losses on these accounts. Warrants The Company accounts for warrants based on an assessment of specific terms and applicable authoritative guidance in the FASB’s ASC 480, “Distinguishing Liabilities from Equity” and ASC 815, “Derivatives and Hedging.” The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company’s own ordinary shares and whether the warrant holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent reporting period while the warrants are outstanding. Because the Company does not control the occurrence of events, such as a tender offer or exchange, that may trigger cash settlement of the Private Warrants where not all of the shareholders also receive cash, the Private Warrants do not meet the criteria for equity treatment thereunder; as such, the Private Warrants must be recorded as derivative liability. For issued warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as non-cash gain or loss on the statements of operations. The Company’s Public Warrants (Note 7) are accounted for as equity, and the Private Warrants (Note 4) are accounted for as liabilities. The Private Warrants were recorded at fair value as of July 22, 2021, the closing date of the IPO, and are re-valued at each reporting date, with changes in the fair value reported in the statements of operations. Ordinary Shares Subject to Possible Redemption The Company accounts for its ordinary shares subject to possible redemption (“Public Shares”) in accordance with the guidance in ASC 480. Ordinary shares subject to mandatory redemption (if any) are classified as a liability instrument and is measured at fair value. Conditionally redeemable ordinary shares (including shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) is classified as temporary equity. At all other times, ordinary shares are classified as shareholders' equity. The Company’s ordinary shares subject to possible redemption feature certain redemption rights that are considered to be outside of the Company’s control and subject to the occurrence of uncertain future events. Accordingly, as of December 31, 2022 and 2021, 953,033 and 8,000,000 ordinary shares subject to possible redemption, respectively, are presented, at redemption value, as temporary equity, outside of the shareholders' deficit section of the Company’s balance sheet. The Company recognizes changes in redemption value immediately as they occur and adjusts the carrying value of redeemable ordinary shares to equal the redemption value at the end of each reporting period. Such changes are reflected in additional paid-in capital, or in the absence of additional capital, in accumulated deficit. On July 22, 2021, the Company recorded an accretion of $6,793,210 , $5,371,731 of which was recorded in additional paid-in capital and $1,421,479 was recorded in accumulated deficit. In connection with the extension of the Business Combination period on July 14, 2022, Public Shareholders elected to redeem an aggregate of 7,046,967 Public Shares. As a result, $ 70,573,278 was paid out of the Trust Account in connection with the redemptions. For the year ended December 31, 2022, the Company recorded an accretion of $ 188,700 (extension funds deposited into the Trust Account) and $ 119,987 (interest income over $ 100,000 ) and $ 308,687 was recorded in accumulated deficit. Derivative Financial Instruments The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with ASC 815. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value on the issuance date and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. The PIPE Derivative Liability is comprised of the Make-Whole Features (as defined in Note 6). The PIPE Derivative Liability meets the criteria for derivative liability classification. As such, the PIPE Derivative Liability is recorded at its initial fair value on the date of issuance and each balance sheet date thereafter. Changes in the estimated fair value of the derivative liability are recognized as non-cash gain or loss on the statements of operations. The fair value of the derivative liability is discussed in Note 8. Income Taxes The Company follows the asset and liability method of accounting for income taxes under FASB ASC 740, “Income Taxes.” Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that included the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. There were no unrecognized tax benefits as of December 31, 2022. The Company’s management determined that the Cayman Islands is the Company’s only major tax jurisdiction. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. No amounts were accrued for the payment of interest and penalties for the period from March 19, 2021 (inception) through December 31, 2021 and for the year ended December 31, 2022. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company is subject to income tax examinations by major taxing authorities since inception. The Company is considered to be an exempted Cayman Islands company with no connection to any other taxable jurisdiction and is presently not subject to income taxes or income tax filing requirements in the Cayman Islands or the United States. As such, the Company’s tax provision was zero for the period presented. While the Company is not expected to be subject to United States taxation (other than as a result of a Business Combination involving a U.S. target), the Company may become subject to United States taxation if it were or deemed to be engaged in a United States trade or business. Any interest payable in respect of U.S. debt obligations (if any) held by the Trust Account is intended to qualify for the portfolio interest exemption or otherwise be exempt from U.S. withholding taxes. Furthermore, shareholders of the Company’s shares may be subject to tax in their respective jurisdictions based on applicable law, for instance, United States persons may be subject to tax on amounts deemed received depending on whether the Company is a passive foreign investment company and whether U.S. persons have made any applicable tax elections permitted under applicable law. Net Income (Loss) Per Share Net income (loss) per share is computed by dividing net loss by the weighted average number of ordinary shares outstanding during the period, excluding ordinary shares forfeited. The Company has not considered the effect of (1) the 9,400,000 ordinary shares issuable upon exercise of the Public Warrants and Private Warrants, and (2) the PIPE in the calculation of diluted loss per share, since the exercise of such Warrants and PIPE are contingent upon the occurrence of future events and the inclusion of such Warrants and PIPE would be anti-dilutive. As a result, diluted loss per share is the same as basic loss per share for the period presented. The Company’s statement of operations includes a presentation of net income (loss) per share for ordinary shares subject to possible redemption in a manner similar to the two-class method of net income (loss) per share. As of December 31, 2022, the Company has 953,033 ordinary shares subject to possible redemption and 2,000,000 Founder Shares. For the year ended, December 31, 2022, earnings and losses are adjusted for the effects of accretion to ordinary shares subject to possible redemption and are allocated pro rata, reflective of the respective participation rights, between the two classes of ordinary shares. The net income (loss) per share presented in the statements of operations is based on the following: From March 19, 2021 For the Year ended (inception) through December 31, 2022 December 31, 2021 Net loss from inception to IPO date in year 2021 $ — $ (85,612) Net income from IPO date to year-end (total loss from inception to 12/31/2021) less the loss from inception to IPO) — 446,671 Net income (loss) $ (776,129) $ 361,059 Accretion of temporary equity to redemption value (308,687) (6,793,210) Net income (loss) including accretion of temporary equity to redemption value $ (1,084,816) $ (6,432,151) For the Year ended From March 19, 2021 (inception) through December 31, 2022 December 31, 2021 Public Shares Founder Shares Public Shares Founder Shares Basic and diluted net income per share: Total number of shares 4,795,078 2,000,000 8,000,000 2,000,000 Ownership percentage 71 % 29 % 80 % 20 % Numerator: Allocation of net loss – inception to IPO date $ — $ — $ — $ (85,612) Allocation of net income – IPO date to year end (allocated based on ownership percentage) — — 357,337 89,334 Total net income allocation $ — $ — $ 357,337 $ 3,722 Net income (loss) including accretion of temporary equity to redemption value (765,521) (319,295) (5,434,568) (1,358,642) Plus: Accretion applicable to the redeemable class 308,687 — 6,793,210 — Allocation of net income (loss) $ (456,834) $ (319,295) $ 1,715,979 $ (1,354,920) Denominator: Weighted-average shares outstanding 4,795,078 2,000,000 4,527,778 1,868,056 Basic and diluted net income (loss) per share: $ (0.10) $ (0.16) $ 0.38 $ (0.73) Risks and Uncertainties In February 2022, the Russian Federation commenced a military action with the country of Ukraine. Although the length and impact of the ongoing military conflict is highly unpredictable, the conflict in Ukraine could lead to market disruptions, including significant volatility in commodity prices, credit and capital markets, as well as supply chain interruptions. As a result of this action, various nations, including the United States, have instituted economic sanctions against the Russian Federation. Further, the impact of this action and related sanctions on the world economy are not determinable as of the date of these financial statements. Recent Accounting Pronouncements The Company does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Company’s financial statements.

Private Placement_2

Private Placement	3 Months Ended	12 Months Ended
Private Placement	Mar. 31, 2023	Dec. 31, 2022
Private Placement
Private Placement	Note 3 — Private Placement Simultaneously with the closing of the IPO, the Sponsor and the underwriters purchased an aggregate of 3,400,000 Private Warrants at an average price of $1.00 per Private Warrant, for an aggregate purchase price of $3,400,000 . Each Private Warrant will entitle the holder to purchase one ordinary share at a price of $11.50 per full share, subject to adjustment. The proceeds from the Private Warrants and the proceeds from the IPO, less underwriting discounts and commissions, were placed in the Trust Account. If the Company does not complete a business combination within the Combination Period, the proceeds from the sale of the Private Warrants will be used to fund the redemption of the Public Shares (subject to the requirements of applicable law). Private Warrant Liability The Company accounts for the Private Warrants as a liability as the number of shares used to calculate the settlement amount are not fixed. This liability is subject to re-measurement at each balance sheet date until exercised, and any change in fair value is recognized in the Company’s statements of operations.	Note 4 — Private Placement Simultaneously with the closing of the IPO , the Sponsor and the underwriters purchased an aggregate of 3,400,000 Private Warrants at an average price of $1.00 per Private Warrant, for an aggregate purchase price of $3,400,000 . Each Private Warrant will entitle the holder to purchase one ordinary share at a price of $11.50 per full share, subject to adjustment (see Note 7). The proceeds from the Private Warrants and the proceeds from the IPO, less underwriting discounts and commissions, were placed in the Trust Account. If the Company does not complete a Business Combination within the Combination Period, the proceeds from the sale of the Private Warrants will be used to fund the redemption of the Public Shares (subject to the requirements of applicable law). Private Warrant Liability The Company accounts for the Private Warrants as liabilities as the number of shares used to calculate the settlement amount are not fixed. This liability is subject to re-measurement at each balance sheet date until exercised, and any change in fair value is recognized in the Company’s statements of operations.

Related Party Transactions_2

Related Party Transactions	3 Months Ended	12 Months Ended
Related Party Transactions	Mar. 31, 2023	Dec. 31, 2022
Related Party Transactions
Related Party Transactions	Note 4 – Related Party Transactions Founder Shares The Company’s Initial Shareholders have agreed, subject to limited exceptions, not to transfer, assign or sell any of their Founder Shares until the earlier to occur of: (i) one year after the completion of the initial business combination or (ii) the date following the completion of the initial business combination on which the Company completes a liquidation, merger, share exchange or other similar transaction that results in all of the shareholders having the right to exchange their ordinary shares for cash, securities or other property. Notwithstanding the foregoing, if the closing price of the ordinary shares equals or exceeds $12.00 per share (as adjusted for share subdivisions, share capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within any 30 - trading day period commencing at least 150 days after the initial business combination, the Founder Shares will be released from the lockup. Working Capital Loans In order to finance transaction costs in connection with a business combination, the Sponsor or an affiliate of the Sponsor, or certain of the Company’s officers and directors may, but are not obligated to, loan the Company funds as may be required (“Working Capital Loans”). Such Working Capital Loans would be evidenced by promissory notes. The notes may be repaid upon completion of a business combination, without interest, or, at the lender’s discretion, up to $1,500,000 of notes may be converted upon completion of business combination into warrants at a price of $1.00 per warrant. Such warrants would be identical to the Private Warrants. In the event that business combination does not close, the Company may use a portion of proceeds held outside the Trust Account to repay the Working Capital Loans but no proceeds held in the Trust Account would be used to repay the Working Capital Loans. On June 20, 2022, the Company issued an unsecured convertible promissory note in the aggregate principal amount of $360,000 to the Sponsor under which the Company may draw down Working Capital Loans from time to time prior to the maturity date up to such aggregate principal amount. On July 18, 2022, the Company issued an additional unsecured convertible promissory note in the aggregate principal amount of $490,000 to the Sponsor under which the Company may draw down Working Capital Loans from time to time prior to the maturity date up to such aggregate principal amount. Any Working Capital Loans under the promissory notes issued on June 20, 2022 and July 18, 2022 are due on the earlier of five business days after the Company’s initial business combination and December 31, 2023. On January 6, 2023, the Company issued an unsecured convertible promissory note in the aggregate principal amount of $300,000 to the Sponsor, under which the Company was permitted to draw down Working Capital Loans from time to time prior to the maturity date up to such aggregate principal amount, to fund the Company’s ongoing working capital requirements and to fund a portion of the amounts that the Company has agreed to deposit into the Company’s Trust Account as a result of obtaining shareholder approval of the extension amendment proposal. The Company drew down the full amount of the Working Capital Loans under such promissory note. The Working Capital Loan under this promissory note is due on the earlier of five business days after the Company’s initial business combination and July 31, 2024. As of March 31, 2023 and December 31, 2022, the Company had drawn down $962,000 and $662,000 , respectively, of Working Capital Loans under the promissory notes. Administrative Services Arrangement On July 26, 2021, the Company entered into an administrative services agreement with the Sponsor, effective as of the date that the Company’s securities were first listed on The Nasdaq Stock Market (“Nasdaq”), to make available to the Company certain general and administrative services, including office space, utilities and administrative services, as the Company may require from time to time. The Company has agreed to pay $10,000 per month for these services. Upon completion of the Company’s business combination or its liquidation, the Company will cease paying these monthly fees. For the three months ended March 31, 2023 and 2022, the Company incurred expenses of $30,000 and $30,000 under the administrative services agreement, respectively, of which $90,000 and $80,000 are included in accrued expenses as of March 31, 2023 and December 31, 2022, respectively.	Note 5 - Related Party Transactions Founder Shares The Initial Shareholders have agreed, subject to limited exceptions, not to transfer, assign or sell any of their Founder Shares until the earlier to occur of: (i) one year after the completion of the initial Business Combination or (ii) the date following the completion of the initial Business Combination on which the Company completes a liquidation, merger, share exchange or other similar transaction that results in all of the shareholders having the right to exchange their ordinary shares for cash, securities or other property. Notwithstanding the foregoing, if the closing price of the ordinary shares equals or exceeds $12.00 per share (as adjusted for share subdivisions, share capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within any 30 - trading day period commencing at least 150 days after the initial Business Combination, the Founder Shares will be released from the lockup. Promissory Note to Sponsor and Working Capital Loans On April 7, 2021, the Company issued an unsecured promissory note (the “Promissory Note”) to the Sponsor, pursuant to which the Company may borrow up to an aggregate principal amount of $200,000 to cover formation and operating expenses related to the IPO. The Promissory Note is non-interest bearing and payable on the earlier of (i) July 31, 2021 and (ii) the completion of the IPO. The outstanding balance of $129,602 was repaid on July 22, 2021. In order to finance transaction costs in connection with a Business Combination, the Sponsor or an affiliate of the Sponsor, or certain of the Company’s officers and directors may, but are not obligated to, loan the Company funds as may be required (“Working Capital Loans”). Such Working Capital Loans would be evidenced by promissory notes. The notes may be repaid upon completion of a Business Combination, without interest, or, at the lender’s discretion, up to $1,500,000 of notes may be converted upon completion of a Business Combination into warrants at a price of $1.00 per warrant. Such warrants would be identical to the Private Warrants. In the event that a Business Combination does not close, the Company may use a portion of proceeds held outside the Trust Account to repay the Working Capital Loans but no proceeds held in the Trust Account would be used to repay the Working Capital Loans. On June 20, 2022, the Sponsor provided the Company with a Working Capital Loan of $360,000 and the Company issued an unsecured convertible promissory note in the aggregate principal amount of $360,000 to the Sponsor. On July 18, 2022, the Sponsor provided the Company with a Working Capital Loan of $490,000 and the Company issued an unsecured convertible promissory note in the aggregate principal amount of $490,000 to the Sponsor. Any Working Capital Loans under the promissory notes issued on June 20, 2022 and July 18, 2022 are due on the earlier of five business days after the Company's initial Business Combination and December 31, 2023. As of December 31, 2022, the Company had drawn down $662,000 under the Working Capital Loans. On January 6, 2023, the Sponsor provided the Company with an additional Working Capital Loan of $300,000 , and the Company issued an unsecured convertible promissory note in the aggregate principal amount of $300,000 to the Sponsor to fund the Company's ongoing working capital requirements and to fund a portion of the amounts that the Company has agreed to deposit into the Company's Trust Account as a result of obtaining shareholder approval of the extension amendment proposal (See Note 9). The Working Capital Loan under this promissory note is due on the earlier of five business days after the Company's initial Business Combination and July 31, 2024. Administrative Services Arrangement On July 26, 2021, the Company entered into an administrative services agreement with the Sponsor, effective as of the date that the Company’s securities were first listed on The Nasdaq Stock Market LLC, to make available to the Company certain general and administrative services, including office space, utilities and administrative services, as the Company may require from time to time. The Company has agreed to pay $10,000 per month for these services. Upon completion of the Company’s Business Combination or its liquidation, the Company will cease paying these monthly fees. For the year ended December 31, 2022 and for the period from March 19, 2021 (inception) through December 31, 2021 the Company incurred expenses of $120,000 and $60,000 under this agreement, respectively, of which $80,000 and $10,000 are included in accrued expenses as of December 31, 2022 and 2021, respectively.

Commitments and Contingencies_2

Commitments and Contingencies	3 Months Ended	12 Months Ended
Commitments and Contingencies	Mar. 31, 2023	Dec. 31, 2022
Commitments and Contingencies
Commitments and Contingencies	Note 5 — Commitments and Contingencies Registration and Shareholder Rights Pursuant to a registration rights agreement entered into on July 19, 2021, the holders of Founder Shares, Private Warrants and warrants that may be issued upon conversion of Working Capital Loans (and any ordinary shares issuable upon the exercise of the Private Warrants and warrants that may be issued upon conversion of Working Capital Loans) are entitled to registration rights, requiring the Company to register such securities for resale. These holders will be entitled to certain demand and “piggyback” registration rights. However, the registration and shareholder rights agreement provide that the Company will not permit any registration statement filed under the Securities Act to become effective until the termination of the applicable lock-up period for the securities to be registered. The Company will bear the expenses incurred in connection with the filing of any such registration statements. Business Combination Marketing Agreement At the closing of the IPO and in connection with a business combination, the Company and the underwriters entered into an agreement (the “Business Combination Marketing Agreement”), whereby the underwriters are to assist the Company in holding meetings with the Company’s shareholders to discuss potential business combination targets and the target business’s attributes, introduce the Company to potential investors that are interested in purchasing the Company’s securities in connection with the potential business combination, provide financial advisory services to assist the Company in its efforts to obtain any shareholder approval for the business combination and assist the Company with its press releases and public filings in connection with the business combination. Pursuant to the Business Combination Marketing Agreement, the marketing fee payable to the representatives will be 3.5% of the gross proceeds of the IPO, or $2,800,000 , upon the consummation of our business combination. Proposed Mobix Labs Transaction The obligations of the Company and Mobix Labs to consummate the Proposed Mobix Labs Transaction are subject to the satisfaction or waiver of certain customary conditions to closing, including, among other things: (i) the expiration or termination of all applicable waiting periods (or any extension thereof) under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, (ii) the Company having at least $5,000,001 of net tangible assets after giving effect to the PIPE Investment in accordance with the terms of the PIPE Subscription Agreement and following the exercise by Public Shareholders of their redemption rights, (iii) approval by the required shareholders of the Company of the Business Combination Agreement and the Proposed Mobix Labs Transaction, (iv) the absence of any law enacted or order issued or threatened in writing by a governmental authority having the effect of restricting or making the Proposed Mobix Labs Transaction illegal or otherwise prohibiting, restricting or making illegal the consummation of the Proposed Mobix Labs Transaction, (v) shareholder approval of the Company to extend the time period for it to consummate a business combination from January 22, 2023 to July 22, 2023, which shareholder approval has been obtained, (vi) the performance or compliance in all material respects by the parties with all of the agreements and covenants required to be performed by such party under the Business Combination Agreement on or prior to the closing date, (vii) the resignation of certain officers and directors of the Company and Mobix Labs and (viii) the execution and delivery of the amended and restated registration rights agreement. The Business Combination Agreement, as amended, may be terminated by the Company and/or Mobix Labs under certain circumstances at any time prior to the closing, notwithstanding any requisite approval and adoption of the Business Combination Agreement and the Proposed Mobix Labs Transaction by the Mobix Labs stockholders or the Company, including, among others, (i) by the Company or Mobix Labs if the Closing has not occurred on or before July 22, 2023, (ii) by the Company if any Mobix Labs stockholder litigation is commenced or threatened in writing by a Mobix Labs stockholder at any time prior to the effective time and (iii) by the Company if Mobix Labs’ PCAOB audited financial statements were not delivered to the Company, in form and substance reasonably satisfactory to the Company, on or before December 15, 2022 (which right to terminate the Business Combination Agreement under this clause (iii) was required to be exercised before the date of the initial public filing of the registration statement on Form S-4 relating to the Proposed Mobix Labs Transaction with the SEC, and which right the Company elected not to exercise prior to such filing date). PIPE Subscription Agreement Pursuant to the PIPE Subscription Agreement, the Company has agreed and shall use its commercially reasonable efforts to file an SEC registration statement registering the shares of Class A Common Stock acquired by the PIPE Investor (the “PIPE Resale Registration Statement”) for public resale within 45 days of closing. The Company also agreed to issue additional shares of Class A Common Stock to the PIPE Investor (the “Make-Whole Features”) in the event that the volume weighted average price per share of the Class A Common Stock during the 30-day period commencing on the date that is 30 days after the date on which the PIPE Resale Registration Statement is declared effective (the “Adjustment Period VWAP”) is less than $10.00 per share. In such case, the PIPE Investor will be entitled to receive a number of shares of Class A Common Stock equal to the product of (x) the number of shares of Class A Common Stock issued to the PIPE Investor at the closing of the subscription and held by the PIPE Investor through the date that is 30 days after the effective date of the PIPE Resale Registration Statement multiplied by (y) a fraction, (A) the numerator of which is $10.00 minus the Adjustment Period VWAP and (B) the denominator of which is the Adjustment Period VWAP. In the event that the Adjustment Period VWAP is less than $7.00 , the Adjustment Period VWAP will be deemed to be $7.00 . The Company evaluated the accounting treatment for PIPE Subscription Agreement, which contains embedded Make-Whole Features, in accordance with ASC 480 and ASC 815 and has determined to account for the PIPE Subscription Agreement as a freestanding financial instrument and as a liability. The Company has concluded that, although the PIPE Subscription Agreement does not meet the definition of a liability under ASC 480, the PIPE Subscription Agreement should be classified as a liability (the “PIPE derivative liability”) upon the application of ASC 815-40 because (i) the number of additional shares issuable pursuant to the Make-Whole Features depends on whether there is an effective PIPE Resale Registration Statement (i.e., the Adjustment Period VWAP described above cannot be determined until the PIPE Resale Registration Statement has been declared effective) and (ii) an effective registration statement is not an input to the fair value option model for a fixed-for-fixed forward, which precludes the PIPE Subscription Agreement from being considered indexed to the Company’s own stock under Step 2 of the indexation guidance contained in ASC 815-40-15-7. As a result, the Company was required to measure the fair value of the PIPE derivative liability as of the time the Company entered into the PIPE Subscription Agreement and is required to do so at the end of each reporting period and is required to recognize the change in fair value in the Company’s operating results for the current period (See Note 7).	Note 6 — Commitments and Contingencies Registration and Shareholder Rights Pursuant to a registration rights agreement entered into on July 19, 2021, the holders of Founder Shares, Private Warrants and warrants that may be issued upon conversion of Working Capital Loans (and any ordinary shares issuable upon the exercise of the Private Warrants and warrants that may be issued upon conversion of Working Capital Loans) are entitled to registration rights, requiring the Company to register such securities for resale. These holders will be entitled to certain demand and “piggyback” registration rights. However, the registration and shareholder rights agreement provide that the Company will not permit any registration statement filed under the Securities Act to become effective until the termination of the applicable lock-up period for the securities to be registered. The Company will bear the expenses incurred in connection with the filing of any such registration statements. Underwriting Agreement The underwriters received a cash underwriting discounts and commissions of 2.0% of the gross proceeds of the IPO, or $ 1,600,000 . Business Combination Marketing Agreement At the closing of the IPO and in connection with the Business Combination, the Company and the underwriters entered into an agreement (the “Business Combination Marketing Agreement”), whereby the underwriters are to assist the Company in holding meetings with the Company’s shareholders to discuss potential Business Combination targets and the target business’s attributes, introduce the Company to potential investors that are interested in purchasing the Company’s securities in connection with the potential Business Combination, provide financial advisory services to assist the Company in its efforts to obtain any shareholder approval for the Business Combination and assist the Company with its press releases and public filings in connection with the Business Combination. Pursuant to the Business Combination Marketing Agreement, the marketing fee payable to the representatives will be 3.5% of the gross proceeds of the IPO, or $2,800,000 , upon the consummation of our Business Combination. Proposed Mobix Labs Transaction The obligations of the Company and Mobix Labs to consummate the Proposed Mobix Labs Transaction are subject to the satisfaction or waiver of certain customary conditions to closing, including, among other things: (i) the expiration or termination of all applicable waiting periods (or any extension thereof) under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, (ii) the Company having at least $ 5,000,001 of net tangible assets after giving effect to the PIPE Investment in accordance with the terms of the PIPE Subscription Agreement and following the exercise by Public Shareholders of their redemption rights, (iii) approval by the required shareholders of the Company of the business combination agreement and the Proposed Mobix Labs Transaction, (iv) the absence of any law enacted or order issued or threatened in writing by a governmental authority having the effect of restricting or making the Proposed Mobix Labs Transaction illegal or otherwise prohibiting, restricting or making illegal the consummation of the Proposed Mobix Labs Transaction, (v) shareholder approval of the Company to extend the time period for it to consummate a Business Combination from January 22, 2023 to July 22, 2023, which shareholder approval has been obtained, (vi) the performance or compliance in all material respects by the parties with all of the agreements and covenants required to be performed by such party under the business combination agreement on or prior to the closing date, (vii) the resignation of certain officers and directors of the Company and Mobix Labs and (viii) the execution and delivery of the amended and restated registration rights agreement. The business combination agreement may be terminated by the Company and/or Mobix Labs under certain circumstances at any time prior to the closing, notwithstanding any requisite approval and adoption of the business combination agreement and the Proposed Mobix Labs Transaction by the Mobix Labs stockholders or the Company, including, among others, (i) by the Company or Mobix Labs if the Closing has not occurred on or before July 22, 2023, (ii) by the Company if any Mobix Labs stockholder litigation is commenced or threatened in writing by a Mobix Labs stockholder at any time prior to the effective time and (iii) by the Company if Mobix Labs’ PCAOB audited financial statements were not delivered to the Company, in form and substance reasonably satisfactory to the Company, on or before December 15, 2022 (which right to terminate the business combination agreement under this clause (iii) is required to be exercised before the date of the initial public filing of the registration statement on Form S-4 relating to the Proposed Mobix Labs Transaction with the SEC). PIPE Subscription Agreement Pursuant to the PIPE Subscription Agreement, the Company has agreed and shall use its commercially reasonable efforts to file an SEC registration statement registering the shares of Class A Common Stock acquired by the PIPE Investor (the “PIPE Resale Registration Statement”) for public resale within 45 days of closing. The Company also agreed to issue additional shares of Class A Common Stock to the PIPE Investor (the “Make-Whole Features”) in the event that the volume weighted average price per share of the Class A Common Stock during the 30 -day period commencing on the date that is 30 days after the date on which the PIPE Resale Registration Statement is declared effective (the “Adjustment Period VWAP”) is less than $ 10.00 per share. In such case, the PIPE Investor will be entitled to receive a number of shares of Class A Common Stock equal to the product of (x) the number of shares of Class A Common Stock issued to the PIPE Investor at the closing of the subscription and held by the PIPE Investor through the date that is 30 days after the effective date of the PIPE Resale Registration Statement multiplied by (y) a fraction, (A) the numerator of which is $ 10.00 minus the Adjustment Period VWAP and (B) the denominator of which is the Adjustment Period VWAP. In the event that the Adjustment Period VWAP is less than $ 7.00 , the Adjustment Period VWAP will be deemed to be $ 7.00 . The Company evaluated the accounting treatment for PIPE Subscription Agreement, which contains embedded Make-Whole Features, in accordance with ASC 480 and ASC 815 and has determined to account for the PIPE Subscription Agreement as a freestanding financial instrument and as a liability. The Company has concluded that, although the PIPE Subscription Agreement does not meet the definition of a liability under ASC 480, the PIPE Subscription Agreement should be classified as a liability (the “PIPE Derivative Liability”) upon the application of ASC 815-40 because (i) the number of additional shares issuable pursuant to the Make-Whole Features depends on whether there is an effective PIPE Resale Registration Statement (i.e., the Adjustment Period VWAP described above cannot be determined until the PIPE Resale Registration Statement has been declared effective) and (ii) an effective registration statement is not an input to the fair value option model for a fixed-for-fixed forward, which precludes the PIPE Subscription Agreement from being considered indexed to the Company’s own stock under Step 2 of the indexation guidance contained in ASC 815-40-15-7. As a result, the Company is required to measure the fair value of the PIPE Derivative Liability at the time the Company entered into the PIPE Subscription Agreement and at the end of each reporting period and is required to recognize the change in fair value in the Company’s operating results for the current period (See Note 8).

Shareholders' Deficit_2

Shareholders' Deficit	3 Months Ended	12 Months Ended
Shareholders' Deficit	Mar. 31, 2023	Dec. 31, 2022
Shareholders' Deficit
Shareholders' Deficit	Note 6 — Shareholders’ Deficit Preference Shares The Company is authorized to issue 1,000,000 preference shares with a par value of $0.0001 per share and with such designations, voting and other rights and preferences as may be determined from time to time by the Company’s board of directors. There currently are no preference shares issued or outstanding. Ordinary Shares The Company is authorized to issue 200,000,000 ordinary shares with a par value of $0.0001 per share. Prior to the consummation of the IPO, on April 7, 2021, the Sponsor purchased an aggregate of 2,875,000 ordinary shares. On July 19, 2021, the Company effected a cancellation of 575,000 Founder Shares, resulting in an aggregate of 2,300,000 Founder Shares outstanding. On September 5, 2021, the underwriters’ over-allotment option expired unexercised, resulting in the forfeiture of an additional 300,000 Founder Shares and a total of 2,000,000 Founder Shares outstanding as of March 31, 2023 and December 31, 2022. All shares and associated amounts have been retroactively restated to reflect the share cancellation. Ordinary shareholders of record are entitled to one vote for each share held on all matters to be voted on by shareholders. As of March 31, 2023 and December 31, 2022, there were 856,042 and 953,033 ordinary shares issued in the IPO which are subject to possible redemption, respectively. Public Warrants The Company will not issue fractional Public Warrants and only whole Public Warrants will trade. The Public Warrants will become exercisable on 30 days after the completion of a business combination. No Public Warrants will be exercisable for cash unless the Company has an effective and current registration statement covering the ordinary shares issuable upon exercise of the Public Warrants and a current prospectus relating to such ordinary shares. Notwithstanding the foregoing, if a registration statement covering the ordinary shares issuable upon exercise of the Public Warrants is not effective within 120 days following the consummation of a business combination, warrant holders may, until such time as there is an effective registration statement and during any period when the Company shall have failed to maintain an effective registration statement, exercise Public Warrants on a cashless basis pursuant to an available exemption from registration under the Securities Act. The Public Warrants will expire five years from the closing of a business combination. Once the Public Warrants become exercisable, the Company may redeem the Public Warrants in whole and not in part: ● at a price of $0.01 per warrant; ● at any time after the Public Warrants become exercisable; ● upon not less than 30 days ’ prior written notice of redemption to each warrant holder; ● if, and only if, the reported last sale price of the ordinary shares equals or exceeds $18.00 per share (as adjusted for share subdivisions, share capitalizations, reorganizations, recapitalizations and the like and for certain issuances of ordinary shares and equity-linked securities for capital raising purposes in connection with the closing of our initial business combination), for any 20 trading days within a 30 -day trading period commencing after the Public Warrants become exercisable and ending on the third business day prior to the notice of redemption to warrant holders; and ● if, and only if, there is a current registration statement in effect with respect to the ordinary shares underlying such warrants at the time of redemption and for the entire 30 -day trading period referred to above and continuing each day thereafter until the date of redemption, except if the Public Warrants may be exercised on a cashless basis and such cashless exercise is exempt from registration under the Securities Act. If the Company calls the Public Warrants for redemption, management will have the option to require all holders that wish to exercise the Public Warrants to do so on a “cashless basis,” as described in the warrant agreement. The exercise price and number of ordinary shares issuable on exercise of the Public Warrants may be adjusted in certain circumstances including in the event of a share dividend, extraordinary dividend or recapitalization, reorganization, merger or consolidation. However, except as described below, the Public Warrants will not be adjusted for issuances of ordinary shares at a price below their respective exercise prices. Additionally, in no event will the Company be required to net cash settle the Public Warrants. If the Company is unable to complete business combination within the Combination Period and the Company liquidates the funds held in the Trust Account, holders of warrants will not receive any of such funds with respect to their warrants, nor will they receive any distribution from the Company’s assets held outside of the Trust Account with the respect to such warrants. Accordingly, the Public Warrants may expire worthless. In addition, if (x) the Company issues additional ordinary shares or equity-linked securities for capital raising purposes in connection with the closing of a business combination at an issue price or effective issue price of less than $9.20 per ordinary share (with such issue price or effective issue price to be determined in good faith by the Company’s board of directors, and in the case of any such issuance to the Initial Shareholders or their affiliates, without taking into account any Founder Shares held by them prior to such issuance), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of a business combination on the date of the consummation of a business combination (net of redemptions), and (z) the volume weighted average trading price of the Company’s ordinary shares during the 20 trading day period starting on the trading day prior to the day on which the Company consummates a business combination (such price, the “Market Value”) is below $9.20 per share, the exercise price of the Public Warrants will be adjusted (to the nearest cent) to be equal to 115% of the Market Value and the $18.00 per share redemption trigger price described above will be adjusted (to the nearest cent) to be equal to 180% of the Market Price. The Private Warrants are identical to the Public Warrants, except that the Private Warrants and ordinary shares issuable upon the exercise of the Private Warrants are not transferable, assignable or salable until 30 days after the completion of a business combination, subject to certain limited exceptions. Additionally, the Private Warrants are exercisable on a cashless basis and are non-redeemable so long as they are held by the initial purchasers or their permitted transferees. If the Private Warrants are held by someone other than the initial purchasers or their permitted transferees, the Private Warrants will be redeemable by the Company and exercisable by such holders on the same basis as the Public Warrants.	Note 7 — Shareholders’ Deficit Preference Shares The Company is authorized to issue 1,000,000 preference shares with a par value of $0.0001 per share and with such designations, voting and other rights and preferences as may be determined from time to time by the Company’s board of directors. There currently are no preference shares issued or outstanding. Ordinary Shares The Company is authorized to issue 200,000,000 ordinary shares with a par value of $0.0001 per share. On July 19, 2021, the Company effected a cancellation of 575,000 Founder Shares, resulting in an aggregate of 2,300,000 Founder Shares outstanding. On September 5, 2021, the underwriters’ over-allotment option expired unexercised, resulting in the forfeiture of an additional 300,000 Founder Shares and a total of 2,000,000 Founder Shares outstanding as of December 31, 2022 and 2021 All shares and associated amounts have been retroactively restated to reflect the share cancellation. Ordinary shareholders of record are entitled to one vote for each share held on all matters to be voted on by shareholders. As of December 31, 2022 and 2021, there were 953,033 and 8,000,000 ordinary shares issued in the IPO which are subject to possible redemption, respectively Public Warrants The Company will not issue fractional Public Warrants, and only whole Public Warrants trade. The Public Warrants will become exercisable on 30 days after the completion of a Business Combination. No Public Warrants will be exercisable for cash unless the Company has an effective and current registration statement covering the ordinary shares issuable upon exercise of the Public Warrants and a current prospectus relating to such ordinary shares. Notwithstanding the foregoing, if a registration statement covering the ordinary shares issuable upon exercise of the Public Warrants is not effective within 120 days following the consummation of a Business Combination, Public Warrant holders may, until such time as there is an effective registration statement and during any period when the Company shall have failed to maintain an effective registration statement, exercise Public Warrants on a cashless basis pursuant to an available exemption from registration under the Securities Act. The Public Warrants will expire five years from the closing of a Business Combination. Once the Public Warrants become exercisable, the Company may redeem the Public Warrants in whole and not in part; ● at a price of $0.01 per Public Warrant; ● at any time after the Public Warrants become exercisable; ● upon not less than 30 days ’ prior written notice of redemption to each Public Warrant holder; ● if, and only if, the reported last sale price of the ordinary shares equals or exceeds $18.00 per share (as adjusted for share subdivisions, share capitalizations, reorganizations, recapitalizations and the like and for certain issuances of ordinary shares and equity-linked securities for capital raising purposes in connection with the closing of our initial Business Combination), for any 20 trading days within a 30-day trading period commencing after the Public Warrants become exercisable and ending on the third business day prior to the notice of redemption to Public Warrant holders; and ● if, and only if, there is a current registration statement in effect with respect to the ordinary shares underlying such Public Warrants at the time of redemption and for the entire 30-day trading period referred to above and continuing each day thereafter until the date of redemption, except if the Public Warrants may be exercised on a cashless basis and such cashless exercise is exempt from registration under the Securities Act. If the Company calls the Public Warrants for redemption, management will have the option to require all holders that wish to exercise the Public Warrants to do so on a “cashless basis,” as described in the Warrant Agreement. The exercise price and number of ordinary shares issuable on exercise of the Public Warrants may be adjusted in certain circumstances including in the event of a share dividend, extraordinary dividend or recapitalization, reorganization, merger or consolidation. However, except as described below, the Public Warrants will not be adjusted for issuances of ordinary shares at a price below their respective exercise prices. Additionally, in no event will the Company be required to net cash settle the Public Warrants. If the Company is unable to complete a Business Combination within the Combination Period and the Company liquidates the funds held in the Trust Account, holders of Public Warrants will not receive any of such funds with respect to their Public Warrants, nor will they receive any distribution from the Company’s assets held outside of the Trust Account with the respect to such Public Warrants. Accordingly, the Public Warrants may expire worthless. In addition, if (x) the Company issues additional ordinary shares or equity-linked securities for capital raising purposes in connection with the closing of a Business Combination at an issue price or effective issue price of less than $9.20 per ordinary share (with such issue price or effective issue price to be determined in good faith by the Company’s board of directors, and in the case of any such issuance to the Initial Shareholders or their affiliates, without taking into account any Founder Shares held by them prior to such issuance), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of a Business Combination on the date of the consummation of a Business Combination (net of redemptions), and (z) the volume weighted average trading price of the Company’s ordinary shares during the 20 trading day period starting on the trading day prior to the day on which the Company consummates Business Combination (such price, the “Market Value”) is below $9.20 per share, the exercise price of the Public Warrants will be adjusted (to the nearest cent) to be equal to 115% of the Market Value and the $18.00 per share redemption trigger price described above will be adjusted (to the nearest cent) to be equal to 180% of the Market Price. The Private Warrants are identical to the Public Warrants, except that the Private Warrants and ordinary shares issuable upon the exercise of the Private Warrants are not transferable, assignable or salable until 30 days after the completion of a Business Combination, subject to certain limited exceptions. Additionally, the Private Warrants are exercisable on a cashless basis and are non-redeemable so long as they are held by the initial purchasers or their permitted transferees. If the Private Warrants are held by someone other than the initial purchasers or their permitted transferees, the Private Warrants will be redeemable by the Company and exercisable by such holders on the same basis as the Public Warrants.

Fair Value Measurements_2

Fair Value Measurements	3 Months Ended	12 Months Ended
Fair Value Measurements	Mar. 31, 2023	Dec. 31, 2022
Fair Value Measurements
Fair Value Measurements	Note 7 — Fair Value Measurements The fair value of the Company’s assets and liabilities, which qualify as financial instruments under ASC 820 approximates the carrying amounts represented in the balance sheet, primarily due to their short-term nature. The Company determines fair value based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels: Level 1 Inputs: Unadjusted quoted prices for identical assets or instruments in active markets. Level 2 Inputs: Quoted prices for similar instruments in active markets and quoted prices for identical or similar instruments in markets that are not active and model derived valuations whose inputs are observable or whose significant value drivers are observable. Level 3 Inputs: Significant inputs into the valuation model are unobservable. The following presents the Company’s fair value hierarchy for assets and liabilities measured at fair value on a recurring basis as of March 31, 2023 and December 31, 2022: Description Level March 31, 2023 Level December 31, 2022 Assets: Investments held in Trust Account 1 $ 9,092,522 1 $ 9,835,409 Liabilities: PIPE derivative liability-Make-Whole Features 3 $ 1,281,465 3 $ 1,065,297 Warrant liability 2 $ 102,000 2 $ 335,240 The Private Warrants are considered to be a Level 2 fair value measurement as of March 31, 2023 and are valued the same as the Public Warrants, which are traded on the market. Transfers to/from Levels 1, 2 and 3 are recognized at the ending of the reporting period. The estimated fair value of the Private Warrants ( $680,000 ) was transferred from a Level 3 measurement to a Level 2 fair value measurement as of March 31, 2022, as the transfer of Private Warrants to anyone who is not a permitted transferee would result in the Private Warrants having substantially the same terms as the Public Warrants, and the Company determined that the fair value of each Private Warrant is equivalent to that of each Public Warrant. Other than as described above, there were no other transfers to/from Level 3 during the three months ended March 31, 2023 and 2022. The PIPE derivative liability was accounted for as a liability in accordance with ASC 815-40 and is presented within non-current liabilities on the balance sheets as of March 31, 2023 and December 31, 2022. The PIPE derivative liability is measured at fair value at inception and on a recurring basis, with changes in fair value presented within change in fair value of derivative liability in the statements of operations. The Make-Whole Features were, initially and as of March 31, 2023, valued using a Monte-Carlo model, which is considered to be a Level 3 fair value measurement. The primary unobservable input utilized in determining the fair value of the PIPE derivative liability is the expected volatility of the Company’s ordinary shares. The expected volatility of the Company’s ordinary shares was determined based on the implied volatility of the Public Warrants and from historical volatility of the common stock of select peer companies of Mobix Labs and comparable “blank-check” companies that had recently completed the business combination. The key inputs into the Monte-Carlo model for the PIPE derivative liability were as follows: Input March 31, 2023 December 31, 2022 Historical 30-days VWAP* as of measurement date $ 10.69 $ 10.19 Risk-free rate 4.76 % 4.46 % Dividend yield — % — % Volatility 0.43% and 58.0 % 1.60% and 64.0 % Term (in years) 0.55 0.31 * Volume-Weighted Average Price The following table presents the changes in the fair value of the PIPE derivative liability and the Private Warrant liability: Private Warrants PIPE Derivative Liability Fair value as of December 31, 2021 $ 1,667,262 $ — Change in fair value (987,262) — Fair value as of March 31, 2022 $ 680,000 $ — Change in fair value (425,000) — Fair value as of June 30, 2022 $ 255,000 $ — Change in fair value (119,000) — Fair value as of September 30, 2022 $ 136,000 $ — Initial measurement on November 15, 2022 — 1,108,709 Change in fair value 199,240 (43,412) Fair value as of December 31, 2022 335,240 $ 1,065,297 Change in fair value (233,240) 216,168 Fair value as of March 31, 2023 $ 102,000 $ 1,281,465	Note 8 — Fair Value Measurements The fair value of the Company’s assets and liabilities, which qualify as financial instruments under the FASB ASC 820, “ Fair Value Measurement ,” approximates the carrying amounts represented in the balance sheet, primarily due to their short-term nature. The Company determines fair value based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels: Level 1 Inputs: Unadjusted quoted prices for identical assets or instruments in active markets. Level 2 Inputs: Quoted prices for similar instruments in active markets and quoted prices for identical or similar instruments in markets that are not active and model derived valuations whose inputs are observable or whose significant value drivers are observable. Level 3 Inputs: Significant inputs into the valuation model are unobservable. As of December 31, 2022 and 2021, assets held in the Trust Account were comprised of $9,835,409 and $80,002,777 , respectively, in money market funds which are invested primarily in U.S. Treasury Securities. Through December 31, 2022, the Company has not withdrawn any of interest earned on the Trust Account. The following presents the Company’s fair value hierarchy for assets and liabilities measured at fair value on a recurring basis as of December 31, 2022 and 2021: Description Level December 31, 2022 Level December 31, 2021 Assets: Investments held in Trust Account 1 $ 9,835,409 1 $ 80,002,777 Liabilities: PIPE Derivative Liability-Make-Whole Features 3 $ 1,065,297 — $ — Warrant Liability 2 $ 335,240 3 $ 1,667,262 The Private Warrants are considered to be a Level 2 fair value measurement as of December 31, 2022 and are valued the same as the Public Warrants which are traded on the market. Transfers to/from Levels 1, 2 and 3 are recognized at the ending of the reporting period. The estimated fair value of the Private Warrants ($ 680,000 ) was transferred from a Level 3 measurement to a Level 2 fair value measurement as of March 31, 2022, as the transfer of Private Warrants to anyone who is not a permitted transferee would result in the Private Warrants having substantially the same terms as the Public Warrants, and the Company determined that the fair value of each Private Warrant is equivalent to that of each Public Warrant. Other than as described above, there were no other transfers to/from Level 3 during the year ended December 31, 2022 and the period from March 7, 2021 (inception) to December 31, 2021. The Private Warrants were considered a Level 3 fair value measurement prior to December 31, 2021, using a Monte-Carlo simulation model. Inherent in a Monte-Carlo simulation model are assumptions related to expected stock-price volatility (pre-merger and post-merger, expected term, dividend yield and risk-free interest rate). The Company estimates the volatility ( 10.50% ) of its ordinary shares based on management’s understanding of the volatility associated with instruments of other similar entities. The risk-free interest rate ( 1.19% ) is based on the U.S. Treasury rate matching the expected term of the Private Warrants. The expected life of the Private Warrant is simulated based on management assumptions regarding the timing and likelihood of completing a Business Combination. The dividend rate is based on the historical rate, which the Company anticipates remaining at zero. The following table provides quantitative information regarding fair value measurement inputs for the Private Warrants at measurement dates for Level 3 fair value measurement: July 22, 2021 December 31, 2021 Exercise price $ 11.50 $ 11.50 Stock price $ 9.39 $ 9.84 Volatility 16.8 % 10.50 % Expected term 5.0 5.0 Risk-free rate 0.71 % 1.19 % Dividend yield 0 % 0 % The PIPE Derivative Liability was accounted for as a liability in accordance with ASC 815-40 and is presented within current liabilities on the balance sheet as of December 31, 2022. The PIPE Derivative Lability is measured at fair value at inception and on a recurring basis, with changes in fair value presented within change in fair value of derivative liability in the statements of operations. The Make-Whole Features were, initially and as of December 31, 2022, valued using a Monte-Carlo model, which is considered to be a Level 3 fair value measurement. The primary unobservable input utilized in determining the fair value of the PIPE Derivative Liability is the expected volatility of the Company’s common stock. The expected volatility of the Company’s common stock was determined based on the implied volatility of the Public Warrants and from historical volatility of the common stock of select peer companies of Mobix Labs and comparable ‘blank-check’ companies that recently completed the business combination. The key inputs into the Monte-Carlo model for the PIPE Derivative Liability were as follows: November 15, 2022 Input (Initial Measurement) December 31, 2022 Historical 30-days VWAP* as of measurement date $ 10.09 $ 10.19 Risk-free rate 4.47 % 4.46 % Dividend yield 0 % 0 % Volatility 2.21% and 64 % 1.60% and 64.0 % Term (in years) 0.43 0.31 * Volume-Weighted Average Price The following table presents the changes in the fair value of the PIPE Derivative Liability and the Private Warrant liability: Private Warrants PIPE Derivative Liability Fair value as of July 22, 2021 (inception) $ — $ — Initial measurement 2,788,000 — Change in fair value (1,120,738) — Fair value as of December 31, 2021 $ 1,667,262 $ — Initial measurement on November 15, 2022 — 1,108,709 Change in fair value (1,332,022) (43,412) Fair value as of December 31, 2022 $ 335,240 $ 1,065,297

Subsequent Events_2

Subsequent Events	3 Months Ended	12 Months Ended
Subsequent Events	Mar. 31, 2023	Dec. 31, 2022
Subsequent Events.
Subsequent Events	Note 8 – Subsequent Events On April 3, 2023, the Company drew down an additional $60,000 of Working Capital Loans from the Sponsor under the existing promissory notes (see Note 4). On April 7, 2023, the Company entered into Amendment No. 1 to the Business Combination Agreement, as discussed in Note 1. The following events occurred subsequent to the date the unaudited condensed financial statements were issued: Additional Working Capital Loan On May 23, 2023 and July 18, 2023, the Company drew down an additional $80,000 and 48,000 , respectively, in Working Capital Loans from the Sponsor under the existing promissory notes. On June 22, 2023, the Company issued an unsecured non-convertible note in the aggregate principal amount of $500,000 to the Sponsor under which the Company may draw down Working Capital Loans from time to time prior to the maturity date up to such aggregate principal amount. The promissory note bears interest at the rate of 10.0% per annum and is payable in full in cash upon the earlier of (i) the consummation of an initial business combination and (ii) one year from the date of issuance. As of July 31, 2023, the Company had drawn down $100,000 under this promissory note. The Chairman of the board of directors of the Company or an entity affiliated with him and the Chief Executive Officer of the Company provided or will provide the funds to the Sponsor for the Working Capital Loans under this promissory note. As of July 31, 2023, the Company had drawn down an aggregate of $1,250,000 of Working Capital Loans under the promissory notes issued to the Sponsor (see Note 5). Third Extension On July 18, 2023, the Company held an extraordinary general meeting of shareholders and obtained shareholder approval of (i) the extension of the Business Combination period to January 22, 2024 (“Third Extension” and, together with the First Extension and the Second Extension, the “Extensions”), and (ii) the amendment of the Amended and Restated Memorandum and Articles of Association to eliminate from the Amended and Restated Memorandum and Articles (a) the limitation that the Company shall not redeem the Public Shares (as defined below) to the extent that such redemption would cause the Company’s net tangible assets to be less than $5,000,001 and (b) the limitation that the Company shall not consummate a business combination unless the Company has net tangible assets of at least $5,000,001 immediately prior to, or upon consummation of, or any greater net tangible asset or cash requirement that may be contained in the agreement relating to, such business combination (collectively, the “Redemption Limitation”). In connection with the meeting, Public Shareholders holding 77,130 Public Shares elected to exercise their right to redeem such shares and $841,807 (approximately $10.91 per share) was paid out of the Trust Account in connection with the redemptions. In connection with the approval of the extension amendment, the Company made an initial deposit into the Trust Account of $38,946 (at a rate of $0.05 per non-redeeming Public Share per month) and will continue to deposit $38,946 for each subsequent monthly period, or portion thereof, that is needed by the Company to complete a business combination by January 22, 2024.	Note 9 – Subsequent Events Additional Working Capital Loan On January 6, 2023, the Sponsor provided the Company with an additional Working Capital Loan of $300,000 , and the Company issued an unsecured convertible promissory note in the aggregate principal amount of $300,000 to the Sponsor . As of March 30, 2023, the Company had drawn down $962,000 under the Working Capital Loans (see Note 5). Nasdaq Notice of Non-Compliance with a Continued Listing Rule On March 23, 2023, the Company received a notice from the Listing Qualifications staff of The Nasdaq Stock Market LLC that, for the previous 30 consecutive business days, the minimum Market Value of Listed Securities ("MVLS") for the Company's ordinary shares was below the $35 million minimum MVLS requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(2) (the "MVLS Rule"). In accordance with the Nasdaq Listing Rules, the Company will have 180 calendar days (until September 19, 2023) to regain compliance with the MVLS Rule. To regain compliance with the MVLS Rule, the MVLS for the Company's ordinary shares must be at least $35 million for a minimum of 10 consecutive business days at any time during this 180 -day period. If the Company does not regain compliance with the rule by September 19, 2023, The Nasdaq Stock Market LLC will provide notice that the Company's ordinary shares will be delisted from The Nasdaq Capital Market. In the event of such notification, the Nasdaq Listing Rules permit the Company an opportunity to appeal The Nasdaq Stock Market LLC's determination. The Company is monitoring the MVLS of its ordinary shares and will consider options available to it to potentially achieve compliance. The Company's securities are expected to continue to trade on The Nasdaq Capital Market during the 180 -day period.

Summary of Significant Accoun_7

Summary of Significant Accoun_8

Summary of Significant Accounting Policies (Tables)	3 Months Ended	12 Months Ended
Summary of Significant Accounting Policies (Tables)	Mar. 31, 2023	Dec. 31, 2022
Summary of Significant Accounting Policies
Schedule of basic and diluted net income (loss) per common share	For the three months ended For the three months ended March 31, 2023 March 31, 2022 Net (loss) income $ (312,060) $ 604,359 Accretion of temporary equity to redemption value (261,713) — Net (loss) income including accretion of temporary equity to redemption value $ (573,773) $ 604,359 Public Shares Founder Shares Public Shares Founder Shares Basic and diluted net income per share: 873,285 2,000,000 8,000,000 2,000,000 Ownership percentage 30 % 70 % 80 % 20 % Numerator: Net income (loss) including accretion of temporary equity to redemption value $ (174,388) $ (399,384) $ 483,487 $ 120,872 Plus: Accretion applicable to the redeemable class $ 261,713 — — — Allocation of net income (loss) $ 87,325 $ (399,384) $ 483,487 $ 120,872 Denominator: Weighted-average shares outstanding 873,285 2,000,000 8,000,000 2,000,000 Basic and diluted net income (loss) per share: $ 0.10 $ (0.20) $ 0.06 $ 0.06	From March 19, 2021 For the Year ended (inception) through December 31, 2022 December 31, 2021 Net loss from inception to IPO date in year 2021 $ — $ (85,612) Net income from IPO date to year-end (total loss from inception to 12/31/2021) less the loss from inception to IPO) — 446,671 Net income (loss) $ (776,129) $ 361,059 Accretion of temporary equity to redemption value (308,687) (6,793,210) Net income (loss) including accretion of temporary equity to redemption value $ (1,084,816) $ (6,432,151) For the Year ended From March 19, 2021 (inception) through December 31, 2022 December 31, 2021 Public Shares Founder Shares Public Shares Founder Shares Basic and diluted net income per share: Total number of shares 4,795,078 2,000,000 8,000,000 2,000,000 Ownership percentage 71 % 29 % 80 % 20 % Numerator: Allocation of net loss – inception to IPO date $ — $ — $ — $ (85,612) Allocation of net income – IPO date to year end (allocated based on ownership percentage) — — 357,337 89,334 Total net income allocation $ — $ — $ 357,337 $ 3,722 Net income (loss) including accretion of temporary equity to redemption value (765,521) (319,295) (5,434,568) (1,358,642) Plus: Accretion applicable to the redeemable class 308,687 — 6,793,210 — Allocation of net income (loss) $ (456,834) $ (319,295) $ 1,715,979 $ (1,354,920) Denominator: Weighted-average shares outstanding 4,795,078 2,000,000 4,527,778 1,868,056 Basic and diluted net income (loss) per share: $ (0.10) $ (0.16) $ 0.38 $ (0.73)

Fair Value Measurements (Tabl_2

Fair Value Measurements (Tables)	3 Months Ended	12 Months Ended
Fair Value Measurements (Tables)	Mar. 31, 2023	Dec. 31, 2022
Fair Value Measurements
Schedule of Company fair value hierarchy for assets and liabilities measured at fair value on a recurring basis	Description Level March 31, 2023 Level December 31, 2022 Assets: Investments held in Trust Account 1 $ 9,092,522 1 $ 9,835,409 Liabilities: PIPE derivative liability-Make-Whole Features 3 $ 1,281,465 3 $ 1,065,297 Warrant liability 2 $ 102,000 2 $ 335,240	Description Level December 31, 2022 Level December 31, 2021 Assets: Investments held in Trust Account 1 $ 9,835,409 1 $ 80,002,777 Liabilities: PIPE Derivative Liability-Make-Whole Features 3 $ 1,065,297 — $ — Warrant Liability 2 $ 335,240 3 $ 1,667,262
Schedule of quantitative information regarding fair value measurement inputs for the warrants	Input March 31, 2023 December 31, 2022 Historical 30-days VWAP* as of measurement date $ 10.69 $ 10.19 Risk-free rate 4.76 % 4.46 % Dividend yield — % — % Volatility 0.43% and 58.0 % 1.60% and 64.0 % Term (in years) 0.55 0.31 * Volume-Weighted Average Price	July 22, 2021 December 31, 2021 Exercise price $ 11.50 $ 11.50 Stock price $ 9.39 $ 9.84 Volatility 16.8 % 10.50 % Expected term 5.0 5.0 Risk-free rate 0.71 % 1.19 % Dividend yield 0 % 0 %
Schedule of change fair value of the derivative warrant liabilities, measured with Level 3	Private Warrants PIPE Derivative Liability Fair value as of December 31, 2021 $ 1,667,262 $ — Change in fair value (987,262) — Fair value as of March 31, 2022 $ 680,000 $ — Change in fair value (425,000) — Fair value as of June 30, 2022 $ 255,000 $ — Change in fair value (119,000) — Fair value as of September 30, 2022 $ 136,000 $ — Initial measurement on November 15, 2022 — 1,108,709 Change in fair value 199,240 (43,412) Fair value as of December 31, 2022 335,240 $ 1,065,297 Change in fair value (233,240) 216,168 Fair value as of March 31, 2023 $ 102,000 $ 1,281,465	Private Warrants PIPE Derivative Liability Fair value as of July 22, 2021 (inception) $ — $ — Initial measurement 2,788,000 — Change in fair value (1,120,738) — Fair value as of December 31, 2021 $ 1,667,262 $ — Initial measurement on November 15, 2022 — 1,108,709 Change in fair value (1,332,022) (43,412) Fair value as of December 31, 2022 $ 335,240 $ 1,065,297

Organization and Business Ope_4

Organization and Business Operations (Details)														1 Months Ended	3 Months Ended	9 Months Ended	12 Months Ended
Organization and Business Operations (Details)	Jul. 22, 2023	Jul. 18, 2023 USD ($) $ / shares shares	Apr. 03, 2023 USD ($)	Jan. 06, 2023 USD ($) $ / shares shares	Nov. 17, 2022 USD ($)	Nov. 15, 2022 USD ($) $ / shares shares	Jul. 18, 2022 USD ($)	Jul. 14, 2022 USD ($) $ / shares shares	Jun. 20, 2022 USD ($)	Sep. 05, 2021 shares	Jul. 22, 2021 USD ($) $ / shares shares	Jun. 25, 2021 USD ($) shares	Apr. 07, 2021 USD ($) $ / shares shares	Jul. 31, 2023 USD ($)	Mar. 31, 2023 USD ($) item $ / shares shares	Dec. 31, 2021 $ / shares shares	Dec. 31, 2022 USD ($) $ / shares shares	Mar. 30, 2023 USD ($)
Organization and Business Operations
Ordinary shares subject to possible redemption, per share \| $ / shares															$ 10	$ 10	$ 10.22
Price of warrant \| $ / shares															$ 1		$ 1
Underwriting option period											45 days
Aggregate purchase price																	$ 25,000
Number of shares issued \| shares																	2,000,000
Condition for future business combination number of businesses minimum															1		1
Cash held outside of the trust account															$ 105,038		$ 175,788
Loans convertible into warrants															$ 1,500,000		$ 1,500,000
Condition for future business combination use of proceeds percentage															80		80
Condition for future business combination threshold percentage ownership															50		50
Condition for future business combination threshold net tangible assets															$ 5,000,001		$ 5,000,001
Redeem price per share \| $ / shares															$ 10	$ 10	$ 10.22
Redemption limit percentage without prior consent															15		15
Obligation to redeem Public Shares if entity does not complete a Business Combination (as a percent)															100%		100%
Maturity period											185 days				185 days		185 days
Redemption period upon closure															10 days		10 days
Maximum interest to pay dissolution expenses															$ 100,000		$ 100,000
Amount drawn down under working capital					$ 962,000		$ 490,000		$ 360,000						962,000		662,000
Redemption of ordinary shares \| shares				96,991
Cash withdrawn from Trust Account in connection with redemption				$ 1,004,600													$ 70,573,278
Initial deposit into Trust Account				$ 42,802
Monthly deposit of per share amount in trust account to complete business combination \| $ / shares				$ 0.05
Agreed monthly deposit in trust account to complete business combination				$ 42,802
Aggregate deposit in trust account				317,107
Assets held-in-trust				$ 9,092,522
Business combination agreement
Organization and Business Operations
Price per share \| $ / shares						$ 10
PIPE Subscription Agreement
Organization and Business Operations
Number of units sold \| shares						3,000,000
Ordinary shares subject to possible redemption, per share \| $ / shares						$ 10
Gross proceeds						$ 30,000,000
Redeem price per share \| $ / shares						$ 10
Proposed transaction committed common stock						$ 30,000,000
Price per share \| $ / shares																	$ 10
Subsequent Event
Organization and Business Operations
Ordinary shares subject to possible redemption, per share \| $ / shares		$ 10.91
Redeem price per share \| $ / shares		$ 10.91
Obligation to redeem Public Shares if entity does not complete a Business Combination (as a percent)	100%
Redemption of ordinary shares \| shares		77,130		96,991
Cash withdrawn from Trust Account in connection with redemption		$ 841,807		$ 1,004,600
Initial deposit into Trust Account		$ 38,946		$ 42,802
Monthly deposit of per share amount in trust account to complete business combination \| $ / shares		$ 0.05		$ 0.05
Agreed monthly deposit in trust account to complete business combination		$ 38,946		$ 42,802
Aggregate deposit in trust account															317,107
Assets held-in-trust																		$ 9,090,881
Amount drawn down as of date																		$ 962,000
IPO
Organization and Business Operations
Number of units sold \| shares											8,000,000
Ordinary shares subject to possible redemption, per share \| $ / shares											$ 10
Gross proceeds											$ 80,000,000				$ 2,800,000		$ 2,800,000
Underwriting option period											45 days
Offering costs											$ 2,058,249
Additional units purchased \| shares											1,200,000
Redeem price per share \| $ / shares											$ 10
Private Placement \| Private Warrants
Organization and Business Operations
Sale of Private Placement Warrants (in shares) \| shares															3,400,000		3,400,000
Price of warrant \| $ / shares															$ 1		$ 1
Proceeds from sale of private placement															$ 3,400,000		$ 3,400,000
Over-allotment option
Organization and Business Operations
Ordinary shares subject to possible redemption, per share \| $ / shares											$ 10
Additional units purchased \| shares											1,200,000
Redeem price per share \| $ / shares											$ 10
Founder shares
Organization and Business Operations
Number of shares issued \| shares										2,000,000					2,000,000		2,000,000
Founder shares \| Over-allotment option
Organization and Business Operations
Forfeiture of Founder Shares in connection with the expiration of overallotment option \| shares										300,000
Working Capital loans
Organization and Business Operations
Amount drawn down as of date																	$ 662,000
Ordinary Shares Subject To Possible Redemption
Organization and Business Operations
Number of units sold \| shares																8,000,000
Redemption price per share \| $ / shares								$ 31,450
Redemption of ordinary shares \| shares								7,046,967
Cash withdrawn from Trust Account in connection with redemption				$ 96,991				$ 70,573,278
Monthly deposit of per share amount in trust account to complete business combination \| $ / shares								$ 0.033
Agreed monthly deposit in trust account to complete business combination								$ 31,450
Aggregate deposit in trust account															$ 188,700		$ 188,700
Ordinary Shares Subject To Possible Redemption \| Subsequent Event
Organization and Business Operations
Redemption price per share \| $ / shares				$ 10.36
Redemption of ordinary shares \| shares				96,991
Cash withdrawn from Trust Account in connection with redemption				$ 1,004,600
Sponsor
Organization and Business Operations
Ordinary shares subject to possible redemption, per share \| $ / shares													$ 0.009
Aggregate purchase price													$ 25,000
Number of shares issued \| shares													2,875,000
Redeem price per share \| $ / shares													$ 0.009
Sponsor \| Subsequent Event
Organization and Business Operations
Amount drawn down under working capital			$ 60,000											$ 1,250,000
Representative Designee \| Founder shares
Organization and Business Operations
Aggregate purchase price												$ 3,675
Number of shares issued \| shares												422,581

Summary of Significant Accoun_9

Summary of Significant Accounting Policies (Details) - USD ($)					3 Months Ended	9 Months Ended	12 Months Ended
	Jan. 06, 2023	Jul. 14, 2022	Sep. 05, 2021	Jul. 22, 2021	Mar. 31, 2023	Dec. 31, 2021	Dec. 31, 2022
Summary of Significant Accounting Policies
Investments held in the Trust Account						$ 80,002,777	$ 9,835,409
Federal Depository Insurance Coverage							$ 250,000
Ordinary shares subject to possible redemption, shares outstanding					856,042	8,000,000	953,033
Unrecognized tax benefits					$ 0		$ 0
Unrecognized tax benefits accrued for interest and penalties					0	$ 0
Provision for income taxes					$ 0		$ 0
Anti-dilutive securities attributable to warrants (in shares)					9,400,000		9,400,000
Offering costs						125,039
Subsequent measurement of ordinary shares subject to redemption				$ 6,793,210
Number of shares issued							2,000,000
Redemption of ordinary shares	96,991
Cash withdrawn from Trust Account in connection with redemption	$ 1,004,600						$ 70,573,278
Funds deposited in trust account						80,000,000	188,700
Additional Paid-in Capital
Summary of Significant Accounting Policies
Offering costs						125,039
Subsequent measurement of ordinary shares subject to redemption				5,371,731
Accumulated Deficit
Summary of Significant Accounting Policies
Offering costs						0
Subsequent measurement of ordinary shares subject to redemption				$ 1,421,479	$ 261,713		308,687
Ordinary Shares Subject To Possible Redemption
Summary of Significant Accounting Policies
Offering costs						$ 1,933,210
Redemption of ordinary shares		7,046,967
Cash withdrawn from Trust Account in connection with redemption	$ 96,991	$ 70,573,278
Redemption price per share		$ 31,450
Funds deposited in trust account					128,407		188,700
Accretion of cash into trust account					261,713
Interest income on trust deposits					133,306		119,987
Interest generating deposits in trust account					$ 100,000		$ 100,000
Founder shares
Summary of Significant Accounting Policies
Number of shares issued			2,000,000		2,000,000		2,000,000

Summary of Significant Accou_10

Summary of Significant Accounting Policies - Net Income (Loss) Per Shares (Details) - USD ($)		3 Months Ended		9 Months Ended	12 Months Ended
	Jul. 22, 2021	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2022	Sep. 05, 2021
Summary of Significant Accounting Policies
Net loss from inception to IPO date				$ (85,612)
Net income from IPO date to year-end (total loss from inception to 12/31) less the loss from inception to IPO)				446,671
Net income (loss)		$ (312,060)	$ 604,359	361,059	$ (776,129)
Accretion of temporary equity to redemption value		(261,713)		(6,793,210)	(308,687)
Net income (loss) including accretion of temporary equity to redemption value		$ (573,773)	604,359	$ 6,432,151	$ 1,084,816
Basic and diluted net income per share:
Total number of shares		2,000,000		2,000,000	2,000,000
Numerator:
Plus: Accretion applicable to the redeemable class	$ 6,793,210
Public Shares
Summary of Significant Accounting Policies
Accretion of temporary equity to redemption value		$ (261,713)
Net income (loss) including accretion of temporary equity to redemption value		$ (174,388)	$ 483,487
Basic and diluted net income per share:
Total number of shares		873,285	8,000,000	8,000,000	4,795,078
Ownership percentage		30%	80%	80%	71%
Numerator:
Allocation of net income - IPO date to year end (allocated based on ownership percentage)				$ 357,337
Total net income allocation		$ 87,325	$ 483,487	(357,337)
Net income (loss) including accretion of temporary equity to redemption value				(5,434,568)	$ (765,521)
Plus: Accretion applicable to the redeemable class				6,793,210	308,687
Allocation of net income (loss)				$ 1,715,979	$ (456,834)
Denominator:
Weighted average ordinary shares outstanding, basic		873,285	8,000,000	4,527,778	4,795,078
Weighted average ordinary shares outstanding, diluted		873,285	8,000,000	4,527,778	4,795,078
Basic net income (loss) per ordinary share		$ 0.10	$ 0.06	$ 0.38	$ (0.10)
Diluted net income (loss) per ordinary share		$ 0.10	$ 0.06	$ 0.38	$ (0.10)
Founder shares
Summary of Significant Accounting Policies
Net income (loss) including accretion of temporary equity to redemption value		$ (399,384)	$ 120,872
Basic and diluted net income per share:
Total number of shares		2,000,000	2,000,000	2,000,000	2,000,000	2,000,000
Ownership percentage		70%	20%	20%	29%
Numerator:
Allocation of net loss - inception to IPO date				$ (85,612)
Allocation of net income - IPO date to year end (allocated based on ownership percentage)				89,334
Total net income allocation		$ (399,384)	$ 120,872	(3,722)
Net income (loss) including accretion of temporary equity to redemption value				(1,358,642)	$ (319,295)
Allocation of net income (loss)				$ (1,354,920)	$ (319,295)
Denominator:
Weighted average ordinary shares outstanding, basic		2,000,000	2,000,000	1,868,056	2,000,000
Weighted average ordinary shares outstanding, diluted		2,000,000	2,000,000	1,868,056	2,000,000
Basic net income (loss) per ordinary share		$ (0.20)	$ 0.06	$ (0.73)	$ (0.16)
Diluted net income (loss) per ordinary share		$ (0.20)	$ 0.06	$ (0.73)	$ (0.16)

Private Placement (Details)_2

Private Placement (Details) - USD ($)	3 Months Ended	12 Months Ended
Private Placement (Details) - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Private Placement
Price of warrants	$ 1	$ 1
Private Placement \| Private Warrants
Private Placement
Number of warrants to purchase shares issued	3,400,000	3,400,000
Price of warrants	$ 1	$ 1
Aggregate purchase price	$ 3,400,000	$ 3,400,000
Number of shares per warrant	1	1
Exercise price of warrant	$ 11.50	$ 11.50

Related Party Transactions - _2

Related Party Transactions - Founder Shares (Details) - Founder shares - Sponsor - Class B Common Stock	Apr. 07, 2021 $ / shares
Related Party Transactions
Restrictions on transfer period of time after business combination completion	1 year
Stock price trigger to transfer, assign or sell any shares or warrants of the company, after the completion of the initial business combination (in dollars per share)	$ 12
Threshold trading days for transfer, assign or sale of shares or warrants, after the completion of the initial business combination	20 days
Transfer assign or sell any shares or warrants after completion of initial business combination threshold consecutive trading days	30 days
Threshold period after the business combination in which the 20 trading days within any 30 trading day period commences	150 days

Related Party Transactions (D_2

Related Party Transactions (Details) - USD ($)

1 Months Ended

3 Months Ended

9 Months Ended

12 Months Ended

Apr. 03, 2023

Jan. 06, 2023

Nov. 17, 2022

Jul. 18, 2022

Jun. 20, 2022

Jul. 26, 2021

Jul. 31, 2023

Mar. 31, 2023

Mar. 31, 2022

Dec. 31, 2021

Dec. 31, 2022

Jun. 22, 2023

Jul. 22, 2021

Apr. 07, 2021

Related Party Transactions

Repayment of promissory note - related party

$ 129,602

Loan conversion agreement warrant

$ 1,500,000

Price of warrant

$ 1

Aggregate principal amount

$ 490,000

$ 360,000

Amount drawn down under working capital

$ 962,000

490,000

360,000

$ 962,000

$ 662,000

Sponsor

Related Party Transactions

Additional amount drawn down under working capital

$ 300,000

Sponsor | Subsequent Event

Related Party Transactions

Maximum borrowing capacity of related party promissory note

300,000

Amount drawn down under working capital

$ 60,000

$ 1,250,000

Promissory Note with Related Party

Related Party Transactions

Maximum borrowing capacity of related party promissory note

$ 200,000

Outstanding balance of related party note

$ 129,602

Loan conversion agreement warrant

$ 1,500,000

Price of warrant

$ 1

Aggregate principal amount

300,000

Promissory Note with Related Party | Subsequent Event

Related Party Transactions

Aggregate principal amount

$ 300,000

Promissory Note with Related Party | Sponsor

Related Party Transactions

Aggregate principal amount

$ 360,000

Amount drawn down under working capital

$ 490,000

Promissory Note with Related Party | Sponsor | Subsequent Event

Related Party Transactions

Aggregate principal amount

$ 500,000

Administrative Support Agreement

Related Party Transactions

Expenses incurred and paid

$ 30,000

120,000

60,000

Expenses per month

$ 10,000

10,000

Expenses accrued

$ 90,000

$ 10,000

80,000

Related Party Loans

Related Party Transactions

Loan conversion agreement warrant

$ 1,500,000

Price of warrant

$ 1

Commitments and Contingencies_3

Commitments and Contingencies (Details)			3 Months Ended	12 Months Ended
Commitments and Contingencies (Details)	Nov. 15, 2022 USD ($)	Jul. 22, 2021 USD ($)	Mar. 31, 2023 USD ($) $ / shares	Dec. 31, 2022 USD ($) $ / shares
Commitments and Contingencies
Net tangible assets after giving effect to the PIPE Investment			$ 5,000,001
PIPE Subscription Agreement
Commitments and Contingencies
Value of gross proceeds from IPO	$ 30,000,000
Minimum period of resale of stock			45 days	45 days
Adjustment VWAP period			30 days	30 days
Share price \| $ / shares			$ 10	$ 10
PIPE Subscription Agreement \| Volume-Weighted Average Price
Commitments and Contingencies
Share price \| $ / shares			$ 7	$ 7
IPO
Commitments and Contingencies
Cash underwriting discount and commission (in percentage)				2%
Aggregate underwriter cash discount and commissions			$ 10	$ 1,600,000
Gross proceeds of the IPO			3.5	3.5
Value of gross proceeds from IPO		$ 80,000,000	$ 2,800,000	$ 2,800,000

Shareholders' Deficit - Prefe_2

Shareholders' Deficit - Preference Shares (Details) - $ / shares	Mar. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Shareholders' Deficit
Preferred stock, par value	$ 0.0001	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	1,000,000	1,000,000	1,000,000
Preferred stock, shares issued	0	0	0
Preferred stock, shares outstanding	0	0	0
Preference Shares
Shareholders' Deficit
Preferred stock, par value		$ 0.0001
Preferred stock, shares authorized		1,000,000
Preferred stock, shares issued		0
Preferred stock, shares outstanding		0

Shareholders' Deficit - Ordin_2

Shareholders' Deficit - Ordinary Shares (Details)			12 Months Ended
Shareholders' Deficit - Ordinary Shares (Details)	Jul. 19, 2021 shares	Apr. 07, 2021 shares	Dec. 31, 2022 Vote $ / shares shares	Mar. 31, 2023 Vote $ / shares shares	Dec. 31, 2021 $ / shares shares	Sep. 05, 2021 shares
Shareholders' Deficit
Common shares, shares outstanding			2,000,000	2,000,000	2,000,000
Number of shares issued			2,000,000
Common shares, shares authorized (in shares)			200,000,000	200,000,000	200,000,000
Common shares, par value (in dollars per share) \| $ / shares			$ 0.0001	$ 0.0001	$ 0.0001
Common shares, votes per share \| Vote			1	1
Founder shares
Shareholders' Deficit
Number of shares cancellation	575,000
Common shares, shares outstanding	2,300,000
Sponsor
Shareholders' Deficit
Number of shares cancellation	575,000
Common shares, shares outstanding	2,300,000		2,000,000	2,000,000
Number of shares issued		2,875,000
Over-allotment option \| Founder shares
Shareholders' Deficit
Common shares, shares outstanding			2,000,000		2,000,000
Over-allotment option \| Sponsor
Shareholders' Deficit
Shares subject to forfeiture						300,000
Ordinary shares subject to redemption \| IPO
Shareholders' Deficit
Ordinary shares issued			953,033	856,042	8,000,000

Shareholders' Deficit - Publi_2

Shareholders' Deficit - Public Warrants (Details) - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Shareholders' Deficit
Warrants exercisable term from the completion of business combination		30 days
Public Warrants
Shareholders' Deficit
Warrants exercisable term from the completion of business combination	30 days
Period of time within which registration statement is expected to become effective	120 days	120 days
Public Warrants expiration term	5 years	5 years
Redemption price per public warrant (in dollars per share)	$ 0.01	$ 0.01
Minimum threshold written notice period for redemption of public warrants	30 days	30 days
Stock price trigger for redemption of public warrants (in dollars per share)	$ 18	$ 18
Threshold period for filling registration statement after business combination	20 days	20 days
Redemption period	30 days	30 days
Share Price	$ 9.20	$ 9.20
Percentage of gross proceeds on total equity proceeds	60%	60%
Threshold consecutive trading days for redemption of public warrants	20 days	20 days
Adjustment of exercise price of warrants based on market value and newly issued price (as a percent)	115%	115%
Public Warrants \| Redemption of Warrants When the Price per Class A Ordinary Share Equals or Exceeds $18.00
Shareholders' Deficit
Stock price trigger for redemption of public warrants (in dollars per share)	$ 18	$ 18
Adjustment of exercise price of warrants based on market value and newly issued price (as a percent)	180%	180%

Fair Value Measurements - Com_2

Fair Value Measurements - Company fair value hierarchy for assets and liabilities (Details) - USD ($)		3 Months Ended
	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022	Dec. 31, 2021
Assets:
Investment held in trust account		$ 9,092,522		$ 9,835,409	$ 80,002,777
Liabilities:
PIPE derivative liability-Make-Whole Features		1,281,465		1,065,297
Warrant liability		102,000		335,240	1,667,262
Transfer to/from Level 3		0	$ 0
Private Warrants
Liabilities:
Transferred from Level 3 to Level 2	$ 680,000		$ 680,000
U.S. Treasury Securities
Assets:
Investment held in trust account				9,835,409	80,002,777
Level 1 \| Recurring
Assets:
Investment held in trust account		9,092,522		9,835,409	80,002,777
Level 2
Liabilities:
Warrant liability		102,000		335,240
Level 2 \| Recurring
Liabilities:
Warrant liability				335,240
Level 3 \| Recurring
Liabilities:
PIPE derivative liability-Make-Whole Features		$ 1,281,465		$ 1,065,297
Warrant liability					$ 1,667,262

Fair Value Measurements - Qua_2

Fair Value Measurements - Quantitative information regarding fair value measurement inputs for the warrants (Details)	Mar. 31, 2023 Y $ / shares	Dec. 31, 2022 Y $ / shares	Nov. 15, 2022	Dec. 31, 2021	Jul. 22, 2021 Y $ / shares
Exercise Price \| Private Warrants
Quantitative information regarding fair value measurement inputs for the Private Placement Warrants
Derivative liability, measurement input		11.50			11.50
Volume-Weighted Average Price \| PIPE Derivative Liability
Quantitative information regarding fair value measurement inputs for the Private Placement Warrants
Derivative liability, measurement input		0.1019	0.1009
Stock Price
Quantitative information regarding fair value measurement inputs for the Private Placement Warrants
Derivative liability, measurement input	10.69	10.19
Stock Price \| Private Warrants
Quantitative information regarding fair value measurement inputs for the Private Placement Warrants
Derivative liability, measurement input		9.84			9.39
Volatility \| Private Warrants
Quantitative information regarding fair value measurement inputs for the Private Placement Warrants
Derivative liability, measurement input		0.1050		0.1050	0.168
Volatility \| Maximum
Quantitative information regarding fair value measurement inputs for the Private Placement Warrants
Derivative liability, measurement input		0.640	0.64
Volatility \| Maximum \| Level 3
Quantitative information regarding fair value measurement inputs for the Private Placement Warrants
Derivative liability, measurement input	0.580
Volatility \| Minimum
Quantitative information regarding fair value measurement inputs for the Private Placement Warrants
Derivative liability, measurement input	0.43	0.0160	0.0221
Expected term
Quantitative information regarding fair value measurement inputs for the Private Placement Warrants
Derivative liability, measurement input \| Y	0.55	0.31
Expected term \| Private Warrants
Quantitative information regarding fair value measurement inputs for the Private Placement Warrants
Derivative liability, measurement input \| Y		5			5
Expected term \| PIPE Derivative Liability
Quantitative information regarding fair value measurement inputs for the Private Placement Warrants
Derivative liability, measurement input		0.0031	0.0043
Risk-free rate
Quantitative information regarding fair value measurement inputs for the Private Placement Warrants
Derivative liability, measurement input	0.0476	0.0446
Risk-free rate \| Private Warrants
Quantitative information regarding fair value measurement inputs for the Private Placement Warrants
Derivative liability, measurement input		0.0119		0.0119	0.0071
Risk-free rate \| PIPE Derivative Liability
Quantitative information regarding fair value measurement inputs for the Private Placement Warrants
Derivative liability, measurement input		0.0446	0.0447
Dividend yield \| Private Warrants
Quantitative information regarding fair value measurement inputs for the Private Placement Warrants
Derivative liability, measurement input		0			0
Dividend yield \| PIPE Derivative Liability
Quantitative information regarding fair value measurement inputs for the Private Placement Warrants
Derivative liability, measurement input		0	0

Fair Value Measurements - Cha_2

Fair Value Measurements - Change in the Fair Value of the Warrant Liabilities (Details) - USD ($)	3 Months Ended				5 Months Ended	9 Months Ended	12 Months Ended
	Mar. 31, 2023	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2021	Dec. 31, 2022
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Change in fair value of warrant liability	$ (233,240)			$ (987,262)		$ (1,120,738)	$ (1,332,022)
Fair value					Change in fair value of warrant liability		Change in fair value of warrant liability
Private Warrants
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Warrant liability at beginning of period	335,240			1,667,262	$ 0		$ 1,667,262
Initial measurement					2,788,000		0
Change in fair value of warrant liability					(1,120,738)		(1,332,022)
Warrant Liability at end of period					1,667,262	1,667,262	335,240
PIPE Derivative Liability
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Warrant liability at beginning of period	1,065,297
Initial measurement							1,108,709
Change in fair value of warrant liability							(43,412)
Warrant Liability at end of period							1,065,297
Level 3 \| Private Warrants
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Warrant liability at beginning of period	335,240	$ 255,000	$ 680,000	1,667,262			1,667,262
Change in fair value of warrant liability	(233,240)	(119,000)	(425,000)	(987,262)			199,240
Warrant Liability at end of period	102,000	$ 136,000	$ 255,000	$ 680,000	$ 1,667,262	$ 1,667,262	335,240
Level 3 \| PIPE Derivative Liability
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Warrant liability at beginning of period	1,065,297
Initial measurement							1,108,709
Change in fair value of warrant liability	216,168						(43,412)
Warrant Liability at end of period	$ 1,281,465						$ 1,065,297

Subsequent Events (Details)_2

Subsequent Events (Details) - USD ($)

1 Months Ended

3 Months Ended

12 Months Ended

Jul. 18, 2023

Jun. 22, 2023

May 23, 2023

Apr. 03, 2023

Jan. 06, 2023

Nov. 17, 2022

Jul. 18, 2022

Jun. 20, 2022

Jul. 31, 2023

Mar. 31, 2023

Dec. 31, 2022

Dec. 31, 2021

Apr. 07, 2021

Subsequent Events

Amount drawn down under working capital

$ 962,000

$ 490,000

$ 360,000

$ 962,000

$ 662,000

Aggregate principal amount

490,000

360,000

Condition for future business combination threshold net tangible assets

$ 5,000,001

5,000,001

Redemption of ordinary shares

96,991

Cash withdrawn from Trust Account in connection with redemption

$ 1,004,600

$ 70,573,278

Redeem price per share

$ 10

$ 10.22

$ 10

Initial deposit into Trust Account

$ 42,802

Monthly deposit of per share amount in trust account to complete business combination

$ 0.05

Agreed monthly deposit in trust account to complete business combination

$ 42,802

Promissory Note with Related Party

Subsequent Events

Aggregate principal amount

$ 300,000

Sponsor

Subsequent Events

Redeem price per share

$ 0.009

Sponsor | Promissory Note with Related Party

Subsequent Events

Amount drawn down under working capital

$ 490,000

Aggregate principal amount

$ 360,000

Subsequent Event

Subsequent Events

Amount drawn down under promissory note

$ 100,000

Redemption of ordinary shares

77,130

96,991

Cash withdrawn from Trust Account in connection with redemption

$ 841,807

$ 1,004,600

Redeem price per share

$ 10.91

Initial deposit into Trust Account

$ 38,946

$ 42,802

Monthly deposit of per share amount in trust account to complete business combination

$ 0.05

Agreed monthly deposit in trust account to complete business combination

$ 38,946

$ 42,802

Subsequent Event | Minimum [Member]

Subsequent Events

Condition for future business combination threshold net tangible assets

5,000,001

Subsequent Event | Maximum [Member]

Subsequent Events

Condition for future business combination threshold net tangible assets

5,000,001

Subsequent Event | Promissory notes.

Subsequent Events

Amount drawn down under working capital

$ 80,000

Promissory note interest rate (in percent)

10%

Subsequent Event | Promissory Note with Related Party

Subsequent Events

Aggregate principal amount

$ 300,000

Subsequent Event | Sponsor

Subsequent Events

Amount drawn down under working capital

$ 60,000

$ 1,250,000

Subsequent Event | Sponsor | Promissory notes.

Subsequent Events

Amount drawn down under working capital

$ 48,000

Subsequent Event | Sponsor | Promissory Note with Related Party

Subsequent Events

Aggregate principal amount

$ 500,000